<!DOCTYPE html><html lang="en" class="scroll-smooth"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>055 Pharmacology Ini-Cet 2022 - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / PYQ / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">57</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls="">
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd"></path>
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z"></path>
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>const _0x6eced6=_0x3e0e;(function(_0x20771a,_0x15a343){const _0x50696d=_0x3e0e,_0x47e561=_0x20771a();while(!![]){try{const _0x2aae03=parseInt(_0x50696d(0x351))/0x1*(-parseInt(_0x50696d(0x427))/0x2)+parseInt(_0x50696d(0x328))/0x3+-parseInt(_0x50696d(0x32d))/0x4*(-parseInt(_0x50696d(0x22f))/0x5)+-parseInt(_0x50696d(0x2b3))/0x6+parseInt(_0x50696d(0x3e6))/0x7+parseInt(_0x50696d(0x356))/0x8+parseInt(_0x50696d(0x1b7))/0x9*(parseInt(_0x50696d(0x445))/0xa);if(_0x2aae03===_0x15a343)break;else _0x47e561['push'](_0x47e561['shift']());}catch(_0x3fb181){_0x47e561['push'](_0x47e561['shift']());}}}(_0x33d7,0xcb8af));const _0x35ba67=(function(){const _0x5e2b91=_0x3e0e,_0x31ab1c={'hrEZB':function(_0x3db55a,_0x5e7e2b){return _0x3db55a-_0x5e7e2b;},'DXcFV':function(_0x55ba2a,_0x4f2ffa){return _0x55ba2a!==_0x4f2ffa;},'OqVmM':_0x5e2b91(0x25b)};let _0x2f1bd1=!![];return function(_0x239343,_0xc1c5b6){const _0x28834a=_0x5e2b91,_0x3fb808={'pWBPy':function(_0x5ad6c5,_0x50db5d){return _0x31ab1c['hrEZB'](_0x5ad6c5,_0x50db5d);},'eaYHd':function(_0x50038c,_0x1c2fad){return _0x31ab1c['DXcFV'](_0x50038c,_0x1c2fad);},'WXwSH':_0x31ab1c[_0x28834a(0x442)]},_0x48ff45=_0x2f1bd1?function(){const _0x2d0fc3=_0x28834a;if(_0x3fb808['eaYHd'](_0x3fb808['WXwSH'],_0x3fb808[_0x2d0fc3(0x23d)]))_0x4de1e7[_0x280033]['timeSpent']+=_0x3fb808['pWBPy'](_0x317832[_0x2d0fc3(0x2e0)](),_0x3cc2ac);else{if(_0xc1c5b6){const _0x12c1dd=_0xc1c5b6[_0x2d0fc3(0x25d)](_0x239343,arguments);return _0xc1c5b6=null,_0x12c1dd;}}}:function(){};return _0x2f1bd1=![],_0x48ff45;};}()),_0x5bcf9d=_0x35ba67(this,function(){const _0x5f5022=_0x3e0e,_0x91659f={'jkUhQ':_0x5f5022(0x432)};return _0x5bcf9d['toString']()[_0x5f5022(0x342)](_0x91659f[_0x5f5022(0x27a)])[_0x5f5022(0x2e3)]()['constructor'](_0x5bcf9d)[_0x5f5022(0x342)](_0x91659f[_0x5f5022(0x27a)]);});_0x5bcf9d();function _0x33d7(){const _0x2b73e9=['stringify','HSGMv','Option\x20','KMLCu','yruyx','iXoUx','GsFkO','nav-btn-incorrect','<p>The\x20correct\x20pairs\x20are\x20as\x20follows:</p>\x0a<table\x20style=\x22height:\x20121px;\x20width:\x20271px;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20114.1875px;\x22>A.\x20Trastuzumab&nbsp;</td>\x0a<td\x20style=\x22width:\x20142.8125px;\x22>4.\x20HER2/neu</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20114.1875px;\x22>B.\x20Infliximab</td>\x0a<td\x20style=\x22width:\x20142.8125px;\x22>3.&nbsp;\x20TNF\x20&alpha;&nbsp;&nbsp;</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20114.1875px;\x22>C.\x20Sirolimus&nbsp;</td>\x0a<td\x20style=\x22width:\x20142.8125px;\x22>2.&nbsp;mTOR</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20114.1875px;\x22>D.\x20Imatinib</td>\x0a<td\x20style=\x22width:\x20142.8125px;\x22>1.&nbsp;BCR-ABL\x20tyrosine\x20kinase&nbsp;&nbsp;</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>&nbsp;</p>\x0a<p><strong>Trastuzumab</strong>\x20is\x20a\x20<strong>humanized\x20monoclonal\x20antibody\x20against</strong>&nbsp;the\x20external\x20domain\x20of\x20<strong>HER2/neu</strong>.\x20It&nbsp;is\x20indicated\x20as\x20an\x20adjuvant\x20in\x20the\x20management\x20of&nbsp;<strong>metastatic\x20HER-2-positive\x20breast\x20cancer</strong>.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20657\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p><strong>Infliximab</strong>\x20binds\x20with\x20high\x20affinity\x20to\x20<strong>TNF-&alpha;</strong>\x20and\x20prevents\x20the\x20cytokine\x20from\x20binding\x20to\x20its\x20receptors.\x20Infliximab\x20is\x20used\x20for\x20the\x20treatment\x20of\x20<strong>rheumatoid\x20arthritis</strong>;&nbsp;it\x20is\x20used&nbsp;<strong>in\x20combination\x20with\x20methotrexate</strong>&nbsp;in\x20patients\x20who\x20do\x20not\x20respond\x20to\x20methotrexate\x20alone.\x20Infliximab\x20is\x20also\x20used\x20for\x20the\x20treatment\x20of\x20the\x20symptoms\x20of\x20<strong>moderate-to-severe\x20Crohn\x27s\x20disease</strong>.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a<p><strong>Sirolimus</strong>\x20is\x20an\x20antimetabolic\x20and\x20antiproliferative\x20drug.\x20It\x20acts\x20by\x20forming\x20a\x20complex\x20with\x20an\x20immunophilin\x20called&nbsp;<strong>FKBP-12</strong>,\x20which\x20in\x20turn\x20inhibits\x20the&nbsp;mammalian\x20target\x20of\x20rapamycin\x20(<strong>mTOR</strong>).\x20mTOR\x20is\x20a\x20protein\x20kinase\x20that\x20blocks\x20cell\x20cycle\x20progression\x20at\x20the\x20G1\x20phase\x20to\x20S\x20phase\x20transition.\x20It\x20is\x20used\x20in\x20the\x20prophylaxis\x20of\x20organ\x20transplant\x20rejection.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201218\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p><strong>Imatinib&nbsp;</strong>is\x20a\x20first-generation&nbsp;<strong>tyrosine\x20kinase\x20inhibitor.\x20</strong>Imatinib\x20attacks\x20<strong>BCR-ABL\x20translocation</strong>&nbsp;and\x20is\x20used\x20in&nbsp;<strong>chronic\x20myelocytic\x20leukemia.</strong>\x20It\x20also\x20inhibits\x20c-kit\x20and\x20produces\x20extended\x20control\x20of\x20<strong>GI\x20stromal\x20tumors</strong>.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','TzZIm','avgTimeResult','xvZFv','<p><strong>Beta\x20lactams</strong>\x20act\x20on\x20<strong>step\x204</strong>\x20in\x20the\x20given\x20image.</p>\x0a<p>Mechanism\x20of\x20action\x20of\x20beta-lactams:\x20They\x20are\x20the\x20<strong>cell\x20wall\x20synthesis\x20inhibitor</strong>.\x20The\x20β-lactam\x20antibiotics\x20inhibit\x20this\x20last\x20step\x20in\x20peptidoglycan\x20synthesis.\x20They\x20inhibit\x20the\x20enzyme\u00a0<strong>transpeptidase</strong>\u00a0which\x20is\x20required\x20for\x20cross-linking\x20of\x20the\x20peptidoglycan\x20chain.\x20Transpeptidases\x20cleave\x20the\x20terminal\x20<strong>D-alanine</strong>\x20of\x20the\x20peptide\x20chains\x20and\x20form\x20cross-linkages\x20between\x20them.\x20This\x20cross-linking\x20provides\x20<strong>rigidity</strong>\x20and\x20stability\x20to\x20the\x20cell\x20wall.\u00a0\x20\u00a0</p>\x0a<p>Transpeptidases\x20and\x20other\x20related\x20proteins\x20constitute\x20<strong>penicillin-binding\x20proteins(PBP)</strong>\x20and,\x20are\x20located\x20in\x20the\x20bacterial\x20cell\x20membrane.\x20β-lactam\x20antibiotics\x20are\x20<strong>bactericidal</strong>.\x20This\x20is\x20because\x20bacterias\x20swell\x20and\x20burst\x20due\x20to\x20deficient\x20cell\x20walls\x20when\x20they\x20divide\x20in\x20the\x20presence\x20of\x20β-lactam\x20antibiotics.\x20<strong>Penicillins,\x20cephalosporins,\x20monobactams</strong>,\x20and\x20<strong>carbapenems</strong>\x20are\x20examples\x20of\x20β-lactam\x20antibiotics.</p>\x0a<p><strong>Gram-positive\x20bacteria</strong>\x20are\x20more\x20susceptible\x20to\x20β-lactam\x20antibiotics\x20than\x20gram-negative\x20because\x20their\x20cell\x20wall\x20is\x20almost\x20entirely\x20made\x20of\x20peptidoglycan.</p>\x0a<p>Resistance\x20to\u00a0β-lactam\x20antibiotics\x20develops\x20due\x20to\x20the\x20production\x20of\x20the<strong>\x20beta-lactamase</strong>\x20enzyme\x20and\x20the\x20development\x20of\x20altered\x20penicillin-binding\x20proteins\x20like\x20in\x20methicillin-resistant\x20<em>Staphylococcus\x20aureus</em>\x20(<strong>MRSA</strong>).\x20β-lactamases\u00a0inactivate\x20β-lactam\x20antibiotics\x20by\x20opening\x20the\x20β-lactam\x20ring.\x20This\x20could\x20be\x20overcome\x20by\x20using\x20drugs\x20that\u00a0inhibit\x20this\x20enzyme.\x20Examples\x20of\x20<strong>β-lactamase\x20inhibitors</strong>\x20are\x20<strong>clavulanic\x20acid</strong>,\x20<strong>sulbactam</strong>,\x20and\x20<strong>tazobactam.</strong></p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Fosfomycin</strong>\x20inhibits\x20<strong>step\x201</strong>\x20in\x20the\x20image.\x20It\x20inhibits\x20the\x20cytoplasmic\x20enzyme<strong>\u00a0enol\x20pyruvate\x20transferase\x20</strong>that\x20catalyses\x20the\x20initial\x20step\x20in\x20the\x20bacterial\x20cell\x20wall\x20and\x20hence\x20cell\x20wall\x20synthesis.\x20It\x20is\x20used\x20for\x20the\x20treatment\x20of\x20urinary\x20tract\x20infections.</p>\x0a<p>Option\x20B:\x20<strong>Bacitracin</strong>\x20inhibits\x20<strong>step\x202</strong>\x20in\x20the\x20image.\x20It\x20is\x20a\x20cell\x20wall\x20synthesis\x20inhibitor\x20that\x20interferes\x20with\u00a0<strong>dephosphorylation</strong>\x20in\x20the\x20cycling\x20of\x20the\x20<strong>lipid\x20carrier</strong>\x20which\x20transfers\u00a0peptidoglycan\x20subunits\x20to\x20the\x20growing\x20cell\x20wall.\x20It\x20is\x20only\x20given\x20for\x20topical\x20application\x20because\x20of\x20its\x20severe\x20nephrotoxicity\x20when\x20given\x20systemically.</p>\x0a<p>Option\x20C:\x20<strong>Vancomycin</strong>\x20inhibits\x20<strong>step\x203</strong>\x20in\x20the\x20image.\x20It\x20binds\x20to\x20the\x20<strong>D-Ala-D-Ala\x20terminus</strong>\x20of\x20the\x20newly\x20formed\x20peptidoglycan\x20pentapeptide.\x20This\x20<strong>prevents\x20further\x20elongation</strong>\x20of\x20<strong>the\x20peptidoglycan</strong>\x20and\x20its\x20cross-linking.\x20It\x20is\x20used\x20against\x20MRSA\x20and\x20<em><strong>Clostridium\x20difficile\x20</strong></em>infection.\x20<strong>Redman\x20syndrome</strong>\x20due\x20to\x20histamine\x20release\x20following\x20infusion\x20is\x20an\x20important\x20side\x20effect.</p>\x0a<p>Note:\x20The\x20FDA\x20has\x20approved\x20the\x20use\x20of\x20<strong>cefepime-enmetazobactam</strong>,\x20a\x20combination\x20of\x20a\x20fourth-generation\x20cephalosporin\x20and\x20beta-lactamase\x20inhibitor\x20for\x20use\x20in<strong>\x20complicated\x20UTI</strong>s\x20(including\x20pyelonephritis).</p>','Which\x20of\x20the\x20following\x20statement\x20is\x20correct\x20regarding\x20the\x20given\x20graph?','solutionVideo','<p>The\x20correctly\x20matched\x20pairs\x20of\x20teratogenic\x20drugs\x20and\x20their\x20effects\x20is\x20<strong>1-d,\x202-c,\x203-b,\x204-a</strong>.</p>\x0a<p><span\x20data-preserver-spaces=\x22true\x22>Lithium\x20use\x20in\x20early\x20pregnancy\x20causes\x20<strong>Ebstein\x20anomaly</strong>\x20in\x20the\x20fetus.\x20Fetal\x20lithium\x20exposure\x20is\x20associated\x20with\x20<strong>neonatal\x20goiter</strong>,\x20CNS\x20depression,\x20hypotonia\x20(floppy\x20baby\x20syndrome),\x20and\x20cardiac\x20murmur.</span></p>\x0a<p><strong>Gray\x20baby\x20syndrome\x20</strong>occurs\x20in\x20neonates,\x20especially\x20premature\x20ones,\x20exposed\x20to&nbsp;<strong>high\x20doses\x20of\x20chloramphenicol&nbsp;</strong>(100\x20mg/kg),\x20which\x20are\x20administered\x20prophylactically.</p>\x0a<p><span\x20data-preserver-spaces=\x22true\x22><strong>Fetal\x20warfarin\x20syndrome\x20</strong>or<strong>\x20warfarin\x20embryopathy&nbsp;</strong>presents\x20with&nbsp;</span><span\x20data-preserver-spaces=\x22true\x22>CNS\x20abnormalities,\x20<strong>d</strong></span><span\x20data-preserver-spaces=\x22true\x22><strong>epressed\x20nasal\x20bridge</strong>/\x20saddle\x20nose\x20at\x20birth,\x20b</span><span\x20data-preserver-spaces=\x22true\x22>leeding\x20diathesis,\x20and\x20g</span><span\x20data-preserver-spaces=\x22true\x22>rowth\x20retardation.\x20Hypoplasia\x20of\x20the\x20nose,\x20eye\x20sockets,\x20and\x20long\x20bones\x20with\x20stippling\x20of\x20epiphyses\x20are\x20also\x20seen.</span></p>\x0a<p>Fetal\x20thalidomide\x20exposure\x20causes\x20phocomelia.\x20This\x20disorder\x20is\x20associated\x20with\x20<strong>underdeveloped\x20limbs</strong>\x20and\x20<strong>absent\x20pelvic\x20bones.</strong>\x20Both\x20<strong>upper</strong>\x20and\x20<strong>lower</strong>\x20limbs\x20are\x20<strong>affected</strong>,\x20and\x20a\x20part\x20of\x20the\x20limbs\x20may\x20be\x20missing.\x20Fused\x20fingers\x20and\x20missing\x20thumbs\x20are\x20also\x20seen.\x20Thalidomide\x20was\x20originally\x20used\x20for\x20the\x20treatment\x20of\x20<strong>pregnancy-associated\x20morning\x20sickness</strong>\x20but\x20was\x20<strong>withdrawn</strong>\x20due\x20to\x20this\x20adverse\x20effect.&nbsp;It\x20re-entered\x20the\x20market\x20for\x20the\x20treatment\x20of\x20erythema\x20nodosum\x20leprosum.\x20It\x20also\x20has&nbsp;<strong>antiangiogenic</strong>\x20and\x20<strong>immunomodulatory</strong>\x20effects.</p>\x0a<p>&nbsp;</p>','bipUa','1-c,\x202-d,\x203-a,\x204-b','<p>The\x20drug\x20that\x20increases\x20trabecular\x20outflow\x20is\x20<strong>netarsudil</strong>.</p>\x0a<p>Netarsudil\x20is\x20a\x20<strong>rho-kinase\x20inhibitor</strong>\x20used\x20in\x20the\x20treatment\x20and\x20management\x20of\x20<strong>glaucoma</strong>\x20and\x20ocular\x20hypertension.\x20It\x20lowers\x20the\x20intra-ocular\x20pressure\x20directly\x20through\x20the\x20relaxation\x20of\x20the\x20<strong>trabecular\x20meshwork</strong>,\x20leading\x20to\x20an\x20<strong>increase</strong>\x20in\x20<strong>aqueous\x20outflow</strong>.\x20It\x20also\x20reduces\x20aqueous\x20humor\x20production.&nbsp;</p>\x0a<p>Netarsudil\x20ophthalmic\x20solution\x20is\x20instilled\x20in\x20<strong>one\x20drop</strong>\x20into\x20the\x20affected\x20eye\x20once\x20daily\x20in\x20the\x20<strong>evening</strong>.\x20Adverse\x20effects\x20are\x20conjunctival\x20hyperemia,\x20and\x20<strong>corneal\x20verticillata</strong>.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A-\x20Timolol\x20is\x20a\x20<strong>non-selective&nbsp;&beta;-blocker</strong>\x20that\x20decreases\x20the\x20IOP\x20by\x20<strong>reducing</strong>\x20the\x20<strong>aqueous\x20humor\x20production</strong>\x20through\x20the\x20blockade\x20of\x20the&nbsp;<strong>&beta;-receptors</strong>\x20on\x20the\x20<strong>ciliary\x20epithelium.\x20</strong>Ocular\x20adverse\x20effects\x20are\x20allergy,\x20decreased\x20corneal\x20sensation,\x20and\x20<strong>punctate\x20keratitis.</strong></p>\x0a<p>Option\x20C-&nbsp;<strong>Brimonidine</strong>&nbsp;is\x20a\x20<strong>selective\x20alpha-2</strong>\x20<strong>agonist&nbsp;</strong>which\x20decreases\x20aqueous\x20synthesis\x20and\x20increases\x20<strong>uveoscleral\x20outflow</strong>.\x20It\x20can\x20cross\x20the\x20blood-brain\x20barrier\x20and,\x20hence,\x20causes\x20<strong>drowsiness\x20and\x20CNS\x20depression</strong>.\x20It\x20is&nbsp;<strong>contraindicated</strong>\x20in\x20<strong>infants</strong>\x20and\x20<strong>children</strong>.</p>\x0a<p>Option\x20D-\x20<strong>Acetazolamide</strong>\x20is\x20a\x20topical\x20<strong>carbonic\x20anhydrase\x20inhibitor</strong>\x20that\x20decreases\x20IOP\x20by\x20reducing\x20<strong>aqueous\x20formation</strong>.\x20The\x20main\x20adverse\x20effect\x20is\x20the\x20<strong>bitter\x20taste</strong>\x20following\x20administration.\x20It\x20is\x20<strong>contraindicated</strong>\x20in\x20people\x20with\x20allergies\x20to\x20sulfonamide\x20antibiotics.&nbsp;</p>','Zidovudine','https://dhmbxeygs57ff.cloudfront.net/uploads/8d7167c153aa42a5bdc0787fd454473ex1280x1252.JPEG','Blockage\x20of\x20voltage-gated\x20calcium\x20channels','4138446cqyXlL','reload','Are\x20you\x20sure\x20you\x20want\x20to\x20submit\x20the\x20quiz?','https://cdn1.dailyrounds.org/uploads/b742dd38b7fe4bfb8634f08f18183953.JPEG','notAttempted','<div\x20class=\x22p-3\x20rounded-lg\x20border\x20','Marked','PYQ','A,B,D','A\x20patient\x20with\x20erectile\x20dysfunction\x20is\x20given\x20sildenafil.\x20The\x20penile\x20erectile\x20function\x20is\x20found\x20to\x20be\x20improved\x20after\x20the\x20therapy.\x20Which\x20of\x20the\x20following\x20mediates\x20the\x20action\x20of\x20sildenafil?','mlPch','akeZA','A\x20-\x20Aspirin,\x20B\x20-\x20Prasugrel,\x20C\x20-\x20Eptifibatide','WtCTI','Paracetamol','accuracyScore','red','A\x20patient\x20who\x20is\x20a\x20known\x20addict\x20is\x20brought\x20to\x20the\x20hospital\x20with\x20the\x20intoxication\x20of\x20an\x20agent.\x20An\x20ocular\x20examination\x20shows\x20the\x20following\x20finding.\x20Which\x20of\x20the\x20following\x20is\x20true\x20regarding\x20this\x20condition?','getItem','AkjIA','toLowerCase','A-3,\x20B-4\x20,\x20C-2\x20,\x20D-1','A-1,\x20B-2,\x20C-4,\x20D-3','custom_quiz.html','STqfS','scttb','DZEXR','Jzprt','cfIPE','IIzNA','vXKLO','<div\x20class=\x22mt-4\x22><video\x20id=\x22review-video-','dJHXh','cGMP','hajmn','Alprazolam','ykLXg','ExYZA','<p>Option\x20C:&nbsp;<strong>Oxcarbazepine\x20</strong>was\x20earlier\x20associated\x20with\x20teratogenicity\x20and\x20fetal\x20malformations,\x20however,\x20recent\x20studies\x20suggest\x20that\x20oxcarbazepine\x20monotherapy\x20during\x20pregnancy\x20does\x20not\x20carry\x20a\x20significant\x20risk\x20of\x20fetal\x20malformations.</p>\x0a<p>Option\x20D:&nbsp;<strong>Olanzapine</strong>&nbsp;is\x20an\x20antipsychotic\x20and\x20an\x20antimanic\x20and\x20it\x20is\x20not\x20associated\x20with&nbsp;teratogenicity.&nbsp;</p>','MAzub','KKWMC','EMzGc','questionIndex','NznxF','ijZSl','now','study','nav-btn-answered','toString','90\x20hours','Potency\x20of\x20drug\x20B\x20is\x20more\x20than\x20that\x20of\x20drug\x20A.','pCaKh','<div\x20class=\x22mt-4\x22><img\x20src=\x22','test','reviewQuestionsContainer','Furosemide','DDddo','aGLaY','EVGFF','XcMkf','AYmBb','.m3u8','solution','BPMzZ','1-d,\x202-c,\x203-a,\x204-b','Phase\x202','They\x20can\x20be\x20given\x20with\x20verapamil\x20and\x20other\x20enzyme\x20inhibitors.','A-2,\x20B-3,\x20C-1,\x20D-4','Calcium\x20channel\x20blockers','xXYTY','Rosuvastatin\x2010\x20mg','Phospholipase\x20C\x20acts\x20via\x20which\x20of\x20the\x20following\x20G\x20protein-coupled\x20receptors?','Enfuvirtide','uPujY','A\x20-\x20Aspirin,\x20B\x20-\x20Eptifibatide,\x20C\x20-\x20Prasugrel','submitSection','strokeDasharray','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22mb-4\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22flex\x20justify-between\x20items-center\x20mb-3\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h4\x20class=\x22text-lg\x20font-bold\x20text-white\x22>Question\x20','rswCp','Timolol','Hyponatremia','MrLlU','ysSZC','iUxHW','mQeOm','Phase\x203\x20is\x20always\x20double-blinded','Topically\x20applied\x20sulfonamide\x20antibacterial','CPLxV','Only\x203','Strong\x20electrolytes','gGSep','review-question\x20','This\x20action\x20can\x20be\x20reversed\x20by\x20phenylephrine.','quizPerformanceData','fill','HuAhA','DjPEL','nIctD','xOIWb','question_images','href','Nivolumab','https://dhmbxeygs57ff.cloudfront.net/uploads/672ca9540c3b4fe7b9d71a5ec95b1f1dx1280x1585.JPEG','HXgsN','PaPHJ','pXosA','Match\x20the\x20following\x20diuretics\x20in\x20column\x20A\x20to\x20their\x20site\x20of\x20action\x20in\x20column\x20B.','Nfhul','correctCount','Rosuvastatin\x20+\x20Fenofibrate','45\x20hours','CTHnP','Progress\x20loaded.','The\x20manufacturer\x20of\x20a\x20drug\x20company\x20labels\x20a\x20drug\x20as\x20having\x20500\x20mg\x20paracetamol.\x20On\x20quantitative\x20analysis\x20of\x20the\x20drug,\x20it\x20actually\x20contained\x20only\x20200\x20mg\x20of\x20paracetamol.\x20What\x20is\x20this\x20type\x20of\x20drug\x20called?','endsWith','NKwyM','ldlNJ','318765YouOka','status','selected','sgMLc','VeHMW','95380jjfGBM','navBtn_','A,C,D','Verapamil\x20-\x20constipation','QBJlQ','Diclofenac','gMcGl','\x22><span\x20class=\x22font-bold\x20mr-3\x22>','Synthesized\x20from\x20arachidonic\x20acid','A\x20-\x20Aspirin,\x20B\x20-Vorapaxar,\x20C\x20-\x20Prasugrel','Ilazp','oKeuP','fnDoA','getElementById','https://dhmbxeygs57ff.cloudfront.net/uploads/faee105612ff4db99088f395111a460ex1280x1008.JPEG','bXcsa','Inj.\x20Amphotericin\x20B\x204-8\x20weeks,\x20followed\x20by\x20oral\x20itraconazole','Aliskiren\x20-\x20hypokalemia','Opioid\x20receptor\x20agonist','ADYLz','ttBeu','search','UOZfc','not_attempted','gVkTL','lNZxy','FGkKz','Which\x20of\x20the\x20following\x20drugs\x20increases\x20trabecular\x20outflow?','Phase\x203','<p>The\x20most\x20likely\x20drug\x20causing\x20hyperpigmentation\x20of\x20the\x20hands\x20and\x20soles\x20would\x20be\x20<strong>emtricitabine.&nbsp;</strong></p>\x0a<p>Emtricitabine\x20is\x20an\x20anti-retroviral\x20drug\x20that\x20acts\x20by\x20<strong>inhibiting\x20nucleoside\x20reverse\x20transcriptase</strong>\x20(<strong>NRTI</strong>).\x20It\x20is\x20well-tolerated\x20and\x20has\x20minimal\x20toxic\x20effects.\x20Adverse\x20effects\x20include\x20<strong>hyperpigmentation</strong>\x20of<strong>&nbsp;</strong>the\x20<strong>skin</strong>\x20(especially\x20sun-exposed\x20areas,\x20palms,\x20and\x20soles),\x20headache,\x20vomiting,\x20and\x20nausea.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20Nelfinavir\x20is\x20a\x20protease\x20inhibitor\x20that\x20causes\x20<strong>diarrhea</strong>\x20or\x20loose\x20stools.\x20It\x20usually\x20<strong>resolves\x20within\x20a\x20month</strong>\x20of\x20starting\x20the\x20drug.&nbsp;</p>\x0a<p>Option\x20C:\x20Abacavir\x20is\x20an\x20NRTI\x20that\x20can\x20cause\x20a\x20life-threatening\x20hypersensitivity\x20syndrome.\x20The\x20syndrome\x20presents\x20with\x20<strong>fever,\x20abdominal\x20pain,</strong>\x20and&nbsp;<strong>maculopapular\x20rash</strong>&nbsp;<strong>within\x206\x20weeks</strong>\x20of\x20initiating\x20abacavir.\x20The\x20drug\x20must\x20be\x20immediately\x20discontinued\x20and\x20must\x20not\x20be\x20administered\x20to\x20the\x20patient\x20thereafter.\x20Rarely,\x20there\x20might\x20be\x20respiratory\x20and\x20musculoskeletal\x20side\x20effects.&nbsp;</p>\x0a<p>Option\x20D:\x20Zidovudine\x20is\x20an\x20NRTI\x20that\x20causes\x20malaise,\x20fatigue,\x20myalgia,\x20anorexia,\x20and\x20insomnia.\x20Chronic\x20use\x20leads\x20to\x20<strong>nail\x20hyperpigmentation</strong>.\x20It\x20can\x20also\x20cause\x20bone\x20marrow\x20suppression.</p>','Tenofovir','data-option-index','<p><strong>Dipivefrine\x20</strong>and<strong>\x20dopexamine\x20</strong>are&nbsp;&beta;<sub>2</sub>-adrenergic\x20receptor\x20agonists.</p>\x0a<p><strong>Dipivefrine</strong>\x20causes\x20a\x20decrease\x20in\x20aqueous\x20production\x20and\x20increases\x20outflow.\x20It\x20was\x20used\x20in\x20the\x20treatment\x20of<strong>\x20open-angle\x20glaucoma</strong>\x20and<strong>\x20ocular\x20hypertension</strong>&nbsp;but\x20has\x20since\x20been\x20replaced.</p>\x0a<p><strong>Dopexamine</strong>\x20is\x20a\x20synthetic\x20analogue\x20related\x20to\x20dopamine\x20with\x20activity\x20at\x20<strong>D1\x20</strong>and\x20<strong>D2</strong>\x20receptors\x20as\x20well\x20as\x20at\x20<strong>&beta;2\x20receptors</strong>.\x20It\x20is\x20used\x20in\x20patients\x20with\x20severe\x20congestive\x20heart\x20failure,\x20sepsis,\x20and\x20shock.</p>\x0a<p>Other\x20options:</p>\x0a<p>B.\x20<strong>Fenoldopam</strong>\x20is\x20a\x20peripheral\x20<strong>D1\x20agonist</strong>\x20with\x20moderate\x20affinity\x20for\x20<strong>&alpha;2-adrenergic\x20receptors</strong>.\x20It\x20is\x20a\x20rapidly\x20acting\x20<strong>vasodilator</strong>\x20that\x20is\x20used\x20in\x20<strong>severe\x20hypertension.</strong></p>\x0a<p>D.\x20<strong>Mirabegron</strong>\x20is\x20a\x20<strong>&beta;3-adrenergic\x20receptor\x20agonist</strong>\x20which\x20is\x20used\x20for\x20<strong>bladder\x20incontinence</strong>.\x20Activation\x20of\x20this\x20receptor\x20in\x20the\x20bladder\x20leads\x20to\x20detrusor\x20muscle\x20relaxation\x20and\x20increased\x20bladder\x20capacity.\x20This\x20action\x20prevents\x20voiding\x20and\x20provides\x20relief\x20for\x20those\x20with\x20an\x20overactive\x20bladder\x20and\x20urinary\x20incontinence.&nbsp;&nbsp;</p>','Bookmarked','Misbranded\x20drug','<div\x20class=\x22ng-star-inserted\x22>\x0a<div\x20class=\x22table-responsive\x20font-weight-light\x20answer-scroll\x20ng-star-inserted\x22>\x0a<p>Treatment\x20of\x20the\x20infection\x20includes\x204\x20steps:</p>\x0a<ol>\x0a<li>Initiation\x20of\x20therapy\x20<strong>(amphotericin</strong>\x20<strong>B</strong>)\x20as\x20early\x20as\x20possible.\x20Posaconazole\x20can\x20also\x20be\x20used\x20in\x20the\x20management\x20of\x20this\x20condition.</li>\x0a<li><strong>Surgical</strong>\x20debridement</li>\x0a<li><strong>Reversal</strong>\x20of\x20underlying\x20conditions\x20and\x20<strong>risk\x20factors</strong></li>\x0a<li><strong>Treatment</strong>\x20of\x20underlying\x20<strong>malignancy</strong>\x20if\x20present</li>\x0a</ol>\x0a<p><strong>Amphotericin\x20B</strong>&nbsp;is\x20a\x20<strong>broad-spectrum\x20antifungal</strong>.&nbsp;It&nbsp;binds\x20to\x20<strong>ergosterol</strong>\x20in\x20the\x20fungal\x20membrane\x20and\x20forms\x20<strong>pores\x20or\x20channels</strong>\x20in\x20the<strong>\x20fungal\x20cell\x20membrane</strong>.\x20This\x20allows\x20the\x20leakage\x20of\x20cytosolic\x20molecules\x20and\x20ions,\x20leading\x20to\x20a\x20loss\x20of\x20membrane\x20integrity.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Itraconazole\x20</strong>can\x20be\x20used\x20for\x20the\x20treatment\x20of\x20<strong>chronic</strong>\x20aspergillosis\x20if\x20there\x20is\x20<strong>resistance\x20</strong>or<strong>\x20failure\x20of\x20voriconazole</strong>.&nbsp;<span\x20data-preserver-spaces=\x22true\x22><span\x20class=\x22s1\x22><strong>Ketoconazole\x20</strong>is\x20used\x20for\x20both\x20<strong>dermatophytosis</strong>\x20and\x20deep\x20mycosis,\x20but\x20it\x20has\x20been\x20replaced\x20by\x20<strong>itraconazole</strong>.</span></span></p>\x0a<p><span\x20data-preserver-spaces=\x22true\x22><span\x20class=\x22s1\x22>Option\x20C:\x20<strong>Fluconazole\x20</strong>is\x20used\x20for\x20the\x20treatment\x20of\x20<strong>candidiasis</strong>&nbsp;and\x20cryptococcosis.</span></span></p>\x0a<p>Option\x20D:\x20<strong>Amphotericin\x20B</strong>&nbsp;in\x20combination\x20with\x205-flucytosine\x20is\x20used\x20as&nbsp;<strong>induction\x20treatment</strong>\x20for\x20<strong>cryptococcal\x20meningitis.</strong>&nbsp;</p>\x0a</div>\x0a</div>','1603130JCyLjH','These\x20drugs\x20should\x20not\x20be\x20stopped\x20even\x20in\x20severe\x20conditions\x20like\x20injury,\x20surgery,\x20etc.','\x22\x20controls\x20class=\x22w-full\x20rounded-lg\x22></video></div>','Mark\x20for\x20Review','click','9366520SEKpfu','COdbj','optionsContainer','dQOBA','attachMedia','cERNh','CxNoq','not-attempted','none','name','You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','hZiEj','Mmdbr','Emtricitabine','round','GVFRe','qAJLC','title','NAPQI\x20is\x20the\x20metabolite\x20of\x20which\x20of\x20the\x20following\x20drug\x20toxicity?','AOJhN','markedForReview','yCFmk','Atezolimumab','ZGYYI','qIAnz','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English:</p><audio\x20src=\x22','GOHaS','A-3,\x20B-2,\x20C-4,\x20D-1','DfSQY','getAttribute','oWlPD','BeJnH','vGCMB','aAQiO','push','pmste','Avpzh','https://dhmbxeygs57ff.cloudfront.net/uploads/52b96313ea0e49d49c0cf2421b8a135cx720x527.PNG','bJYfo','Drug\x203\x20represents\x20agonist\x20and\x20drug\x204\x20represents\x20inverse\x20agonist','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22','ZRomv','Lithium','https://cdn1.dailyrounds.org/uploads/bef9557aa4ee45d5ac653541181d4996.JPEG','What\x20is\x20the\x20mechanism\x20of\x20action\x20of\x20sildenafil?','https://cdn1.dailyrounds.org/uploads/1cdc3b043f0b47cbac9a11aee230237c.JPEG','questionStates','jOSoq','qSSbL','EfQzB','Which\x20among\x20the\x20following\x20is\x20the\x20false\x20statement\x20regarding\x20statins?','fCojv','Isoniazid','text','bookmarked','trace','XFqbK','<p><strong>Canagliflozin</strong>\x20is\x20associated\x20with\x20an\x20increased\x20risk\x20of\x20<strong>fractures</strong>.&nbsp;</p>\x0a<p>Canagliflozin\x20is\x20a\x20<strong>sodium-glucose\x20transporter-2\x20</strong>(SGLT2)\x20inhibitor.\x20SGLT2\x20is\x20a\x20Na+-glucose\x20<strong>cotransporter</strong>\x20that\x20is\x20located\x20in\x20the\x20<strong>proximal\x20convoluted\x20tubule</strong>.\x20They\x20reabsorb\x20glucose\x20and\x20sodium\x20from\x20the\x20tubular\x20lumen\x20back\x20into\x20the\x20blood\x20through\x20the\x20epithelial\x20cells.\x20SGLT2\x20inhibitors\x20block\x20the\x20transport\x20of\x20glucose&nbsp;in\x20the\x20proximal\x20tubule\x20and\x20promote\x20<strong>glycosuria</strong>\x20and\x20hence,&nbsp;lowering\x20blood\x20glucose.</p>\x0a<p>The\x20currently\x20available\x20SGLT2\x20inhibitors\x20are\x20canagliflozin,\x20dapagliflozin,\x20and\x20empagliflozin.\x20Other\x20than\x20decreasing\x20blood\x20glucose\x20they\x20also\x20decrease&nbsp;blood\x20pressure\x20and,&nbsp;cause\x20<strong>weight\x20loss</strong>\x20of\x202&ndash;4\x20kg.\x20Empagliflozin\x20and\x20canagliflozin\x20reduce\x20the\x20risk\x20for\x20major\x20cardiovascular\x20events.</p>\x0a<p>The\x20main\x20side\x20effect\x20of\x20SGLT2\x20inhibitors\x20is\x20an\x20increase\x20in\x20<strong>lower\x20urinary\x20tract\x20infections</strong>\x20and&nbsp;genital\x20mycotic\x20infections.\x20This\x20is\x20because\x20of\x20their\x20glycosuric\x20properties.\x20A\x20recent\x20warning\x20from\x20the\x20FDA\x20says\x20that\x20SGLT2\x20inhibitors\x20may\x20increase\x20the\x20risk\x20of\x20<strong>fractures</strong>.\x20They\x20also<strong>&nbsp;</strong>affect&nbsp;circulating\x20levels\x20of\x20parathyroid\x20hormone,\x20and\x201,25-hydroxy\x20vitamin\x20D\x20thereby\x20affecting&nbsp;the\x20mineral\x20balance\x20in\x20bone.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Rosiglitazone</strong>\x20is\x20a\x20thiazolidinedione\x20that\x20acts\x20as\x20a\x20peroxisome\x20proliferator-activated\x20receptor\x20&gamma;\x20agonist\x20in\x20the\x20adipose\x20tissue\x20which\x20increases\x20insulin\x20sensitivity\x20and\x20adipose\x20differentiation.\x20Side\x20effects\x20are\x20<strong>weight\x20gain,\x20edema,&nbsp;</strong>and<strong>\x20increased\x20risk\x20of\x20fractures.</strong>&nbsp;Compared\x20to\x20rosiglitazone,\x20canagliflozin\x20is\x20commonly\x20used\x20in\x20clinical\x20practice.\x20American\x20diabetes\x20association\x20recommends\x20canagliflozin\x20as\x20the\x20first-line\x20drug\x20along\x20with\x20metformin,\x20in\x20patients\x20with\x20a\x20high\x20risk\x20of\x20cardiovascular\x20disease,\x20renal\x20failure,\x20and\x20heart\x20failure.\x20Even\x20when\x20thiazolidinediones\x20are\x20required,\x20clinicians\x20prefer\x20pioglitazone\x20over\x20rosiglitazone\x20due\x20to\x20the\x20higher\x20risk\x20of\x20cardiovascular-related\x20mortality\x20in\x20rosiglitazone.\x20Therefore,\x20<strong>canagliflozin</strong>\x20would\x20be\x20a\x20<strong>better</strong>\x20option\x20compared\x20to\x20rosiglitazone.&nbsp;</p>\x0a<div\x20class=\x22ng-star-inserted\x22>\x0a<div\x20class=\x22table-responsive\x20font-weight-light\x20answer-scroll\x20ng-star-inserted\x22>\x0a<p>Option\x20B:\x20<strong>Liraglutide</strong>\x20is\x20a\x20long-acting\x20glucagon-like\x20peptide-1\x20agonist.\x20Nausea,\x20diarrhea,\x20and\x20<strong>acute\x20pancreatitis</strong>\x20are\x20some\x20frequent\x20side\x20effects.</p>\x0a</div>\x0a</div>\x0a<p>Option\x20C:\x20<strong>Voglibose</strong>\x20reduces\x20the\x20intestinal\x20absorption\x20of\x20starch,\x20dextrin,\x20and\x20disaccharides\x20by\x20inhibiting\x20the\x20action\x20of<strong>\x20&alpha;-glucosidase\x20</strong>in\x20the\x20intestinal\x20brush\x20border.\x20The\x20most\x20prominent\x20adverse\x20effects\x20are\x20malabsorption,\x20flatulence,\x20diarrhea,\x20and\x20abdominal\x20bloating.</p>','map','<p><strong>Phospholipase\x20C</strong>\x20acts\x20via\x20the&nbsp;<strong>Gq</strong>\x20type\x20of\x20G\x20protein-coupled\x20receptors.</p>\x0a<p><strong>G\x20protein-coupled\x20receptors</strong>\x20(GPCRs)\x20are<strong>&nbsp;cell\x20membrane\x20receptors</strong>&nbsp;that\x20span\x20across\x20the\x20membrane\x207\x20times.\x20They\x20also\x20serve\x20as\x20receptors\x20for\x20various\x20<strong>peptide\x20hormones</strong>,\x20neurotransmitters,\x20amino\x20acids,\x20etc.</p>\x0a<p>Subtypes\x20of\x20GPCRs\x20are\x20distinguished\x20by\x20their\x20alpha\x20subunits.\x20The\x20important\x20subtypes\x20of\x20GPCRs\x20are\x20Gs,\x20Gp,\x20<strong>Gq</strong>,\x20and\x20Go.</p>\x0a<p>GPCRs\x20act\x20via\x20various\x20second\x20messengers.&nbsp;The\x20important\x20ones\x20with\x20their\x20action\x20on\x20the\x20effector\x20are:</p>\x0a<ul>\x0a<li>Gs\x20causes\x20activation\x20of\x20adenylyl\x20cyclase\x20and\x20results\x20in\x20Ca2+\x20channel\x20opening.</li>\x0a<li>Gi\x20causes\x20inhibition\x20of\x20adenylyl\x20cyclase\x20and\x20results\x20in\x20K+\x20channel\x20opening.</li>\x0a<li>Go\x20causes\x20Ca2+\x20channel\x20inhibition.</li>\x0a<li><strong>Gq</strong>\x20causes\x20activation\x20of\x20<strong>p</strong><strong>hospholipase\x20C</strong>&nbsp;which\x20generates\x20the\x20second\x20messengers\x20inositol\x201,4,5-trisphosphate\x20(<strong>IP3</strong>)\x20and\x20diacylglycerol\x20(<strong>DAG</strong>).\x20The&nbsp;water-soluble\x20IP3\x20diffuses\x20to\x20the\x20cytosol\x20and\x20mobilizes\x20<strong>Ca2+</strong>\x20from\x20endoplasmic\x20reticular\x20depots.</li>\x0a</ul>\x0a<p>The\x20given\x20below\x20image\x20shows\x20the\x20effects\x20of\x20phospholipase\x20C\x20after\x20activation\x20by\x20<strong>Gq</strong></p>','return\x20(function()\x20','BYvOX','Diazepam','3|0|4|1|2|5','IDVMA','NUkVG','ZLDLN','smwNr','<p>Finasteride\x20is\x20used\x20to\x20treat\x20male\x20pattern\x20baldness\x20acts\x20by\x20inhibiting&nbsp;<strong>5-alpha\x20reductase.</strong></p>\x0a<p>Finasteride&nbsp;is\x20a\x20competitive\x20inhibitor\x20of\x20the&nbsp;5-alpha-reductase\x20enzyme\x20that<strong>\x20inhibits\x20the\x20conversion</strong>\x20of\x20<strong>testosterone</strong>\x20into\x20its\x20active\x20form\x20<strong>dihydrotestosterone</strong>\x20(DHT).&nbsp;</p>\x0a<p>Finasteride\x20inhibits\x20<strong>type\x202\x205-alpha\x20reductase</strong>\x20within\x20the\x20hair\x20follicle\x20and\x20reduces\x20the\x20production\x20of\x20DHT.\x20Hence,\x20it\x20is\x20used\x20in\x20the\x20treatment\x20of\x20male\x20pattern\x20hair\x20loss.\x20But,&nbsp;<strong>new\x20hair\x20growth\x20will\x20be\x20lost</strong>\x20when\x20finasteride\x20is\x20discontinued,\x20similar\x20to\x20minoxidil.</p>\x0a<p>On\x20long-term\x20use\x20(nearly\x206\x20months),\x20it\x20produces\x20an\x20effect\x20by\x20<strong>reducing\x20prostatic\x20epithelial\x20cell\x20proliferation,&nbsp;</strong>thereby\x20reducing\x20the\x20size\x20of\x20the\x20prostate\x20and\x20improving\x20urine\x20flow.</p>\x0a<p>Adverse\x20effects\x20of\x20finasteride:</p>\x0a<ul>\x0a<li>Decreased\x20libido</li>\x0a<li>Erectile\x20dysfunction</li>\x0a<li>Ejaculation\x20disorder\x20and\x20decreased\x20ejaculate\x20volume</li>\x0a</ul>\x0a<p>Finasteride&nbsp;is\x20<strong>highly\x20teratogenic</strong>\x20and<strong>\x20pregnant\x20women</strong>\x20should\x20not\x20be\x20exposed\x20to\x20the\x20drug\x20because\x20of\x20the\x20<strong>potential\x20for\x20inducing\x20genital\x20abnormalities\x20in\x20male\x20fetuses.</strong></p>','Tmax','question_video','<p>The\x20new\x20FDA-approved\x20<strong>immune\x20checkpoint\x20inhibitor</strong>\x20for\x20carcinoma\x20endometrium\x20is\x20<strong>pembrolizumab</strong>.</p>\x0a<p>Pembrolizumab\x20acts\x20by\x20inhibiting\x20programmed\x20death\x20receptor\x20-\x201\x20(<strong>PD-1</strong>)\x20and\x20was\x20used\x20for\x20the\x20treatment\x20of&nbsp;<strong>advanced\x20melanoma</strong>.\x20Now,\x20the\x20FDA\x20has&nbsp;approved\x20the\x20use\x20of\x20pembrolizumab\x20for\x20any\x20cancer\x20with\x20mismatch\x20repair\x20(<strong>MMR</strong>)\x20deficiency\x20or\x20high\x20microsatellite\x20instability\x20(<strong>MSI-H</strong>).</p>\x0a<p>On\x20March\x2021,\x202022,\x20the\x20food\x20and\x20drug\x20administration\x20approved\x20pembrolizumab,\x20as\x20a\x20single\x20agent,\x20for\x20patients\x20with\x20<strong>advanced\x20endometrial\x20carcinoma</strong>\x20that\x20is\x20microsatellite\x20instability-high\x20(MSI-H)\x20or\x20mismatch\x20repair\x20deficient\x20(dMMR),\x20as\x20determined\x20by\x20an\x20FDA-approved\x20test.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:&nbsp;<strong>Nivolumab</strong>\x20is\x20an&nbsp;immune\x20checkpoint\x20inhibitor\x20that\x20acts\x20by\x20inhibiting\x20programmed\x20death\x20receptor\x20-\x201\x20(<strong>PD-1</strong>)\x20and\x20is\x20used\x20for\x20the\x20treatment\x20of&nbsp;<strong>advanced\x20melanoma\x20</strong>and<strong>&nbsp;</strong>relapsed/refractory<strong>&nbsp;classical\x20Hodgkin\x20lymphoma.</strong></p>\x0a<p>Option\x20C:<strong>&nbsp;\x20Trastuzumab&nbsp;</strong>is\x20a\x20monoclonal\x20antibody\x20that\x20inhibits\x20the\x20<strong>HER2\x20receptor</strong>.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>HER2-positive\x20breast\x20cancer</strong>.</p>\x0a<p>Option\x20D:&nbsp;<strong>Ipilimumab</strong>\x20is\x20a\x20monoclonal\x20antibody\x20that\x20binds\x20to\x20cytotoxic\x20T\x20lymphocyte&ndash;associated\x20Protein\x204\x20(<strong>CTLA-4</strong>)\x20and\x20is\x20approved\x20for\x20the\x20treatment\x20of\x20late-stage\x20<strong>melanoma</strong>.</p>','atmej','lEqvM','Amlodipine','A\x20-\x20Aspirin,\x20B\x20-\x20Eptifibatide,\x20C\x20-\x20Vorapaxar','Acetazolamide','mAlFZ','progressBar','70\x20hours','{}.constructor(\x22return\x20this\x22)(\x20)','innerHTML','replace','Abacavir','button','Marrow','<p><span\x20style=\x22font-size:\x2014px;\x22>The\x20correct\x20option\x20among\x20the\x20following\x20is<strong>\x20A,\x20C,\x20and\x20D.</strong></span></p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x2061\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Bioavailability\x20is\x20defined\x20as\x20the\x20<strong>fraction\x20</strong>of\x20a\x20<strong>drug</strong>\x20reaching<strong>\x20systemic\x20circulation\x20</strong>in\x20an&nbsp;unchanged\x20form\x20after\x20administration\x20by\x20any\x20route.<span\x20style=\x22font-size:\x2014px;\x22>&nbsp;The&nbsp;</span>area\x20under\x20the\x20blood\x20concentration-time\x20curve\x20(AUC)<span\x20style=\x22font-size:\x2014px;\x22>\x20is\x20proportional\x20to\x20the\x20dose\x20and\x20the\x20extent\x20of\x20bioavailability\x20for\x20a\x20drug.</span></p>\x0a</div>\x0a</div>\x0a</div>\x0a<p><strong>Bioavailability\x20(F)\x20=\x20Quantity\x20of\x20drug\x20reaching\x20systemic\x20circulation/Quantity\x20of\x20drug\x20administered</strong></p>\x0a<p>Bioavailability\x20depends\x20on\x20two\x20factors,\x20absorption\x20and&nbsp;1st\x20pass\x20metabolism.&nbsp;The\x20bioavailability\x20of\x20the\x20drug&nbsp;<strong>injected\x20intravenously</strong>\x20is\x20<strong>100%.</strong>&nbsp;But\x20it\x20is\x20lower&nbsp;after\x20<strong>oral\x20ingestion</strong>\x20because\x20of&nbsp;incomplete\x20absorption\x20and\x20first-pass&nbsp;metabolism\x20in\x20the\x20intestinal\x20wall\x20or\x20liver\x20and\x20lies\x20between\x20<strong>5%\x20to\x20&lt;100%</strong>.\x20The\x20bioavailability\x20of&nbsp;<strong>subcutaneous\x20</strong>and\x20<strong>intramuscular\x20</strong>routes\x20lies\x20between\x20<strong>75%\x20to&nbsp;<span\x20style=\x22font-size:\x2014px;\x22>&le;100%.</span></strong></p>\x0a<p>The\x20image\x20given\x20below\x20shows\x20the\x20difference\x20between\x20the\x20bioavailability\x20of\x20drugs\x20injected\x20intravenously\x20(IV)\x20and\x20administered\x20per\x20orally\x20(PO).\x20Note\x20the\x20area\x20under\x20the\x20respective\x20curves\x20shaded\x20in\x20red\x20and\x20blue\x20colors\x20which\x20represent\x20the\x20absorption\x20of\x20the\x20drug.</p>','className','The\x20extent\x20of\x20drug\x20absorption\x20is\x20represented\x20by:','RCCBn','A\x20young\x20man\x20sustained\x20a\x20scorpion\x20sting\x202\x20hours\x20ago.\x20On\x20examination,\x20his\x20blood\x20pressure\x20is\x20108/\x2060\x20mm\x20Hg;\x20HR,\x2072\x20beats/minute,\x20and\x20respiratory\x20rate,\x2032\x20breaths/minute.\x20He\x20also\x20complains\x20of\x20breathlessness.\x20How\x20do\x20you\x20manage\x20this\x20patient?','CAAQi','iDPUi','incorrect','jUDrs','ZBRLt','SRMnB','createElement','maLDg','Liraglutide','<p><strong>Sildenafil\x20</strong>is\x20a<strong>\x20phosphodiesterase\x205\x20inhibitor\x20</strong>and<strong>&nbsp;</strong>the<strong>&nbsp;</strong>action\x20of\x20the\x20drug\x20is\x20mediated\x20through<strong>\x20cGMP</strong>.\x20Erectile\x20dysfunction&nbsp;is\x20treated\x20by\x20phosphodiesterase-5&nbsp;(PDE-5)\x20inhibitors\x20like\x20sildenafil,\x20vardenafil,\x20and\x20tadalafil<strong>.&nbsp;</strong></p>\x0a<p>The\x20corpus\x20cavernosum\x20produces\x20nitric\x20oxide\x20during\x20arousal\x20that\x20stimulates\x20the\x20formation\x20of\x20cGMP.\x20cGMP\x20causes\x20relaxation\x20of\x20the\x20smooth\x20muscle\x20of\x20the\x20corpus\x20cavernosum\x20and\x20penile\x20arteries,\x20engorgement\x20of\x20the\x20corpus\x20cavernosum,\x20and\x20erection.&nbsp;</p>\x0a<p>The\x20above-mentioned\x20drugs<strong>\x20compete</strong>\x20for\x20<strong>cyclic\x20GMP</strong>,\x20binding\x20at\x20the\x20site\x20of\x20cyclic\x20GMP\x20hydrolysis\x20on\x20PDE5,\x20enhancing\x20the\x20<strong>accumulation\x20</strong>of<strong>\x20cGMP&nbsp;</strong>and\x20hence\x20used\x20in\x20the\x20management\x20of\x20erectile\x20dysfunction.\x20They\x20are\x20useful\x20in\x20treating\x20pulmonary\x20arterial\x20hypertension.</p>\x0a<p><strong>Adverse\x20effects</strong>\x20of\x20the\x20drug\x20are&nbsp;headache,\x20flushing,\x20nasal\x20congestion,\x20nasopharyngitis,\x20and\x20dyspepsia.&nbsp;Sildenafil\x20and\x20Vardenafil&nbsp;also\x20cause\x20<strong>retinal</strong>\x20<strong>PDE-6\x20inhibition</strong>\x20and\x20can\x20result\x20in\x20blurring\x20of\x20vision\x20and\x20<strong>blue-green\x20tinting\x20of\x20the\x20vision</strong>.</p>\x0a<p>&nbsp;</p>','120\x20hours','target','slUec','Which\x20of\x20the\x20following\x20is\x20the\x20most\x20effective\x20oral\x20drug\x20in\x20smoking\x20cessation?','join','Unethical\x20drug','explanation_video','nav-btn-marked-review','parse','kKwdM','UGiRn','Xoayp','GXzlA','referrer','https://dhmbxeygs57ff.cloudfront.net/uploads/796e4a43627f4b17b0530b4e3b118f9ex1280x2080.JPEG','The\x20given\x20diagram\x20shows\x20the\x20steps\x20in\x20bacterial\x20cell\x20wall\x20formation.\x20Identify\x20the\x20site\x20of\x20action\x20of\x20beta-lactam\x20antibiotics.','ouEmB','A\x20hospital\x20is\x20conducting\x20a\x20study\x20to\x20check\x20the\x20efficacy\x20of\x20statins\x20in\x20multiple\x20centers.\x20There\x20are\x204-5\x20patients\x20per\x20center\x20and\x20half\x20of\x20the\x20patients\x20receive\x20the\x20drug\x20and\x20the\x20other\x20half\x20receive\x20the\x20placebo.\x20Neither\x20the\x20patients\x20nor\x20clinicians\x20know\x20which\x20drug\x20is\x20being\x20administered.\x20What\x20phase\x20of\x20the\x20clinical\x20trial\x20describes\x20the\x20above\x20scenario?','CViqQ','cUdhn','questionText','split','Calcium','block','A-1,\x20B-3,\x20C-2,\x20D-4','totalTimeResult','ilsLS','Nicotinic\x20action\x20of\x20acetylcholine','COcRw','https://dhmbxeygs57ff.cloudfront.net/uploads/1fed3123012943dd8852893c0cf05c83x1279x914.JPEG','WaIuO','performanceModal','testModeLegend','VNosc','UqqXs','UlfYG','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','nsMxv','bVeYH','Muscle\x20fasciculations','Inhibition\x20of\x20phosphodiesterase-5','\x22\x20data-src=\x22','lIlsg','4850440ZDVgRh','Losartan','location','get','Quinidine','Drug\x201\x20represents\x20agonist\x20and\x20drug\x202\x20represents\x20inverse\x20agonist','correctAnswers','<p>The\x20correct\x20option\x20is\x20Option\x20C:&nbsp;<strong>1-a,\x202-d,\x203-b,\x204-c</strong></p>\x0a<p><strong>Quinidine\x20</strong>is\x20a<strong>&nbsp;class\x20IA</strong>\x20anti-arrhythmic\x20agent.\x20Class\x201a\x20agents\x20are\x20<strong>sodium\x20channel\x20blockers</strong>\x20with\x20significant\x20potassium\x20channel\x20blocking\x20properties.\x20This\x20slows\x20conduction\x20and\x20<strong>prolongs\x20the\x20QRS\x20duration\x20</strong>and\x20<strong>action\x20potential\x20duration</strong>.&nbsp;</p>\x0a<p><strong>Digoxin</strong>\x20is\x20a&nbsp;<strong>Na+\x20K+\x20ATPase\x20inhibitor</strong>\x20that\x20works\x20by\x20increasing\x20AV\x20node\x20refractoriness.</p>\x0a<p><strong>Esmolol</strong>&nbsp;is\x20a&nbsp;<strong>&beta;-receptor-blocker\x20</strong>and&nbsp;a<strong>&nbsp;class\x20II\x20antiarrhythmic.</strong></p>\x0a<p><strong>Ibutilide</strong>\x20is\x20a\x20<strong>class\x20III&nbsp;</strong>anti-arrhythmic\x20agent.\x20It\x20works\x20by\x20<strong>blocking\x20K+</strong>\x20channels.</p>','Canagliflozin','dFimx','New\x20drug\x20application\x20is\x20done\x20after\x20phase\x204','Polar\x20drugs','qYzPd','\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','https://dhmbxeygs57ff.cloudfront.net/uploads/222629548464450caaf40ff6f14c9debx1280x681.PNG','JYSVE','solutionText','wkaBl','YIRTb','1,\x203,\x20and\x204','5-alpha\x20reductase','DslDU','Phosphatidyl\x20glycerol\x20and\x20inositol\x20phosphate','remove','https://dhmbxeygs57ff.cloudfront.net/uploads/d2ce95171f29405e8b920760512c5d76x800x600.JPEG','ERlvb','keydown','pathname','RXsUS','tmHkj','<p>The\x20correct\x20match\x20is\x20as\x20follows:</p>\x0a<table\x20style=\x22height:\x20115px;\x22\x20width=\x22348\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20166.3px;\x22>Column\x20A</td>\x0a<td\x20style=\x22width:\x20166.3px;\x22>Column\x20B</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20166.3px;\x22>A.\x20Acetazolamide</td>\x0a<td\x20style=\x22width:\x20166.3px;\x22>4.\x20Proximal\x20convoluted\x20tubule</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20166.3px;\x22>B.\x20Torsemide</td>\x0a<td\x20style=\x22width:\x20166.3px;\x22>1.\x20Thick\x20ascending\x20loop\x20of\x20Henle</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20166.3px;\x22>C.\x20Chlorthalidone</td>\x0a<td\x20style=\x22width:\x20166.3px;\x22>3.\x20Distal\x20convoluted\x20tubule</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20166.3px;\x22>D.\x20Vasopressin</td>\x0a<td\x20style=\x22width:\x20166.3px;\x22>2.\x20Collecting\x20duct</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>&nbsp;</p>\x0a<p><strong>Acetazolamide,</strong>\x20a\x20<strong>carbonic\x20anhydrase\x20inhibitor,</strong>\x20acts\x20on\x20the\x20enzyme\x20in\x20epithelial\x20cells\x20of\x20the\x20<strong>proximal\x20convoluted\x20tubule.</strong>\x20Acetazolamide\x20is\x20mainly\x20used\x20in\x20patients\x20with\x20secondary\x20glaucoma\x20to\x20reduce\x20intra-ocular\x20pressure,\x20provide\x20symptomatic\x20relief\x20in\x20acute\x20mountain\x20sickness,\x20and\x20as\x20treatment\x20for\x20absence\x20seizures.</p>\x0a<p><strong>Torsemide,</strong>\x20a\x20loop\x20diuretic,\x20inhibits\x20the\x20Na<sup>+</sup>-K<sup>+</sup>-ATPase\x20symporter\x20in\x20the\x20<strong>thick\x20ascending\x20loop\x20of\x20Henle.</strong>&nbsp;It\x20is\x20used\x20in\x20<strong>acute\x20pulmonary\x20edema,</strong>\x20edema\x20associated\x20with\x20<strong>congestive\x20cardiac\x20failure,\x20hypertension</strong>\x20with\x20renal\x20insufficiency,\x20and\x20hyponatremia.</p>\x0a<p><strong>Chlorthalidone</strong>,\x20a\x20thiazide-like\x20diuretic,\x20inhibits\x20the<strong>\x20Na<sup>+</sup>-Cl<sup>-</sup>\x20symporter</strong>\x20in\x20the\x20<strong>distal\x20convoluted\x20tubule</strong>.\x20It\x20is\x20used\x20in&nbsp;<strong>hypertension\x20and</strong>&nbsp;in&nbsp;<strong>edema</strong>\x20associated\x20with\x20<strong>congestive\x20cardiac\x20failure,\x20hepatic\x20cirrhosis,</strong>\x20nephrotic\x20syndrome,\x20and\x20<strong>chronic\x20renal\x20failure</strong><strong>.</strong></p>\x0a<p><strong>Vasopressin</strong>,\x20also\x20known\x20as\x20<strong>anti-diuretic\x20hormone</strong>,\x20is\x20secreted\x20by\x20the\x20<strong>posterior\x20pituitary</strong>\x20and\x20mainly\x20acts\x20on\x20the\x20<strong>collecting\x20duct,</strong>\x20and\x20increases\x20the\x20<strong>reabsorption\x20of\x20water</strong>\x20(anti-diuresis).\x20Vasopressin\x20or\x20its\x20agonists\x20(such\x20as\x20desmopressin)\x20are\x20used\x20in\x20cases\x20of\x20<strong>diabetes\x20insipidus</strong>,\x20<strong>type\x20I\x20and\x20type\x20II\x20von\x20Willebrand\x27s\x20disease</strong>,\x20primary\x20nocturnal\x20enuresis,\x20and\x20postoperative\x20ileus.</p>','ONHKE','\x22\x20controls\x20class=\x22w-full\x22></audio></div>','OlFId','totalTime','Oxcarbazepine','HKdrC','explanationVideoPlayer','<p>The\x20<strong>false</strong>\x20statement\x20regarding\x20statins\x20is\x20that\x20they&nbsp;<strong>can\x20be\x20given\x20with\x20verapamil\x20and\x20other\x20enzyme\x20inhibitors</strong>.</p>\x0a<p>Statins\x20like\x20atorvastatin\x20and\x20rosuvastatin\x20are\x20metabolized\x20by\x20the\x20cytochrome\x203A4\x20enzymes\x20of\x20the\x20liver.\x20<strong>Verapamil</strong>\x20is\x20a\x20<strong>cytochrome\x203A4\x20inhibitor</strong>\x20and\x20may\x20interfere\x20with\x20statin\x20degradation.\x20This\x20leads\x20to\x20an\x20increase\x20in\x20serum\x20statin\x20levels.\x20The\x20most\x20important\x20feature\x20of\x20statin\x20toxicity\x20is\x20myopathy.\x20It\x20can\x20present\x20as\x20myalgia\x20but\x20can\x20sometimes\x20also\x20lead\x20to\x20fatal\x20<strong>rhabdomyolysis</strong>.&nbsp;</p>\x0a<p><strong>Statins</strong>&nbsp;are\x20the\x20most\x20commonly\x20used\x20hypolipidemic\x20drugs.\x20Statins\x20act\x20by&nbsp;<strong>inhibiting</strong>&nbsp;the\x20rate-limiting<strong>&nbsp;HMG-CoA\x20reductase</strong>&nbsp;enzyme,\x20which\x20in\x20turn&nbsp;<strong>inhibits\x20cholesterol\x20synthesis</strong>.\x20They\x20decrease\x20levels\x20of\x20low-density\x20lipoproteins\x20(LDL)\x20and\x20triglycerides\x20and\x20increase\x20the\x20levels\x20of\x20high-density\x20lipoproteins\x20(HDL)\x20in\x20plasma.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:<strong>\x20Lipoprotein\x20(lp)\x20a</strong>\x20is\x20an\x20LDL\x20molecule\x20that\x20has\x20apolipoprotein\x20b\x20and\x20an\x20additional\x20apolipoprotein\x20a.\x20Studies\x20indicate\x20that\x20these\x20molecules\x20are\x20atherogenic\x20and\x20may\x20independently\x20cause\x20cardiovascular\x20disease.\x20Although\x20<strong>HMG-CoA\x20reductase\x20inhibitors</strong>\x20substantially\x20reduce\x20the\x20risk\x20of\x20cardiovascular\x20events,\x20there\x20is\x20a\x20mild\x20<strong>increase</strong>\x20in\x20lipoprotein\x20a\x20levels.</p>\x0a<p>Option\x20B:\x20Statins\x20can\x20be\x20continued\x20during\x20<strong>surgery</strong>.\x20These\x20drugs\x20have\x20proved\x20to\x20decrease\x20overall\x20mortality\x20due\x20to\x20cardiovascular\x20events.\x20Statins\x20also\x20influence\x20inflammatory\x20responses\x20and\x20can\x20be\x20safely\x20used\x20in\x20<strong>trauma.</strong></p>\x0a<p>Option\x20D:\x20Chronic\x20administration\x20of\x20high\x20statin\x20doses\x20also\x20leads\x20to\x20an\x20<strong>increased\x20incidence</strong>\x20of\x20<strong>type\x202\x20diabetes\x20mellitus.</strong></p>','style','ZsyZP','<p>The\x20drug\x20used\x20to\x20manage\x20this\x20condition\x20is\x20<strong>prazosin</strong>\x20as\x20it\x20can\x20counteract\x20the\x20effects\x20of\x20breathlessness\x20most\x20probably\x20caused\x20by\x20pulmonary\x20edema.</p>\x0a<p>The\x20venom\x20is\x20a\x20potent\x20<strong>autonomic\x20stimulator</strong>\x20that\x20causes\x20the\x20release\x20of\x20massive\x20amounts\x20of\x20<strong>catecholamines</strong>\x20from\x20the\x20adrenals.\x20It\x20also\x20has\x20a\x20direct\x20effect\x20on\x20the\x20myocardium.</p>\x0a<p>It\x20can\x20present\x20as\x20<strong>neurotoxicity</strong>\x20with\x20restlessness\x20or\x20seizure-like\x20activity,\x20abnormal\x20oculomotor\x20function,\x20and\x20loss\x20of\x20pharyngeal\x20muscle\x20control\x20that\x20leads\x20to\x20respiratory\x20compromise.\x20Tongue\x20fasciculations\x20and\x20hypersalivation\x20are\x20also\x20common.\x20<strong>Cardiovascular\x20toxicity</strong>\x20from\x20systemic\x20envenomation\x20includes\x20tachycardia,\x20hypertension,\x20pulmonary\x20edema,\x20and\x20cardiogenic\x20shock.</p>\x0a<p>If\x20the\x20scorpion\x20has<strong>\x20hemolytic</strong>\x20venom,\x20the\x20reaction\x20is\x20mainly\x20<strong>local</strong>,\x20with\x20edema,\x20pain,\x20and\x20reddening.\x20This\x20usually\x20lasts\x20for\x20one\x20to\x20two\x20hours.&nbsp;</p>\x0a<p>Treatment:</p>\x0a<ul>\x0a<li>Pain\x20-\x20Paracetamol,\x20NSAIDs,\x20or\x20opioids&nbsp;</li>\x0a<li>Sedation\x20for\x20agitation,\x20oculomotor\x20abnormalities,\x20uncoordinated\x20neuromuscular\x20activity,\x20and\x20muscle\x20spasms\x20-\x20<strong>Benzodiazepines</strong>&nbsp;</li>\x0a<li>Hypertension\x20and<strong>\x20pulmonary\x20edema&nbsp;</strong>-&nbsp;<strong>Prazosin</strong>\x20counteracts\x20the\x20adrenergic\x20surge\x20that\x20can\x20lead\x20to\x20these\x20effects</li>\x0a<li>Cardiogenic\x20shock\x20-\x20Antivenom,\x20prazosin,\x20nitroglycerin,\x20dobutamine</li>\x0a<li>Cholinergic\x20effects\x20-\x20Atropine</li>\x0a<li>Supportive\x20care,\x20wound\x20care</li>\x0a</ul>','https://dhmbxeygs57ff.cloudfront.net/uploads/e96493e16a4840bbac92bc927f00f27dx1159x976.JPEG','rupsS','esJfq','Cetuximab','opdKC','explanation_images','bookmarkBtn','eFLvT','VaawO','index.html','findIndex','timed_study','CrmpE','CeBCO','The\x20image\x20below\x20shows\x20the\x20life\x20cycle\x20of\x20a\x20virus.\x20Which\x20of\x20the\x20following\x20drugs\x20acts\x20at\x20step\x205?','console','hierarchy','dkZIN','HiGoB','The\x20lipid\x20profile\x20of\x20a\x20patient\x20who\x20suffered\x20from\x20acute\x20coronary\x20syndrome\x20is\x20given\x20below.\x20What\x20drug\x20can\x20be\x20used\x20to\x20treat\x20this\x20condition?','pZBMa','Diuresis','UIRqf','2dlXCjJ','Phase\x204','bEFxK','1-a,\x202-b,\x203-c,\x204-d','Hktww','TNZlq','A\x20patient\x20who\x20is\x20a\x20known\x20case\x20of\x20HIV\x20is\x20started\x20on\x20combined\x20active\x20antiretroviral\x20therapy\x20(cART).\x20After\x205\x20months\x20of\x20treatment,\x20he\x20develops\x20hyperpigmentation\x20in\x20the\x20palms\x20and\x20soles.\x20What\x20is\x20the\x20most\x20likely\x20drug\x20causing\x20this?','markReviewBtn','bfqge','solutionAudio','Rifampicin','(((.+)+)+)+$','Choose\x20the\x20correct\x20options\x20regarding\x20the\x20route\x20of\x20administration\x20and\x20bioavailability.','Metoprolol','1,\x202,\x203,\x204','Aromatase','Valproate','Hxwaz','Bradycardia','mPuyI','BXTvb','includes','FfCBc','explanation_audio_eng','dVgzf','Muscarine','<p>Mechanism\x20of\x20action\x20of\x20some\x20common\x20antiepileptics:</p>\x0a<table>\x0a<tbody>\x0a<tr>\x0a<td><strong>Mechanism\x20of\x20action</strong></td>\x0a<td><strong>Antiepileptics</strong></td>\x0a</tr>\x0a<tr>\x0a<td>Sodium-channel\x20blockers</td>\x0a<td>\x0a<p>Phenytoin</p>\x0a<p>Carbamazepine,\x20Oxcarbazepine</p>\x0a<p>Eslicarbazepine</p>\x0a<p>Lamotrigine</p>\x0a<p>Topiramate</p>\x0a<p>Felbamate</p>\x0a<p>Valproate</p>\x0a<p>Rufinamide</p>\x0a<p>Levetiracetam</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td>Calcium-channel\x20blockers</td>\x0a<td>\x0a<p>Valproate</p>\x0a<p>Lamotrigine</p>\x0a<p>Ethosuximide</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td>GABA<sub>A</sub>&nbsp;receptor\x20modulators</td>\x0a<td>\x0a<p>Benzodiazepines</p>\x0a<p>Phenobarbital</p>\x0a<p>Felbamate</p>\x0a<p>Primidone</p>\x0a<p>Topiramate</p>\x0a<p>Carbamazepine,\x20Oxcarbazepine</p>\x0a<p>Stiripentol</p>\x0a<p>Clobazam</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td>\x0a<p\x20class=\x22p1\x22>GABA\x20uptake\x20inhibitors</p>\x0a</td>\x0a<td>\x0a<p\x20class=\x22p1\x22>Tiagabine</p>\x0a<p\x20class=\x22p1\x22>Vigabatrin</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td>NMDA\x20receptor\x20antagonist</td>\x0a<td>Felbamate</td>\x0a</tr>\x0a<tr>\x0a<td>AMPA/Kainate\x20receptor\x20antagonist</td>\x0a<td>\x0a<p>Phenobarbital</p>\x0a<p>Topiramate</p>\x0a<p>Perampanel</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td>HCN\x20channel\x20activity\x20enhancers</td>\x0a<td>Lamotrigine</td>\x0a</tr>\x0a<tr>\x0a<td>Inhibitors\x20of\x20brain\x20carbonic\x20anhydrase</td>\x0a<td>\x0a<p>Acetazolamide</p>\x0a<p>Zonisamide</p>\x0a<p>Topiramate</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td>Potassium-channel\x20openers</td>\x0a<td>\x0a<p>Retigabine</p>\x0a<p>Topiramate</p>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>','OqVmM','Phase\x201','markReviewText','127460FeiFYO','IsPxw','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','https://cdn1.dailyrounds.org/uploads/58ca7aff3ff64887b8cf57ae267880a1.JPEG','https://dhmbxeygs57ff.cloudfront.net/uploads/61c1774501b74506af250308d493739ax850x704.PNG','wrpLc','JsYSs','eovTs','hFHCT','1,\x20and\x203','<div\x20class=\x22ng-star-inserted\x22>\x0a<div\x20class=\x22table-responsive\x20font-weight-light\x20answer-scroll\x20ng-star-inserted\x22>\x0a<p>A\x20false\x20statement\x20about\x20eicosanoids\x20is\x20they\x20are\x20synthesized\x20from\x20arginine.\x20<strong>Eicosanoids</strong>\x20are\x20synthesized\x20from\x20<strong>arachidonic\x20acid\x20</strong>(Option\x20B)</p>\x0a<p><strong>Eicosanoids</strong>\x20are\x20the\x20most\x20universally\x20distributed\x20autocoids\x20in\x20the\x20body.\x20<strong>Prostaglandins,\x20thromboxanes,&nbsp;</strong>and\x20<strong>leukotrienes</strong>\x20comprise\x20eicosanoids.\x20Every\x20cell\x20is\x20capable\x20of\x20synthesizing\x20one\x20or\x20more\x20eicosanoids.\x20<strong>Platelets</strong>\x20primarily\x20synthesize\x20<strong>thromboxanes</strong>\x20(Option\x20D).</p>\x0a<p>Eicosanoids\x20are\x20synthesized\x20from\x20<strong>arachidonic\x20acid</strong>.\x20Arachidonic\x20acid\x20is\x20derived\x20from\x20membrane\x20phospholipids.\x20The\x20release\x20of\x20<strong>arachidonic\x20acid</strong>&nbsp;(AA)\x20from\x20the\x20membrane\x20phospholipids\x20is\x20mainly\x20mediated\x20by\x20<strong>phospholipase</strong>\x20<strong>A.</strong></p>\x0a<p>AA\x20is\x20metabolized\x20by\x20<strong>cyclooxygenases</strong>\x20to\x20produce\x20<strong>prostaglandins\x20</strong>and\x20<strong>lipoxygenases</strong>\x20to\x20produce\x20<strong>leukotrienes</strong>\x20and\x20lipoxins.</p>\x0a<div\x20class=\x22ng-star-inserted\x22>\x0a<div\x20class=\x22table-responsive\x20font-weight-light\x20answer-scroll\x20ng-star-inserted\x22>\x0a<p>Inhibitors\x20of\x20metabolism\x20of\x20arachidonic\x20acid:</p>\x0a<ul>\x0a<li><strong>Corticosteroids</strong>\x20cause\x20inhibition\x20of\x20prostaglandin\x20synthesis\x20by\x20inhibiting<strong>\x20phospholipase\x20A2.\x20<br\x20/></strong></li>\x0a<li>Non-steroidal\x20anti-inflammatory\x20(<strong>NSAIDs</strong>)\x20drugs\x20inhibit\x20the\x20synthesis\x20of\x20<strong>prostaglandins</strong>\x20by\x20inhibiting\x20the\x20enzyme\x20cyclooxygenase.</li>\x0a<li><strong>Zileuton</strong>\x20inhibits\x20the\x20enzyme\x20lipoxygenase\x20thereby\x20decreasing\x20the\x20synthesis\x20of\x20<strong>leukotrienes</strong>.</li>\x0a</ul>\x0a<p>Chemically,\x20all\x20prostaglandins\x20are\x20considered\x20to\x20be\x20derivatives\x20of\x20prostanoic\x20acid,\x20having&nbsp;a<strong>\x20five-carbon\x20ring&nbsp;</strong>(Option\x20C).</p>\x0a<p>The\x20image\x20given\x20below\x20shows\x20the\x20synthesis\x20of\x20various\x20eicosanoids\x20from\x20arachidonic\x20acid:</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','TjDOI','MbTuk','svwof','A\x20lady\x20who\x20had\x20undergone\x20mastectomy\x20for\x20breast\x20cancer\x20is\x20being\x20treated\x20with\x20tamoxifen.\x20How\x20long\x20should\x20it\x20be\x20stopped\x20for\x20before\x20she\x20can\x20conceive?','GguGH','https://dhmbxeygs57ff.cloudfront.net/uploads/c7d2d20a09874772b14772066b893f24x720x542.JPEG','ErCmd','<p>The\x20drugs\x20marked\x20A,\x20B\x20and\x20C\x20are\x20<strong>aspirin</strong>,\x20<strong>eptifibatide</strong>,\x20and\x20<strong>vorapaxar</strong>,<strong>&nbsp;</strong>respectively.</p>\x0a<p><strong>Aspirin</strong>\x20causes\x20inhibition\x20of\x20<strong>cyclooxygenase-1\x20(COX-1)</strong>,<strong>&nbsp;</strong>which\x20would\x20inhibit\x20the\x20formation\x20of\x20<strong>thromboxane\x20A2</strong>.\x20Thromboxane\x20A2\x20is\x20an\x20inducer\x20of\x20platelet\x20aggregation\x20and\x20is\x20a\x20potent\x20vasoconstrictor.\x20Hence,\x20inhibition\x20of\x20its\x20formation\x20is\x20responsible\x20for\x20antiplatelet\x20action.</p>\x0a<p>Aspirin\x20is\x20a\x20<strong>non-competitive,\x20irreversible\x20inhibitor</strong>\x20of\x20the\x20cyclooxygenase\x20(COX)\x20enzyme.\x20It\x20is\x20a\x20<strong>nonselective\x20COX\x20inhibitor</strong>\x20and\x20inhibits\x20both\x20COX-1\x20and\x20COX-2.&nbsp;</p>\x0a<p>Abciximab,\x20tirofiban,\x20and\x20<strong>eptifibatide</strong>\x20act\x20by&nbsp;<strong>blocking\x20Gp\x20IIb/IIIa\x20receptors</strong>.\x20They\x20are\x20mainly\x20used\x20during&nbsp;<strong>percutaneous\x20coronary\x20intervention</strong>&nbsp;for\x20acute\x20coronary\x20syndrome.\x20They\x20carry\x20a&nbsp;<strong>high\x20risk\x20of\x20bleeding</strong>&nbsp;and\x20can\x20cause&nbsp;<strong>thrombocytopenia</strong>.</p>\x0a<p><strong>Vorapaxar&nbsp;</strong>primarily\x20inhibits\x20platelet\x20aggregation\x20caused\x20by&nbsp;<strong>thrombin.&nbsp;</strong>PAR-1\x20activation\x20by\x20thrombin\x20contributes\x20to\x20platelet\x20aggregation.\x20Vorapaxar\x20is\x20a\x20competitive\x20antagonist\x20of\x20protease-activated\x20receptor-1\x20(PAR-1).\x20Vorapaxar\x20is&nbsp;<strong>indicated\x20in\x20combination</strong>&nbsp;with\x20aspirin\x20and/or\x20clopidogrel\x20to\x20reduce\x20thromboembolic\x20events\x20in\x20patients\x20with\x20MI\x20or\x20peripheral\x20vascular\x20disease.</p>\x0a<p><strong>Prasugrel&nbsp;</strong>is\x20an<strong>&nbsp;irreversible\x20P2Y12&nbsp;inhibitor\x20</strong>and\x20lasts\x20for\x20the\x20entire\x20lifetime\x20of\x20a\x20platelet.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20606\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Prasugrel\x20is\x20a&nbsp;<strong>prodrug</strong>&nbsp;that\x20is\x20used\x20in\x20patients\x20with\x20acute\x20coronary\x20syndrome\x20who\x20have\x20undergone&nbsp;<strong>percutaneous\x20coronary\x20intervention.</strong>&nbsp;It<strong>&nbsp;reduces</strong>&nbsp;the\x20rate\x20of&nbsp;<strong>thrombotic\x20cardiovascular\x20events</strong>&nbsp;in\x20such\x20patients.&nbsp;</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','TpGNn','<p>&nbsp;</p>\x0a<p>&nbsp;</p>\x0a<p>Option\x20B:&nbsp;<strong>Propranolol</strong>&nbsp;is\x20a&nbsp;<strong>&beta;-receptor-blocker\x20</strong>and&nbsp;a<strong>&nbsp;class\x20II\x20antiarrhythmic.</strong></p>','bKdWL','2,\x203','oQZXW','BqYSH','IGuxr','4\x20-\x20hydroxy\x20cyclophosphamide','vKtXz','timeDisplay','userHistory','YJjkt','JhQbX','ukLmm','tOdzw','Midazolam','zeEwW','<div\x20class=\x22page\x22\x20title=\x22Page\x20942\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p><strong>Rituximab</strong>\x20is\x20a&nbsp;<strong>monoclonal\x20antibody</strong>\x20that\x20acts\x20against<strong>\x20CD20\x20B&shy;-cell\x20antigen</strong>\x20expressed\x20on\x20the\x20surface\x20of\x20B&shy;-lymphocytes,\x20plasma\x20cells,\x20and\x20B&shy;-cell\x20lymphomas.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20943\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20943\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>It\x20promotes\x20<strong>apoptosis</strong>\x20through\x20transmembrane\x20signal&shy;ling\x20as\x20well\x20as\x20by\x20<strong>antibody\x20&shy;dependent</strong>\x20and\x20<strong>complement</strong>&shy;\x20dependent\x20cytotoxicity.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>B&shy;-cell\x20lymphoma</strong>,\x20<strong>non-&shy;Hodgkin\x20lymphoma,</strong>\x20and\x20<strong>chronic\x20lymphocytic\x20leukemia</strong>.\x20It\x20can\x20be\x20used\x20both\x20as\x20a\x20single\x20agent\x20as\x20well\x20as\x20in\x20combination\x20with\x20cyto&shy;toxic\x20chemotherapy.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20943\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20943\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Adverse\x20effects\x20are\x20infusion\x20reactions\x20like\x20chills,\x20fever,\x20urticarial\x20rashes,\x20pruritus,\x20dyspnea,\x20and\x20hypotension.\x20Pretreatment\x20with\x20antihistaminics\x20and\x20corticosteroids\x20prevents\x20the\x20reactions.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','Inhibition\x20of\x205α-reductase','<p>The\x20active\x20metabolite\x20of\x20cyclophosphamide\x20is&nbsp;<strong>4\x20-\x20hydroxy\x20cyclophosphamide.&nbsp;</strong></p>\x0a<p><strong>Cyclophosphamide&nbsp;</strong>is\x20an\x20<strong>alkylating\x20agent</strong>\x20with\x20antitumor\x20and\x20<strong>immunosuppressant</strong>\x20properties.\x20It\x20is\x20used\x20for\x20many\x20solid\x20tumors.\x20The\x20important\x20side\x20effects\x20are<strong>\x20cystitis</strong>\x20due\x20to\x20metabolite\x20<strong>acrolein</strong>\x20and\x20<strong>bladder\x20carcinoma</strong>.&nbsp;</p>\x0a<p><strong>Cystitis</strong>\x20caused\x20by\x20cyclophosphamide\x20is\x20treated\x20by&nbsp;systemic\x20administration\x20of\x20<strong>mesna</strong>\x20and\x20by\x20irrigating\x20the\x20bladder\x20with\x20<strong>acetylcysteine</strong>.\x20Both\x20these\x20drugs\x20contain\x20&ndash;SH\x20which\x20detoxifies\x20the\x20toxic\x20metabolites.\x20Plenty\x20of\x20fluids\x20and\x20frequent\x20bladder\x20voiding\x20are\x20also\x20helpful.</p>','LdGse','hidden','1,2,4','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','NqgIA','Synthesized\x20from\x20arginine','<p>The<strong>\x20antilipidemic\x20drugs</strong>\x20likely\x20to\x20cause<strong>\x20gallstones\x20</strong>are\x20the\x20peroxisome\x20proliferator-activated\x20receptors\x20(<strong>PPARs</strong>)\x20that\x20act\x20by\x20activating\x20<strong>PPAR\x20alpha.</strong></p>\x0a<p><strong>PPARs</strong>\x20are\x20a\x20superfamily\x20of\x20nuclear\x20receptors\x20involved&nbsp;in\x20the\x20regulation\x20of\x20energy\x20homeostasis\x20and\x20metabolic\x20function.&nbsp;It\x20has\x20three\x20subtypes:</p>\x0a<ul>\x0a<li>PPAR&alpha;\x20-\x20reduces\x20triglyceride\x20level&nbsp;</li>\x0a<li>PPAR&gamma;\x20-\x20causes\x20insulin\x20sensitization&nbsp;</li>\x0a<li>PPAR&delta;\x20-\x20enhances\x20fatty\x20acids\x20metabolism</li>\x0a</ul>\x0a<p>Lipoprotein\x20lipase\x20(LPL)\x20is\x20a\x20key\x20enzyme\x20in\x20the\x20degradation\x20of\x20VLDL.\x20Fibrates\x20bind\x20to\x20PPAR\x20alpha\x20and\x20cause\x20<strong>stimulation</strong>\x20of\x20<strong>lipoprotein\x20lipase</strong>\x20enzyme.\x20Increased\x20LPL\x20synthesis\x20enhances\x20the\x20clearance\x20of\x20triglyceride-rich\x20lipoproteins.\x20Additionally,\x20fibrates\x20also\x20<strong>stimulate\x20fatty\x20acid\x20oxidation</strong>\x20and\x20<strong>reduce</strong>\x20the\x20expression\x20of\x20<strong>apo\x20C-III</strong>\x20(inhibitor\x20of\x20lipolysis).\x20All\x20fibrates\x20increase\x20the\x20lithogenicity\x20of\x20bile,\x20thereby\x20increasing\x20the\x20risk\x20of\x20gall\x20stones</p>\x0a<p>Other\x20options:&nbsp;</p>\x0a<table\x20style=\x22height:\x20531px;\x20width:\x20498px;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x2016.0156px;\x22><span\x20style=\x22text-decoration:\x20underline;\x22><strong>Class</strong></span></td>\x0a<td\x20style=\x22width:\x2010px;\x22><strong>HMG-\x20CoA\x20reductase\x20inhibitors\x20(statins)</strong></td>\x0a<td\x20style=\x22width:\x2070px;\x22><strong>Niacin</strong></td>\x0a<td\x20style=\x22width:\x2010px;\x22><strong>Bile\x20acid-binding\x20resins</strong></td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2016.0156px;\x22><span\x20style=\x22text-decoration:\x20underline;\x22><strong>Examples</strong></span></td>\x0a<td\x20style=\x22width:\x2010px;\x22>\x0a<p\x20class=\x22p1\x22>Lovastatin,\x20atorvastatin</p>\x0a</td>\x0a<td\x20style=\x22width:\x2070px;\x22>Niacin</td>\x0a<td\x20style=\x22width:\x2010px;\x22>\x0a<p>Colestipol,\x20<br\x20/>colesevelam</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2016.0156px;\x22><span\x20style=\x22text-decoration:\x20underline;\x22><strong>Mechanism\x20of\x20action</strong></span></td>\x0a<td\x20style=\x22width:\x2010px;\x22>\x0a<p\x20class=\x22p1\x22>Inhibits\x20HMG-CoA\x20reductase</p>\x0a</td>\x0a<td\x20style=\x22width:\x2070px;\x22>Decreases\x20the\x20production\x20of\x20VLDLs\x20and\x20the\x20catabolism\x20of\x20HDLs</td>\x0a<td\x20style=\x22width:\x2010px;\x22>Binds\x20to\x20bile\x20acids\x20in\x20the\x20intestinal\x20lumen\x20and\x20increases\x20excretion.&nbsp;</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2016.0156px;\x22><span\x20style=\x22text-decoration:\x20underline;\x22><strong>Major\x20effects\x20on\x20lipoprotein\x20levels</strong></span></td>\x0a<td\x20style=\x22width:\x2010px;\x22>\x0a<p>Reduces\x20LDL\x20levels</p>\x0a</td>\x0a<td\x20style=\x22width:\x2070px;\x22>\x0a<ul>\x0a<li>Reduces\x20triglycerides,&nbsp;\x20LDL,\x20and\x20lipoprotein\x20a\x20levels</li>\x0a<li>Significant\x20<strong>increase\x20HDL</strong>\x20levels</li>\x0a</ul>\x0a</td>\x0a<td\x20style=\x22width:\x2010px;\x22>Reduces\x20LDL\x20levels&nbsp;</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2016.0156px;\x22><span\x20style=\x22text-decoration:\x20underline;\x22><strong>Important\x20side\x20effects</strong></span></td>\x0a<td\x20style=\x22width:\x2010px;\x22>\x0a<ul>\x0a<li><strong>Myopathy</strong></li>\x0a<li\x20class=\x22p1\x22>Elevations\x20of\x20serum\x20amino-transferase\x20activity</li>\x0a<li\x20class=\x22p1\x22>Elevation\x20of\x20creatine\x20kinase\x20activity</li>\x0a</ul>\x0a</td>\x0a<td\x20style=\x22width:\x2070px;\x22>\x0a<ul>\x0a<li>Cutaneous\x20vasodilation</li>\x0a<li>Elevations\x20in\x20amino-transferases\x20levels&nbsp;</li>\x0a</ul>\x0a</td>\x0a<td\x20style=\x22width:\x2010px;\x22>\x0a<ul>\x0a<li>Constipation</li>\x0a<li>Bloating&nbsp;</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>&nbsp;</p>','laucg','Which\x20of\x20the\x20following\x20is\x20false\x20regarding\x20disulfiram?','VZdRv','yGgDi','wzoAK','vfFDX','Primaquine','bookmarkText','mEhwq','TsMTi','VQMdE','The\x20half-life\x20of\x20letrozole\x20is:','Weakly\x20acidic\x20drugs','<p><strong>Oxazepam&nbsp;</strong>can\x20be\x20used\x20in\x20patients\x20with\x20elevated\x20transaminases.\x20It\x20is\x20<strong>short-acting</strong>&nbsp;and\x20so,\x20can\x20be\x20used\x20in\x20patients\x20with<strong>\x20liver\x20impairment</strong>\x20or\x20<strong>brain\x20damage.</strong></p>\x0a<p>Oxazepam\x20is\x20an\x20orally\x20available\x20benzodiazepine\x20used\x20to\x20treat\x20anxiety\x20and\x20alcohol\x20withdrawal\x20states.\x20Hepatic\x20oxidation\x20is\x20decreased\x20in\x20persons\x20with\x20liver\x20disease\x20and\x20the\x20elderly.\x20Oxazepam\x20and\x20lorazepam&nbsp;undergo\x20<strong>only</strong>\x20<strong>hepatic\x20glucuronidation</strong>.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:<strong>\x20Midazolam</strong>\x20is\x20the\x20<strong>benzodiazepine\x20of\x20choice</strong>\x20for<strong>\x20induction</strong>\x20of\x20anesthesia.\x20The\x20onset\x20of\x20anesthesia\x20is\x20within\x20<strong>30\x20to\x2060</strong>\x20seconds.\x20It\x20can\x20also\x20be\x20used\x20to\x20control\x20seizures,\x20but\x20there\x20is\x20<strong>no\x20difference</strong>\x20in\x20the\x20efficacy\x20of\x20intravenous\x20midazolam\x20and\x20intravenous\x20diazepam.</p>\x0a<p>Option\x20B:<strong>\x20Diazepam</strong>\x20is\x20a\x20long-acting\x20benzodiazepine.\x20It\x20is\x20<strong>metabolized</strong>\x20in\x20the\x20<strong>liver</strong>\x20to\x20active\x20metabolites\x20like\x20nordazepam\x20which\x20are\x20long-acting.&nbsp;Diazepam\x20and\x20its\x20long-acting\x20metabolites\x20can\x20<strong>accumulate</strong>\x20significantly\x20in\x20<strong>elderly</strong>\x20patients\x20with\x20<strong>liver\x20disease</strong>\x20and\x20therefore\x20should<strong>\x20not</strong>\x20be\x20used\x20in\x20such\x20cases.</p>\x0a<p>Option\x20C:<strong>\x20Alprazolam</strong>&nbsp;is\x20metabolized\x20by\x20hepatic\x20oxidation\x20which\x20is\x20significantly\x20decreased\x20in\x20liver\x20impairment\x20and\x20elderly\x20patients.</p>\x0a<p>&nbsp;</p>','afhLv','Binds\x20to\x20deoxycholic\x20acid','oeNkv','ZhTjm','dsjkZ','tsFSA','Bookmark','textContent','totalAttempted','info','Not\x20Attempted','ArrowLeft','statsBar','Uqath','pop','canPlayType','ICgMg','Chloroquine','XsbbB','WDVwJ','application/vnd.apple.mpegurl','answered','A\x20and\x20C','ZCchI','https://cdn1.dailyrounds.org/uploads/abc89b147ae645269bf56a6a300e37ea.JPEG','accuracy','Drug\x20C\x20is\x20a\x20non-competitive\x20antagonist.','HaYND','Propranolol','testModeReviewLegend','sYtkA','Drug\x20A\x20&\x20drug\x20B\x20are\x20agonists.','YYyIP','A\x20hypertensive\x20patient\x20on\x20medication\x20presents\x20with\x20the\x20lab\x20values\x20as\x20shown\x20below.\x20Which\x20of\x20the\x20following\x20drugs\x20should\x20be\x20stopped?','Atorvastatin\x2080\x20mg','JWTBe','A-2,\x20B-4,\x20C-1,\x20D-3','Aspirin','KEcCg','nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','add','EJMgG','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20','3\x20months','NwFcD','hDfgG','Atropine','zjDoB','suBnf','EPVth','3,\x204','t1/2','N\x20-\x20acetyl\x20cyclophosphamide','DsvoO','cNxNJ','OoBYb','<p><strong>Sildenafil\x20</strong>acts\x20by\x20inhibiting\x20<strong>phosphodiesterase-5&nbsp;</strong>(PDE-5)&nbsp;and\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>erectile\x20dysfunction.</strong></p>\x0a<p>PDE-5\x20inhibitors\x20cause\x20the\x20accumulation\x20of\x20<strong>cGMP</strong>\x20in\x20the\x20corpus\x20cavernosum,\x20which\x20leads\x20to\x20the\x20<strong>relaxation\x20of\x20smooth\x20muscles\x20of\x20penile\x20arteries</strong>\x20that\x20fill\x20the\x20corpus\x20cavernosum,\x20thereby\x20improving\x20erectile\x20function\x20in\x20patients\x20with\x20erectile\x20dysfunction.</p>\x0a<p>In\x20addition\x20to\x20erectile\x20dysfunction,\x20sildenafil\x20can\x20be\x20used\x20in\x20the\x20treatment\x20of\x20<strong>pulmonary\x20arterial\x20hypertension</strong>.</p>\x0a<p>Adverse\x20effects\x20include\x20<strong>headache,\x20flushing,</strong>\x20nasal\x20congestion,&nbsp;<strong>blue-green\x20tinting\x20of\x20vision</strong>,<strong>&nbsp;</strong>and\x20erections\x20lasting\x20more\x20than\x204\x20hours.</p>\x0a<p>Sildenafil\x20is\x20<strong>contraindicated</strong>\x20in\x20patients\x20using\x20<strong>nitrate\x20vasodilators,</strong>&nbsp;which\x20could\x20result\x20in\x20dangerously\x20low\x20blood\x20pressure.</p>','byrFy','<p>Drugs\x20that\x20carry\x20a\x20risk\x20of\x20clinical\x20hemolysis\x20in\x20persons\x20with\x20G6PD\x20deficiency:</p>\x0a<table\x20style=\x22width:\x20494px;\x20height:\x20420px;\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2053px;\x22>\x0a<td\x20style=\x22width:\x20159.36142px;\x20height:\x2053px;\x22>\x0a<p><strong>CLASS</strong></p>\x0a</td>\x0a<td\x20style=\x22width:\x20319.470123px;\x20height:\x2053px;\x22>\x0a<p><strong>DRUGS</strong></p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2054px;\x22>\x0a<td\x20style=\x22width:\x20159.36142px;\x20height:\x2054px;\x22>\x0a<p>Antimalarials</p>\x0a</td>\x0a<td\x20style=\x22width:\x20319.470123px;\x20height:\x2054px;\x22>\x0a<p><strong>Primaquine\x20&gt;&nbsp;</strong><strong>Chloroquine</strong></p>\x0a<p>Dapsone/chlorproguanil</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2055px;\x22>\x0a<td\x20style=\x22width:\x20159.36142px;\x20height:\x2055px;\x22>\x0a<p>Sulphonamides/sulphones</p>\x0a</td>\x0a<td\x20style=\x22width:\x20319.470123px;\x20height:\x2055px;\x22>\x0a<p><strong>Sulfamethoxazole</strong></p>\x0a<p>Sulfasalazine,\x20Sulfisoxazole</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2020px;\x22>\x0a<td\x20style=\x22width:\x20159.36142px;\x20height:\x2020px;\x22>\x0a<p>Antibacterial/antibiotics</p>\x0a</td>\x0a<td\x20style=\x22width:\x20319.470123px;\x20height:\x2020px;\x22>\x0a<p><strong>Cotrimoxazole,&nbsp;</strong>Ciprofloxacin,\x20Chloramphenicol,\x20Nalidixic\x20acid,\x20Norfloxacin,&nbsp;<strong>Nitrofurantoin</strong></p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2016px;\x22>\x0a<td\x20style=\x22width:\x20159.36142px;\x20height:\x2016px;\x22>\x0a<p>Others</p>\x0a</td>\x0a<td\x20style=\x22width:\x20319.470123px;\x20height:\x2016px;\x22>\x0a<p>Naphthalene,\x20Rasburicase&nbsp;</p>\x0a<p><strong>Methylene\x20blue</strong></p>\x0a<p>&nbsp;</p>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22space-y-2\x20mb-4\x22>','correct','Acetaminophen','Prostaglandins\x20have\x205\x20carbon\x20ring','gsfZC','WiLLx','XCerU','Tnxkk','Area\x20under\x20the\x20curve','Cevimeline','Potentiation\x20of\x20acetylcholine','iHCts','Efficacy\x20of\x20drug\x20A\x20is\x20more\x20than\x20that\x20of\x20drug\x20B.','fOiKV','KOJuW','choices','addEventListener','Can\x20be\x20stopped\x20and\x20conceived\x20soon\x20after\x20stopping','Bebtelovimab','jYBHz','No\x20questions\x20available\x20for\x20this\x20quiz.','IMNLd','constructor','Release\x20of\x20nitrous\x20oxide\x20radicals','A\x20patient\x20who\x20is\x20on\x20treatment\x20for\x20hyperlipidemia\x20develops\x20gallstones.\x20What\x20is\x20the\x20mechanism\x20of\x20action\x20of\x20the\x20causative\x20drug\x20that\x20was\x20given\x20to\x20this\x20patient?','correctResult','tCubr','JNKtB','QZuwb','Beta\x20blockers','HdbgV','SMwNd','lGhPN','src','Ethambutol','zxiHD','ErUSm','HJewH','TnrQO','A-4,\x20B-3\x20,\x20C-2\x20,\x20D-1','EYPgE','prevBtn','<p>This\x20type\x20of\x20drug\x20is\x20called\x20a\x20<strong>misbranded\x20drug</strong>.\x20A\x20drug\x20stating\x20that\x20500mg\x20of\x20paracetamol\x20is\x20present\x20in\x20each\x20tablet,\x20but\x20contains\x20only\x20200mg\x20is\x20a&nbsp;<strong>misbranded</strong>&nbsp;<strong>drug</strong>,\x20according\x20to\x20the\x20<strong>Drugs\x20and\x20Cosmetics\x20Act,\x201940</strong>\x20definition\x20of\x20misbranded\x20drugs.</p>\x0a<p>According\x20to\x20the\x20Drugs\x20and\x20Cosmetics\x20act,\x201940,&nbsp;a\x20misbranded\x20drug\x20is\x20a\x20drug\x20if\x20its\x20<strong>label</strong>\x20or\x20container\x20or\x20anything\x20accompanying\x20the\x20drug\x20bears\x20any\x20statement,\x20design,\x20or\x20device\x20which\x20makes\x20any\x20<strong>false\x20claim</strong>\x20for\x20the\x20drug\x20or\x20which\x20is\x20false\x20or\x20misleading\x20in\x20any\x20particular.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:&nbsp;<strong>Spurious\x20drugs</strong>&nbsp;include\x20drugs\x20manufactured\x20under&nbsp;<strong>another\x20drug&nbsp;</strong>or<strong>&nbsp;manufacturer\x27s\x20name</strong>,&nbsp;<strong>imitations</strong>&nbsp;of\x20other\x20drugs,\x20and\x20drugs\x20with\x20labels\x20from\x20a&nbsp;<strong>fictitious\x20company</strong>&nbsp;or\x20individual.\x20It\x20also\x20includes\x20drugs\x20substituted\x20partly\x20or\x20wholly\x20by\x20another\x20drug\x20or\x20substance.</p>\x0a<p>Option\x20B:&nbsp;<strong>Adulterated\x20drugs</strong>&nbsp;include\x20those\x20drugs\x20that\x20contain&nbsp;<strong>filthy</strong>,\x20or\x20decomposed&nbsp;<strong>substances</strong>,\x20substances\x20that\x20are&nbsp;<strong>injurious\x20to\x20health</strong>,\x20or\x20if\x20the\x20drug\x20harmful\x20substances\x20to&nbsp;<strong>reduce&nbsp;</strong>the<strong>&nbsp;quality&nbsp;</strong>or<strong>&nbsp;strength&nbsp;</strong>of\x20the\x20drug.\x20It\x20also\x20includes\x20drugs\x20that\x20were\x20prepared\x20in\x20unsanitary\x20conditions.</p>\x0a<p>Option\x20C:\x20The\x20term&nbsp;unethical\x20drug\x20is\x20not\x20standard\x20terminology\x20in\x20pharmacology.\x20However,\x20the\x20term<strong>\x20ethical\x20drug\x20</strong>is\x20sometimes\x20used\x20to\x20describe\x20those\x20<strong>drugs</strong>\x20that\x20are\x20available\x20<strong>only\x20by\x20prescription</strong>\x20of\x20a\x20medical\x20practitioner.</p>','Identify\x20the\x20drugs\x20marked\x20as\x20A,\x20B,\x20and\x20C.','key','yoJFg','isSupported','\x20-\x20Brain\x20And\x20Scalpel','forEach','jkOqq','Phosphodiesterase','dataset','hjNUX','true','qovCm','https://cdn1.dailyrounds.org/uploads/b656eec2969545cab6981b79ab874ed5.JPEG','Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.','border-green-500','log','1,\x204','783sGEETl','Match\x20the\x20following\x20teratogenic\x20drugs\x20with\x20their\x20teratogenic\x20effects.','oZVxZ','17-hydrolase','pbiID','lXUFk','ArrowRight','Choose\x20the\x20correctly\x20matched\x20pairs\x20regarding\x20the\x20drugs\x20used\x20in\x20schizophrenia:','EJDXD','quizSidebar','1,2,3,4','explanation_audio_hin','dPDIJ','Which\x20of\x20the\x20following\x20statements\x20is\x20true\x20regarding\x20memantine?','qLgST','Mydriasis','oHDRS','gEmVH','timerContainer','questionNav','1,\x202','Correct','xHkwX','GypBz','<p>Alkalinization\x20of\x20urine\x20will\x20be\x20helpful\x20in\x20the\x20removal\x20of\x20aspirin,\x20which\x20is\x20a&nbsp;<strong>weakly\x20acidic\x20drug</strong>&nbsp;and\x20is\x20susceptible\x20to<strong>&nbsp;ion\x20trapping</strong>\x20in\x20the&nbsp;urine.</p>\x0a<p>Aspirin\x20is\x20a\x20weak\x20acid,\x20with\x20a\x20<strong>pKa\x20of\x203.0</strong>.&nbsp;Drugs\x20that\x20are\x20subjected\x20to\x20renal\x20clearance\x20are\x20excreted\x20into\x20the\x20urine\x20by\x20glomerular\x20filtration\x20and\x20active\x20tubular\x20secretion.\x20Nonionized\x20compounds\x20are\x20reabsorbed\x20more\x20rapidly\x20than\x20ionized\x20polar\x20molecules.\x20When\x20the&nbsp;<strong>pH</strong>&nbsp;of\x20the&nbsp;<strong>urine&nbsp;increases</strong>,\x20more\x20salicylate\x20is\x20in\x20its\x20ionized\x20form\x20at\x20equilibrium.\x20Hence,\x20salicylic\x20acid&nbsp;<strong>diffuses</strong>&nbsp;into\x20the&nbsp;<strong>tubular\x20lumen</strong>&nbsp;of\x20the\x20kidney.\x20Urine\x20alkalinization\x20is\x20recommended\x20as\x20a\x20first-line\x20treatment\x20only\x20for\x20moderately\x20severe\x20salicylate\x20poisoning\x20that&nbsp;does\x20not\x20meet\x20the\x20criteria\x20for\x20hemodialysis.</p>\x0a<p>Alkalinization\x20of\x20the\x20urine\x20is\x20achieved\x20by\x20administration\x20of&nbsp;<strong>100&ndash;150\x20mEq</strong>&nbsp;of&nbsp;<strong>sodium\x20bicarbonate</strong>&nbsp;in\x201\x20L\x20of\x205%\x20dextrose\x20in\x20water\x20(D5W).\x20It\x20is\x20infused\x20intravenously&nbsp;at\x20twice\x20the\x20maintenance\x20fluid\x20requirements.</p>\x0a<p>Alkalinization\x20of\x20urine\x20is&nbsp;<strong>contraindicated</strong>&nbsp;in&nbsp;<strong>renal\x20failure</strong>&nbsp;or\x20if\x20fluid\x20administration\x20may\x20worsen&nbsp;<strong>pulmonary\x20edema</strong>&nbsp;or\x20congestive\x20heart\x20failure.</p>','Decreases\x20VLDL','CQEEl','Nelfinavir','A\x20patient\x20presented\x20with\x20a\x20lesion,\x20as\x20shown\x20in\x20the\x20image\x20below.\x20She\x20is\x20an\x20immunocompromised\x20patient\x20currently\x20on\x20HAART.\x20What\x20are\x20the\x20systemic\x20antifungal\x20drugs\x20that\x20can\x20be\x20added\x20along\x20with\x20the\x20HAART\x20in\x20this\x20patient?','nav-btn-current','bsgXA','MYTYZ','div','<p>The\x20given\x20clinical\x20scenario\x20and\x20the\x20image\x20showing\x20a\x20pin-point\x20pupil\x20(miosis)\x20suggest&nbsp;<strong>opioid\x20overdose</strong>.\x20The\x20true\x20statement\x20among\x20those\x20given\x20is\x20that\x20it\x20is\x20caused\x20by\x20activation\x20of\x20the<strong>\x20Edinger-Westphal\x20nucleus.</strong></p>\x0a<p><strong>Edinger-Westphal\x20nucleus</strong>\x20is\x20a\x20part\x20of\x20the\x20<strong>light\x20reflex\x20pathway\x20</strong>and\x20is&nbsp;located\x20in\x20the\x20midbrain.\x20This\x20nucleus\x20is\x20responsible\x20for\x20causing\x20<strong>pupillary\x20constriction</strong>\x20when\x20the\x20retina\x20is\x20exposed\x20to\x20light.&nbsp;</p>\x0a<p>Opioid\x20overdose\x20symptoms\x20are\x20a\x20triad\x20of\x20coma,\x20respiratory\x20depression,\x20and\x20pinpoint\x20pupils\x20(miosis).\x20Other\x20features\x20are\x20hypotension,\x20bradycardia,\x20shallow\x20breathing,\x20and\x20hypothermia.</p>\x0a<p><strong>Tolerance</strong>&nbsp;to\x20miosis\x20does\x20not\x20develop\x20even\x20in\x20addicts\x20who\x20develop\x20a\x20high\x20tolerance\x20to\x20opioids.\x20Miosis\x20is\x20induced\x20by\x20all\x20opioid\x20agonists.</p>\x0a<p><strong>Naloxone&nbsp;</strong>is\x20the\x20drug\x20of\x20choice\x20for\x20opioid\x20overdose.&nbsp;It<strong>&nbsp;</strong>is\x20administered<strong>&nbsp;</strong>after\x20adequate\x20ventilation\x20is\x20established.\x20<strong>Airway\x20protection&nbsp;</strong>and&nbsp;<strong>ventilatory\x20maintenance</strong>&nbsp;are\x20the\x20most\x20important\x20steps\x20in\x20the\x20treatment\x20of\x20opioid\x20overdose;\x20this\x20is\x20because&nbsp;<strong>respiratory\x20depression</strong>&nbsp;is\x20the\x20major\x20cause\x20of\x20mortality\x20in\x20such\x20cases.&nbsp;<strong>Single-dose</strong>&nbsp;<strong>activated\x20charcoal</strong>&nbsp;can\x20be\x20administered\x20if\x20the\x20opioid\x20ingestion\x20occurred\x20within&nbsp;<strong>one\x20hour</strong>.</p>\x0a<p><strong>Levallorphan</strong>\x20is\x20an\x20<strong>opioid\x20antagonist</strong>,\x20with\x20properties\x20similar\x20to\x20those\x20of\x20<strong>naloxone</strong>.\x20It\x20can\x20be\x20used\x20for\x20<strong>opioid\x20overdose</strong>.\x20It\x20reverses\x20severe\x20opioid-induced\x20respiratory\x20depression.</p>\x0a<p><strong>Phenylephrine</strong>\x20is\x20an\x20<strong>&alpha;1-selective\x20agonist</strong>\x20that\x20causes\x20mydriasis,<strong>&nbsp;</strong>but\x20it\x20is\x20not\x20useful\x20in\x20the\x20reversal\x20of\x20opioid-induced\x20miosis.</p>','A-4,\x20B-1,\x20C-3,\x20D-2','Tetracycline','quizFile','xfKgx','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><video\x20src=\x22','HAcCk','GGyGh','YUPlV','modeModal','055\x20Pharmacology\x20Ini-Cet\x202022','RebNE','Pembrolizumab','error','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><audio\x20src=\x22','1\x20month','L-glutamine','questionMedia','currentQuestion','4\x20-\x20acetyl\x20cyclophosphamide','NVCEw','HMZIY','Pharmacology','GOJFj','nav-btn-bookmarked','N\x20-\x20hydroxy\x20cyclophosphamide','Brimonidine','width','scoreCircle','<p>The\x20correct\x20match\x20is\x20<strong>verapamil</strong>\x20causes\x20<strong>constipation</strong>.</p>\x0a<p>Verapamil\x20is\x20a\x20calcium\x20channel\x20blocker\x20used\x20for\x20the\x20treatment\x20of\x20paroxysmal\x20supraventricular\x20tachycardia,\x20atrial\x20fibrillation,\x20and\x20atrial\x20flutter.\x20Bradycardia\x20and\x20<strong>constipation</strong>\x20are\x20the\x20important\x20side\x20effects\x20of\x20verapamil.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Hydralazine</strong>\x20is\x20a\x20<strong>vasodilator</strong>\x20used\x20in\x20the\x20treatment\x20of&nbsp;heart\x20failure,\x20and\x20<strong>hypertensive\x20emergencies</strong>,\x20especially\x20preeclampsia.&nbsp;The\x20drug\x20is\x20used&nbsp;as\x20a\x20combination\x20pill\x20containing\x20isosorbide\x20dinitrate\x20(<strong>BiDil</strong>)\x20in\x20the\x20treatment\x20of\x20heart\x20failure.\x20The\x20important\x20side\x20effect\x20of\x20hydralazine\x20is\x20<strong>drug-induced\x20lupus</strong>.</p>\x0a<p>Option\x20B:\x20<strong>Atenolol</strong>\x20is\x20a\x20<strong>cardioselective\x20beta-1\x20blocker</strong>\x20used\x20in\x20the\x20treatment\x20of\x20angina\x20and\x20hypertension.\x20Atenolol\x20doesn\x27t\x20cause\x20<strong>hemolytic\x20anemia</strong>.</p>\x0a<p>Option\x20C:\x20<strong>Aliskiren</strong>\x20is\x20a\x20<strong>direct\x20renin\x20inhibitor</strong>\x20used\x20as\x20an\x20alternative&nbsp;<strong>antihypertensive</strong>\x20drug\x20for\x20those\x20who\x20do\x20not\x20respond\x20or\x20do\x20not\x20tolerate\x201st\x20line\x20drugs.\x20The\x20side\x20effect\x20of\x20aliskiren\x20is\x20<strong>hyperkalemia</strong>\x20and\x20not\x20hypokalemia.</p>','AmvFr','QIpOx','wkDDk','totalQuestions','incorrectResult','DOMContentLoaded','iCiLm','padStart','<p><strong>N-acetyl-p-benzoquinone\x20imine</strong>&nbsp;(NAPQI)\x20is\x20a\x20metabolite\x20of\x20<strong>paracetamol</strong>\x20drug\x20toxicity.&nbsp;</p>\x0a<p>Paracetamol\x20is\x20an\x20analgesic\x20and\x20antipyretic\x20with\x20<strong>weak\x20anti-inflammatory\x20action</strong>.\x20It\x20is\x20mainly\x20metabolized&nbsp;in\x20the\x20<strong>liver</strong>\x20by\x20conjugation\x20with\x20<strong>glucuronic\x20acid</strong>\x20and\x20sulfate\x20and\x20is\x20excreted\x20in\x20the\x20urine.</p>\x0a<p>At\x20toxic\x20doses,\x20the\x20glucuronide\x20and\x20sulfate\x20conjugation\x20pathway\x20becomes\x20<strong>saturated</strong>.\x20The\x20metabolites\x20of\x20paracetamol\x20get\x20converted\x20into\x20NAPQI.\x20NAPQI\x20is&nbsp;<strong>highly\x20reactive</strong>\x20and\x20causes\x20enzymatic\x20dysfunction\x20in\x20the\x20liver.\x20Normally,\x20minor\x20amounts\x20of\x20NAPQI\x20produced\x20in\x20our\x20body\x20are\x20rapidly\x20eliminated\x20by\x20conjugation\x20with\x20<strong>reduced\x20glutathione(GSH)</strong>\x20and\x20then\x20excreted\x20into\x20the\x20urine.</p>\x0a<p>Therefore,\x20paracetamol\x20toxicity\x20is\x20treated\x20with\x20<strong>N-acetyl\x20cysteine(NAC)</strong>,\x20which\x20<strong>replenishes\x20GSH.&nbsp;</strong>NAC\x20thereby\x20helps\x20in\x20the\x20excretion\x20of\x20NAPQI\x20from\x20the\x20body.\x20N-acetyl\x20cysteine\x20is\x20an\x20<strong>anti-oxidant</strong>\x20and\x20functions\x20by\x20detoxifying\x20NAPQI.</p>\x0a<p>Paracetamol\x20poisoning\x20is\x20the\x20<strong>most\x20common</strong>\x20cause\x20of\x20liver\x20failure\x20necessitating\x20transplantation.</p>\x0a<p>The\x20<strong>maximum\x20dose</strong>\x20of\x20acetaminophen\x20that\x20can\x20be\x20given\x20is\x20<strong>4\x20g/day</strong>.&nbsp;</p>','appendChild','byUNI','VclQZ','<p>The\x20correct\x20option\x20regarding\x20the\x20drugs\x20used\x20to\x20treat\x20schizophrenia\x20symptoms\x20is\x20<strong>option\x20C</strong>.</p>\x0a<p>Drugs\x20used\x20to\x20treat\x20schizophrenia\x20can\x20be\x20classified:</p>\x0a<ul>\x0a<li>Typical\x20or\x201st\x20generation\x20antipsychotics.</li>\x0a<li>Atypical\x20or\x202nd\x20generation\x20antipsychotics.</li>\x0a</ul>\x0a<p>All\x20typical\x20antipsychotics\x20markedly\x20<strong>improve\x20positive\x20symptoms</strong>\x20of\x20schizophrenia,\x20which\x20is\x20attributed\x20to\x20their\x20<strong>antagonism</strong>\x20at&nbsp;the<strong>\x20D<sub>2</sub>\x20receptor</strong>.\x20Some\x20of\x20the\x20drugs\x20included\x20in\x20this\x20class\x20are\x20<strong>chlorpromazine</strong>\x20and\x20<strong>haloperidol.</strong></p>\x0a<p>Atypical\x20antipsychotics\x20are\x20antagonists\x20or\x20inverse\x20agonists\x20at\x20the\x205HT<sub>2A</sub>\x20receptor.\x20<strong>5HT<sub>2A</sub>\x20antagonism</strong>\x20is\x20responsible\x20for\x20<strong>reducing\x20negative\x20symptoms</strong>\x20in\x20schizophrenia.\x20Some\x20of\x20the\x20drugs\x20that\x20belong\x20to\x20this\x20class\x20are\x20clozapine,\x20aripiprazole,\x20and\x20brexpiprazole.</p>\x0a<p>Atypical\x20antipsychotics\x20have\x20lower\x20extrapyramidal\x20symptoms\x20as\x20compared\x20to\x20typical\x20antipsychotics\x20as\x20the\x20former\x20has\x20a\x20lesser\x20affinity\x20to\x20the\x20D2\x20receptor.\x20<strong>Muscarinic\x20antagonists</strong>&nbsp;can\x20be\x20given\x20to\x20decrease\x20the\x20extrapyramidal\x20symptoms.\x20For\x20example,\x20<strong>promethazine</strong>\x20or\x20<strong>hydroxyzine</strong>\x20is\x20given\x20for\x20acute\x20muscular\x20dystonia,\x20which\x20is\x20a\x20form\x20of\x20extrapyramidal\x20symptoms.</p>\x0a<p><strong>5HT<sub>1A</sub>\x20receptor\x20antagonism</strong>,&nbsp;not\x20agonism,\x20has\x20been\x20found\x20to\x20reduce\x20food\x20intake\x20and\x20hence\x20reduce\x20body\x20weight.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20256\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Aripiprazole\x20and\x20brexpiprazole\x20are\x20atypical\x20antipsychotics\x20that\x20have\x20partial\x20agonist\x20effects\x20at\x20the\x205HT<sub>1A</sub>\x20receptor.\x20They\x20have\x20been\x20approved\x20for\x20the\x20treatment\x20of\x20schizophrenia\x20and\x20as\x20an\x20adjunctive\x20treatment\x20for\x20depression.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','055-pharmacology-ini-cet-2022-8a382f9a.html','WJKwn','JLCMl','Elevated\x20levels\x20of\x20gamma\x20glutamyl\x20transpeptidases','length','uyJvg','classList','ceNlS','A-4,\x20B-3\x20,\x20C-1\x20,\x20D-2','Although\x20HMG-CoA\x20reductase\x20inhibitors\x20substantially\x20reduce\x20the\x20risk\x20of\x20cardiovascular\x20events,\x20there\x20is\x20mild\x20increase\x20in\x20lipoprotein\x20a\x20(Lpa)\x20levels.','ORuHf','GUkML','mDPGc','JWoKS','CyQwm','https://dhmbxeygs57ff.cloudfront.net/uploads/644ef3e20c3a40cd848cbccfa38d4188x1280x1006.JPEG','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','nHRel','QtIfz','FyaQH','zGaGM','Tolerance\x20develops\x20due\x20to\x20long-term\x20use.','<p>In\x20this\x20hypertensive\x20patient\x20with\x20<strong>hyperkalemia</strong>,\x20<strong>losartan</strong>\x20must\x20be\x20stopped.</p>\x0a<p><strong>Losartan</strong>&nbsp;is\x20competitive&nbsp;<strong>angiotensin\x20I\x20(AT1)\x20receptor\x20antagonist</strong>,&nbsp;which&nbsp;binds\x20to\x20the\x20AT<sub>1</sub>&nbsp;receptor\x20with\x20high\x20affinity.\x20Uses\x20of\x20losartan\x20are:</p>\x0a<ul>\x0a<li>Antihypertensive</li>\x0a<li>Renoprotective\x20drug\x20in\x20diabetes\x20mellitus</li>\x0a<li>Stroke\x20prophylaxis</li>\x0a<li>Portal\x20hypertension\x20in\x20cirrhosis\x20without\x20compromising\x20renal\x20function</li>\x0a<li>Anti-aggregant\x20as\x20it\x20is\x20a\x20competitive\x20antagonist\x20of\x20the\x20thromboxane\x20A2\x20receptor.</li>\x0a</ul>\x0a<p><strong>Hyperkalemia</strong>&nbsp;is\x20an\x20important\x20side\x20effect\x20of\x20ARBs.&nbsp;<span\x20class=\x22ILfuVd\x22\x20lang=\x22en\x22><span\x20class=\x22hgKElc\x22>Losartan\x20appears\x20to\x20be\x20a\x20safe\x20and\x20efficacious\x20agent\x20to&nbsp;<strong>lower\x20serum\x20uric\x20acid</strong>&nbsp;levels\x20in\x20patients\x20with\x20hyperuricemia.</span></span></p>\x0a<p>Option\x20A:\x20<strong>Gingival\x20hyperplasia</strong>&nbsp;and&nbsp;<strong>ankle\x20swelling</strong>&nbsp;are\x20side\x20effects\x20of&nbsp;<strong>calcium\x20channel\x20blockers</strong>&nbsp;like&nbsp;<strong>amlodipine.</strong>&nbsp;Ankle\x20edema\x20occurs\x20due\x20to&nbsp;<strong>increased</strong>&nbsp;<strong>hydrostatic\x20pressure</strong>&nbsp;in\x20the\x20capillaries\x20present\x20in\x20the&nbsp;<strong>dependent\x20parts</strong>&nbsp;of\x20the\x20body.\x20This\x20is\x20due\x20to&nbsp;<strong>reflex\x20constriction</strong>&nbsp;of&nbsp;<strong>postcapillary\x20vessels</strong>.\x20Other\x20common\x20side\x20effects\x20of\x20amlodipine\x20include\x20headache,\x20dizziness,\x20and\x20abdominal\x20pain.</p>\x0a<p>Option\x20B:\x20<strong>Metoprolol</strong>&nbsp;is\x20a\x20cardioselective\x20beta\x20blocker.<strong>\x20Cardioselective</strong>\x20beta\x20blockers\x20are\x20<strong>less\x20likely\x20to\x20cause\x20hyperkalemia</strong>\x20as\x20an\x20adverse\x20effect.\x20The\x20risk\x20of\x20metoprolol-induced\x20hyperkalemia\x20is\x20increased\x20if\x20the\x20patient\x20is\x20also\x20diabetic.</p>\x0a<p>Option\x20D:\x20<strong>Furosemide</strong>&nbsp;is\x20a&nbsp;<strong>loop\x20diuretic.\x20</strong>It\x20acts\x20by&nbsp;<strong>inhibiting</strong>&nbsp;the<strong>&nbsp;Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup>&nbsp;symporter\x20</strong>in\x20the&nbsp;thick\x20ascending\x20limb&nbsp;of\x20the&nbsp;loop&nbsp;of\x20Henle&nbsp;resulting\x20in\x20increased<strong>\x20excretion\x20of\x20sodium,\x20potassium,</strong>\x20and<strong>\x20chloride</strong>.&nbsp;<strong>Hypokalemia,\x20hyperuricemia,\x20hypocalcemia</strong>,\x20and\x20hypomagnesemia\x20are\x20the\x20important\x20side\x20effects.</p>','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22','LqHih','WbSwo','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>','otnnh','Previous\x20progress\x20cleared.','rxFpw','Dorzolamide\x20is\x20a\x20______.','HYmEb','solutionImages','Match\x20the\x20following\x20drugs\x20in\x20Column\x20A\x20with\x20their\x20contraindications\x20in\x20Column\x20B.','<p><strong>Cetuximab</strong>\x20is\x20not&nbsp;an\x20<strong>immune\x20checkpoint\x20inhibitor</strong>.\x20Cetuximab\x20is\x20a\x20monoclonal\x20antibody\x20against\x20<strong>epidermal\x20growth\x20factor\x20receptor(EGFR)</strong>.\x20It\x20is\x20used\x20for\x20the\x20treatment\x20of\x20<strong>colon\x20cancer</strong>\x20and\x20head\x20and\x20neck\x20squamous\x20cell\x20cancer.</p>\x0a<p>Other\x20options.</p>\x0a<p>Option\x20A:<strong>\x20Nivolumab\x20</strong>is\x20an\x20immune\x20checkpoint\x20inhibitor.\x20It\x20acts\x20by\x20inhibiting\x20programmed\x20death\x20receptor\x20-\x201\x20(<strong>PD-1</strong>)\x20and\x20is\x20used\x20for\x20the\x20treatment\x20of\x20<strong>advanced\x20melanoma</strong>\x20and\x20<strong>classical\x20Hodgkin\x20lymphoma.&nbsp;</strong></p>\x0a<p>Option\x20B:\x20<strong>Pembrolizumab</strong>\x20is\x20an\x20immune\x20checkpoint\x20inhibitor.\x20It\x20acts\x20by\x20inhibiting\x20programmed\x20death\x20receptor\x20-\x201\x20(<strong>PD-1</strong>)\x20and\x20is\x20used\x20for\x20the\x20treatment\x20of\x20<strong>advanced\x20melanoma</strong>.&nbsp;In\x202021,\x20approval\x20was\x20granted\x20for\x20the\x20treatment\x20of\x20patients\x20with\x20<strong>endometrial\x20carcinoma</strong>\x20that\x20progressed\x20after\x20systemic\x20treatment,\x20in\x20combination\x20with\x20<strong>lenvatinib</strong>.</p>\x0a<p>Option\x20C:\x20<strong>Atezolimumab</strong>\x20is\x20an\x20immune\x20checkpoint\x20inhibitor.\x20It\x20acts\x20by&nbsp;inhibiting\x20programmed\x20death-ligand\x20-\x201\x20(<strong>PDL-1</strong>)\x20and\x20is\x20used\x20for\x20the\x20treatment\x20of\x20<strong>non-small\x20cell\x20lung\x20cancer</strong>.&nbsp;</p>\x0a<p>Important\x20note:</p>\x0a<p>The\x20FDA\x20on&nbsp;<strong>May\x202021</strong>&nbsp;approved\x20the\x20use\x20of&nbsp;<strong>nivolumab</strong>&nbsp;in\x20patients\x20having\x20completely\x20resected\x20<strong>esophageal\x20or\x20gastroesophageal\x20junction\x20cancers</strong>&nbsp;with\x20residual\x20pathologic\x20disease\x20who\x20have\x20received\x20neoadjuvant\x20chemoradiotherapy.</p>','fIUbq','questions','StHUw','filter','kRFcQ','incorrectAnswers','ugALS','.option-button','sLQEu','10dYJadT','An\x20anti-arrhythmic\x20drug\x20is\x20shown\x20to\x20have\x20the\x20following\x20effect.\x20It\x20is\x20effective\x20in\x20both\x20atrial\x20and\x20ventricular\x20arrhythmias.\x20Identify\x20the\x20drug.','<p>The\x20correct\x20answer\x20is\x20option\x20B:\x20A-4,\x20B-1,\x20C-3,\x20D-2</p>\x0a<table\x20style=\x22height:\x2049px;\x22\x20width=\x22415\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20200.1px;\x22>A.\x20Morphine</td>\x0a<td\x20style=\x22width:\x20200.1px;\x22>4.\x20Head\x20Injury</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20200.1px;\x22>B.\x20Amiodarone</td>\x0a<td\x20style=\x22width:\x20200.1px;\x22>1.\x20QT\x20prolongation</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20200.1px;\x22>C.\x20Vigabatrin</td>\x0a<td\x20style=\x22width:\x20200.1px;\x22>3.\x20Pregnancy</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20200.1px;\x22>D.\x20Estrogen\x20preparations</td>\x0a<td\x20style=\x22width:\x20200.1px;\x22>2.\x20Thromboembolism</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>In\x20a\x20patient\x20with\x20head\x20injury,\x20<strong>morphine</strong>\x20is\x20contraindicated\x20because\x20it\x20<strong>increases\x20intracranial\x20tension</strong>\x20due\x20to\x20CO₂\x20retention,\x20precipitates\x20<strong>respiratory\x20depression,</strong>\x20and\x20may\x20cause\x20vomiting,\x20miosis,\x20and\x20altered\x20mental\x20state\x20which\x20<strong>interferes\x20with\x20assessment</strong>\x20of\x20mental\x20state.</p>\x0a<p><strong>Amiodarone</strong>\x20should\x20not\x20be\x20used\x20in\x20patients\x20with\x20<strong>prolonged\x20QT\x20interval</strong>\x20because\x20it\x20may\x20cause\x20<strong>marked\x20prolongation</strong>\x20of\x20the\x20QT\x20interval,\x20bradycardia,\x20and<strong>\x20torsades\x20de\x20pointes</strong>.</p>\x0a<p><strong>Vigabatrin</strong>,\x20an\x20inhibitor\x20of\x20GABA-transaminase,\x20an\x20anti-convulsant,\x20is\x20contraindicated\x20in\x20pregnancy\x20due\x20to\x20its\x20potential\x20<strong>teratogenic\x20effect</strong>.</p>\x0a<p><strong>Estrogen\x20preparations&nbsp;</strong>can\x20contribute\x20to\x20the\x20incidence\x20and\x20severity\x20of\x20<strong>t</strong><strong>hromboembolism,&nbsp;</strong>particularly\x20if\x20other\x20risk\x20factors\x20are\x20present.\x20The\x20risk\x20of\x20serious\x20cardiovascular\x20side\x20effects\x20is\x20particularly\x20marked\x20in\x20women\x20more\x20than\x2035\x20years\x20of\x20age\x20who\x20smoke\x20heavily.</p>','incorrectCount','cdroj','<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20Enfuvirtide\x20acts\x20at\x20<strong>step\x202</strong>\x20in\x20the\x20given\x20image.\x20It\x20blocks\x20gp41\x20of\x20the\x20cell\x20membrane\x20and\x20<strong>blocks\x20the\x20entry</strong>\x20of\x20the\x20virus\x20into\x20the\x20cell.\x20It\x20prevents\x20the\x20free\x20viral\x20particles\x20from\x20invading\x20new\x20CD4+\x20cells.\x20It\x20is\x20effective\x20against\x20<strong>HIV-1.</strong></p>\x0a<p>Option\x20C:\x20Tenofovir\x20acts\x20at\x20<strong>step\x203</strong>\x20in\x20the\x20given\x20image.\x20It\x20is\x20a\x20nucleotide\x20reverse\x20transcriptase\x20inhibitor\x20(NRTI)\x20that\x20is\x20effective\x20against\x20<strong>HIV-1,2</strong>\x20and\x20<strong>hepatitis\x20B</strong>\x20infections.\x20It\x20is\x20used\x20in\x20adults\x20and\x20<strong>children\x20&gt;2\x20years\x20old.\x20</strong>It\x20can\x20also\x20be\x20used\x20for<strong>\x20pre-exposure\x20prophylaxis.&nbsp;</strong></p>\x0a<p>Option\x20D:\x20Zidovudine\x20also\x20acts\x20at\x20<strong>step\x203</strong>\x20in\x20the\x20given\x20image.\x20It\x20is\x20an\x20NRTI\x20and\x20is\x20effective\x20against\x20<strong>HIV-1,2</strong>\x20and\x20<strong>Human\x20T-cell\x20Lymphoma\x20Virus\x20(HTLV).</strong>\x20It\x20can\x20be\x20used\x20in\x20adults\x20and\x20children.\x20It\x20can\x20also\x20be\x20used\x20to\x20prevent\x20<strong>mother-to-child\x20transmission.</strong></p>','solutionContainer','MUCTM','ypjgx','toggle','yFszI','gvMDw','https://cdn1.dailyrounds.org/uploads/2b3ddec429404fce9e5a9874a7a2d2f7.JPEG','FQZkc','WXwSH','Ivabradine','3|1|4|2|0|5','currentMode','exception','NGmAK','WkOGE','1,\x202,\x203','NYaKH','PfitN','timed_exam','fromCharCode','bookmarkedQuestions','https://dhmbxeygs57ff.cloudfront.net/uploads/7548819eafdf43d6b3155642ccd9e678x1184x1162.PNG','removeItem','timeSpent','Oxazepam','display','dTAFD','ayFMy','CoXNN','1-a,\x202-c,\x203-d,\x204-b','Drug\x202\x20represents\x20partial\x20agonist\x20and\x20drug\x203\x20represents\x20inverse\x20agonist','Raltegravir','Cmax','Polyclonal\x20antibody\x20which\x20acts\x20against\x20CD50','1,4','cUdLb','green','querySelectorAll','xmWuy','Pyrazinamide','apply','totalQuestionsResult','You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20','JBbMS','contains','xupes','JPbrm','<p><strong>Phase\x204</strong>\x20clinical\x20trials\x20are\x20also\x20called\x20<strong>post-marketing\x20surveillance&nbsp;</strong>is\x20the\x20correct\x20statement.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20New\x20drug\x20application\x20is\x20done\x20after\x20<strong>phase\x203</strong>\x20of\x20clinical\x20trials.</p>\x0a<p>Option\x20C:&nbsp;<strong>Phase\x203</strong>\x20trials\x20<strong>may\x20or\x20may\x20not\x20be\x20blinded</strong>.</p>\x0a<p>Option\x20D:&nbsp;<strong>Phase\x202</strong>\x20trials\x20are\x20the\x20first\x20round\x20of\x20trials\x20in\x20<strong>patients</strong>.\x20<strong>Phase\x201</strong>\x20trials\x20are\x20done\x20in\x20<strong>healthy</strong>\x20volunteers.</p>','bMfXr','Rituximab\x20is\x20a:','jPrLf','setItem','nYSkI','Trastuzumab','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-purple-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','OXHjE','tMeZj','video[data-src]','TuFzo','omcWi','lalJV','questionReviewSection','FVExk','Voglibose','NpkkT','A\x20patient\x20is\x20brought\x20with\x20altered\x20sensorium\x20and\x20seizures.\x20Attender\x20shows\x20the\x20laboratory\x20report\x20which\x20reveals\x20elevated\x20transaminases.\x20Which\x20of\x20the\x20following\x20can\x20be\x20used\x20in\x20this\x20condition?','floor','notAttemptedResult','jkUhQ','A\x20man\x20was\x20brought\x20to\x20the\x20emergency\x20room\x20after\x20poisoning\x20with\x20an\x20unknown\x20substance.\x20Muscarinic\x20poisoning\x20was\x20suspected\x20and\x20he\x20was\x20treated\x20for\x20the\x20same.\x20What\x20is\x20the\x20possible\x20presenting\x20feature\x20which\x20led\x20to\x20the\x20diagnosis?','okzNs','CzJWF','correct_choice_id','bind','yPzdq','<div\x20class=\x22page\x22\x20title=\x22Page\x20108\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>A\x20hospital\x20conducting\x20a\x20<strong>double-blinded</strong>\x20study\x20in\x20<strong>multiple\x20centers</strong>\x20to\x20check\x20the\x20<strong>efficacy\x20of\x20statins</strong>&nbsp;describes\x20<strong>phase\x203</strong>\x20of\x20the\x20clinical\x20trial.\x20A\x20<strong>phase\x202</strong>\x20clinical\x20trial\x20is\x20generally\x20conducted\x20at\x20a\x20<strong>few\x20centers\x20(2-4)</strong>\x20by\x20physicians.</p>\x0a<p><strong>Phase\x203</strong>\x20of\x20a\x20clinical\x20trial\x20is\x20also\x20known\x20as\x20a\x20<strong>multisite\x20trial</strong>.\x20It\x20is\x20conducted\x20on\x20a\x20<strong>large\x20patient\x20population</strong>\x20(500&ndash;3000)\x20by\x20several\x20physicians\x20at\x20<strong>multiple\x20centers</strong>.\x20This\x20phase\x20involves\x20patients\x20who\x20have\x20been\x20diagnosed\x20with\x20the\x20disease\x20that\x20the\x20drug\x20claims\x20to\x20treat.\x20Its\x20purpose\x20is\x20to\x20<strong>confirm\x20the\x20efficacy\x20</strong>of\x20the\x20newly\x20developed\x20drug\x20in\x20a\x20larger\x20population.\x20Phase\x203\x20is\x20<strong>randomized</strong>,\x20<strong>controlled</strong>,\x20and\x20may\x20be\x20<strong>blinded</strong>.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','toISOString','customQuizData','jIUOK','aBpTf','VgHcY','fxzwq','nZyBf','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish:</p><audio\x20src=\x22','VscvI','jOklR','qnXOc','cAMP','closest','nav-btn-correct','Phase\x202\x20is\x20done\x20on\x20healthy\x20individuals','selectedAnswer','loadSource','No\x20solution\x20available.','flex','quizHierarchy','gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','A-2,\x20B-3\x20,\x20C-1\x20,\x20D-4','eMuAZ','Incorrect','<p>New\x20drug\x20application\x20is\x20filed\x20after<strong>\x20phase\x203\x20</strong>of\x20clinical\x20trials.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:&nbsp;<strong>Phase\x204</strong>\x20clinical\x20trials\x20are\x20also\x20called\x20<strong>post-marketing\x20surveillance.</strong></p>\x0a<p>Option\x20C:&nbsp;<strong>Phase\x202</strong>\x20trials\x20are\x20the\x20first\x20round\x20of\x20trials\x20in\x20<strong>patients</strong>.</p>\x0a<p>Option\x20D:&nbsp;<strong>Phase\x201</strong>\x20trials\x20are\x20done\x20in\x20<strong>healthy</strong>\x20volunteers.</p>','yaOXt','<p>In\x20the\x20given\x20image,\x20<strong>drug\x20A\x20&amp;\x20drug\x20B\x20are\x20agonists.</strong>&nbsp;</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x2053\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x2050\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Drugs\x20that\x20bind\x20to\x20physiological\x20receptors\x20and\x20mimic\x20the\x20regulatory\x20effects\x20of\x20endogenous\x20signaling\x20compounds\x27\x20are\x20<strong>agonists</strong>.\x20Drugs\x20that\x20are\x20only\x20partially\x20as\x20effective\x20as\x20agonists\x20are\x20<strong>partial\x20agonists</strong>.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x2053\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>The<strong>\x20efficacy</strong>\x20of\x20a\x20drug\x20indicates\x20the\x20capacity\x20of\x20a\x20drug\x20to\x20activate\x20a\x20receptor\x20and\x20<strong>generate\x20a\x20cellular\x20response</strong>.\x20A\x20drug\x20with\x20high\x20efficacy\x20is\x20a\x20full\x20agonist,\x20eliciting\x20a\x20full\x20response\x20at\x20some\x20concentration.\x20A\x20drug\x20with\x20a\x20low\x20intrinsic\x20efficacy\x20will\x20be\x20a\x20partial\x20agonist.\x20<strong>D</strong><strong>rug\x20A\x20&amp;\x20drug\x20B&nbsp;</strong>are\x20<strong>agonists&nbsp;</strong>(Option\x20C)\x20that\x20have\x20the\x20<strong>same\x20efficacy&nbsp;</strong>(Option\x20A),\x20although,\x20at\x20different\x20concentrations.</p>\x0a<p><strong>Drug\x20C</strong>\x20<strong>does\x20not\x20produce\x20a\x20full\x20response</strong>\x20at\x20any\x20concentration,\x20making\x20it\x20a\x20<strong>partial\x20agonist</strong>.\x20In\x20the\x20<strong>presence\x20of\x20a\x20full\x20agonist</strong>,\x20a\x20partial\x20agonist\x20behaves\x20like\x20a\x20<strong>competitive\x20antagonist</strong>&nbsp;(Option\x20D).</p>\x0a<p>When\x20two\x20drugs\x20produce\x20equivalent\x20responses,\x20the\x20drug\x20whose\x20dose-response\x20curve\x20lies\x20to\x20the\x20left\x20is\x20said\x20to\x20be\x20the\x20more\x20potent\x20since\x20it\x20requires\x20a\x20lower\x20dose\x20to\x20produce\x20the\x20same\x20effect.&nbsp;<strong>Drug\x20A</strong>\x20&amp;\x20<strong>drug</strong>&nbsp;<strong>B</strong>\x20produce\x20the\x20same\x20action\x20and\x20level\x20of\x20response\x20in\x20the\x20tissue.\x20The\x20curve\x20of\x20drug\x20A\x20on\x20the\x20left\x20indicates\x20that\x20it\x20produces\x20the<strong>\x20same\x20response</strong>\x20at\x20a\x20<strong>lower\x20concentration</strong>,\x20making\x20it\x20<strong>more\x20potent</strong>\x20than\x20drug\x20B\x20(Option\x20B).</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>'];_0x33d7=function(){return _0x2b73e9;};return _0x33d7();}const _0x466fe8=(function(){const _0x343b04=_0x3e0e,_0x35d94d={'lEqvM':function(_0x410b65,_0x258439){return _0x410b65!==_0x258439;},'RHvNA':_0x343b04(0x167),'GNgbp':function(_0x1ec9ec,_0x4f4bc5){return _0x1ec9ec===_0x4f4bc5;},'maLDg':'eMxMC'};let _0x8dfec1=!![];return function(_0x35fcf3,_0x559e17){const _0x93cd18=_0x343b04,_0x3b6f34={'UIRqf':function(_0x53f659,_0x228e0e){const _0x259754=_0x3e0e;return _0x35d94d[_0x259754(0x39f)](_0x53f659,_0x228e0e);},'YJjkt':_0x93cd18(0x2e2),'jUDrs':_0x35d94d['RHvNA'],'GsFkO':function(_0x137d1b,_0x601b4){return _0x35d94d['GNgbp'](_0x137d1b,_0x601b4);},'BYvOX':_0x93cd18(0x1e0),'kRFcQ':_0x35d94d[_0x93cd18(0x3b8)]},_0x3a48dd=_0x8dfec1?function(){const _0x124ae0=_0x93cd18,_0xa9372e={'mAlFZ':function(_0x8eb41d,_0x18c25a){const _0x560a42=_0x3e0e;return _0x3b6f34[_0x560a42(0x426)](_0x8eb41d,_0x18c25a);},'ORuHf':_0x3b6f34[_0x124ae0(0x463)],'qAJLC':_0x3b6f34[_0x124ae0(0x3b4)]};if(_0x3b6f34[_0x124ae0(0x2a3)](_0x3b6f34[_0x124ae0(0x393)],_0x3b6f34[_0x124ae0(0x22a)])){if(_0xa9372e[_0x124ae0(0x3a3)](_0x44c86a[_0x124ae0(0x291)],null))_0x49de3c=_0xa9372e[_0x124ae0(0x20d)];else _0x58b41c=_0xa9372e[_0x124ae0(0x366)];}else{if(_0x559e17){const _0x15afc9=_0x559e17[_0x124ae0(0x25d)](_0x35fcf3,arguments);return _0x559e17=null,_0x15afc9;}}}:function(){};return _0x8dfec1=![],_0x3a48dd;};}()),_0x429c96=_0x466fe8(this,function(){const _0x4ebca8=_0x3e0e,_0x19a2d4={'kzLqQ':function(_0x4f4a3b){return _0x4f4a3b();},'QBJlQ':_0x4ebca8(0x29e),'Avpzh':_0x4ebca8(0x19f),'nZyBf':function(_0x447854,_0x3bb4d3){return _0x447854(_0x3bb4d3);},'sxgKt':function(_0x5d1252,_0x3b8eab){return _0x5d1252+_0x3b8eab;},'WiLLx':_0x4ebca8(0x392),'oeNkv':'{}.constructor(\x22return\x20this\x22)(\x20)','AkjIA':_0x4ebca8(0x1b5),'xXYTY':_0x4ebca8(0x149),'KEcCg':_0x4ebca8(0x1e5),'zKnGE':_0x4ebca8(0x241),'xHkwX':_0x4ebca8(0x38d),'VQMdE':function(_0x4a3677,_0x6d37e4){return _0x4a3677<_0x6d37e4;}},_0x5800f3=function(){const _0x28d8c1=_0x4ebca8;let _0x11fb77;try{_0x19a2d4[_0x28d8c1(0x331)]===_0x19a2d4[_0x28d8c1(0x37a)]?_0x19a2d4['kzLqQ'](_0x4042a7):_0x11fb77=_0x19a2d4[_0x28d8c1(0x288)](Function,_0x19a2d4['sxgKt'](_0x19a2d4[_0x28d8c1(0x180)],_0x19a2d4[_0x28d8c1(0x142)])+');')();}catch(_0x279d2f){_0x11fb77=window;}return _0x11fb77;},_0x365e02=_0x5800f3(),_0x206046=_0x365e02['console']=_0x365e02[_0x4ebca8(0x41f)]||{},_0x526614=[_0x19a2d4[_0x4ebca8(0x2c6)],'warn',_0x19a2d4[_0x4ebca8(0x2f8)],_0x19a2d4[_0x4ebca8(0x166)],_0x19a2d4['zKnGE'],'table',_0x19a2d4[_0x4ebca8(0x1cd)]];for(let _0x1d67d6=0x0;_0x19a2d4[_0x4ebca8(0x13c)](_0x1d67d6,_0x526614[_0x4ebca8(0x207)]);_0x1d67d6++){const _0x27ae07=_0x466fe8[_0x4ebca8(0x191)]['prototype']['bind'](_0x466fe8),_0x20daaa=_0x526614[_0x1d67d6],_0x2b1771=_0x206046[_0x20daaa]||_0x27ae07;_0x27ae07['__proto__']=_0x466fe8[_0x4ebca8(0x27f)](_0x466fe8),_0x27ae07['toString']=_0x2b1771['toString'][_0x4ebca8(0x27f)](_0x2b1771),_0x206046[_0x20daaa]=_0x27ae07;}});_0x429c96();let questionsData=[{'text':_0x6eced6(0x3ae),'choices':[{'id':0x1,'text':_0x6eced6(0x39b)},{'id':0x2,'text':_0x6eced6(0x183)},{'id':0x3,'text':_0x6eced6(0x255)},{'id':0x4,'text':_0x6eced6(0x173)}],'correct_choice_id':0x2,'solution':'<p>\u00a0</p>\x0a<p>Bioavailability\x20of\x20drug\u00a0injected\x20intravenously\x20is\x20100%,\x20but\x20it\x20is\x20lower\u00a0after\x20oral\x20ingestion\x20because\x20of\u00a0incomplete\x20absorption\x20and\x20first-pass\x20metabolism\x20in\x20the\x20intestinal\x20wall/liver.</p>\x0a<p>The\x20image\x20below\x20shows\x20the\x20difference\x20between\x20the\x20bioavailability\x20of\x20drugs\x20injected\x20intravenously(iv)\x20and\x20orally(PO).\x20Note\x20the\x20area\x20under\x20the\x20respective\x20curves\x20is\x20shaded\x20in\x20red\x20and\x20blue\x20colours\x20which\x20represent\x20the\x20absorption\x20of\x20the\x20drug.</p>','explanation_video':'','question_images':[],'explanation_images':[_0x6eced6(0x33b),'https://dhmbxeygs57ff.cloudfront.net/uploads/004ea54ec8dd43dab6444638a0d26247x1184x1162.PNG']},{'text':_0x6eced6(0x2aa),'choices':[{'id':0x1,'text':_0x6eced6(0x3eb)},{'id':0x2,'text':_0x6eced6(0x37d)},{'id':0x3,'text':'Drug\x20\x201\x20represents\x20agonist\x20and\x20drug\x204\x20represents\x20inverse\x20agonist'},{'id':0x4,'text':_0x6eced6(0x253)}],'correct_choice_id':0x3,'solution':'<p>The\x20correct\x20statement\x20is\x20<strong>Drug\x201\x20represents\x20agonist\x20and\x20drug\x204\x20represents\x20inverse\x20agonist.</strong></p>\x0a<p><strong>Graph\x201\x20</strong>represents\x20the\x20<strong>agonist:\x20</strong>An\x20agonist\x20is\x20an\x20agent\x20which\x20initiates\x20the\x20<strong>normal</strong>\x20<strong>physiological\x20response</strong>\x20when\x20combined\x20with\x20a\x20receptor.</p>\x0a<p>Example:\x20Salbutamol\x20is\x20a\x20beta-2\x20receptor\x20agonist.</p>\x0a<p><strong>Graph\x202</strong>\x20represents\x20a\x20<strong>partial\x20agonist</strong>:\x20An\x20agent\x20which\x20produces\x20a\x20<strong>submaximal\x20or\x20partial\x20effect</strong>\x20when\x20combined\x20with\x20a\x20receptor.</p>\x0a<p>Example:\x20B<span\x20class=\x22ILfuVd\x22\x20lang=\x22en\x22><span\x20class=\x22hgKElc\x22>uprenorphine\x20and\x20butorphanol\x20are\x20partial\x20agonists\x20at\x20opioid\x20receptors.\x20</span></span></p>\x0a<p><strong>Graph\x203\x20</strong>represents\x20the\x20<strong>antagonist</strong>:\x20An\x20agent\x20which\x20blocks\x20or\x20reduces\x20the\x20action\x20of\x20an\x20agonist\x20on\x20a\x20receptor,\x20but\x20does\x20not\x20have\x20any\x20effect\x20of\x20its\x20own.</p>\x0a<p>Example:\x20N<span\x20class=\x22ILfuVd\x22\x20lang=\x22en\x22><span\x20class=\x22hgKElc\x22>altrexone\x20and\x20naloxone\x20are\x20antagonists\x20at\x20opioid\x20receptors\x20</span></span></p>\x0a<p><strong>Graph\x204</strong>\x20represents\x20an<strong>\x20inverse\x20agonist</strong>:\x20An\x20agent\x20which\x20activates\x20a\x20receptor\x20to\x20produce\x20an\x20effect\x20in\x20the\x20opposite\x20direction\x20to\x20that\x20of\x20the\x20agonist.</p>\x0a<p>Example:\x20&beta;-Carboline\x20is\x20an\x20inverse\x20agonist\x20at\x20benzodiazepine\x20site\x20of\x20GABA-A\x20receptor.</p>\x0a<p>The\x20image\x20given\x20below\x20shows\x20action\x20of\x20various\x20types\x20of\x20selective\x20receptor\x20modulators.</p>','explanation_video':'','question_images':[_0x6eced6(0x381)],'explanation_images':[_0x6eced6(0x2b1)]},{'text':'Which\x20among\x20the\x20following\x20drugs\x20is\x20the\x20new\x20FDA\x20approved\x20immune\x20check\x20point\x20inhibitor\x20for\x20carcinoma\x20endometrium?','choices':[{'id':0x1,'text':'Nivolumab'},{'id':0x2,'text':_0x6eced6(0x1e4)},{'id':0x3,'text':_0x6eced6(0x26b)},{'id':0x4,'text':'Ipilimumab'}],'correct_choice_id':0x2,'solution':_0x6eced6(0x39d),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20is\x20not\x20an\x20immune\x20checkpoint\x20inhibitor?','choices':[{'id':0x1,'text':_0x6eced6(0x318)},{'id':0x2,'text':'Pembrolizumab'},{'id':0x3,'text':_0x6eced6(0x36c)},{'id':0x4,'text':_0x6eced6(0x413)}],'correct_choice_id':0x4,'solution':_0x6eced6(0x225),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x368),'choices':[{'id':0x1,'text':_0x6eced6(0x165)},{'id':0x2,'text':_0x6eced6(0x2c1)},{'id':0x3,'text':_0x6eced6(0x332)},{'id':0x4,'text':'Ketorolac'}],'correct_choice_id':0x2,'solution':_0x6eced6(0x1fe),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Identify\x20the\x20correct\x20match,\x20regarding\x20the\x20drug\x20and\x20its\x20adverse\x20effect.','choices':[{'id':0x1,'text':'Hydralazine\x20-\x20heart\x20failure'},{'id':0x2,'text':'Atenolol\x20-\x20hemolytic\x20anemia'},{'id':0x3,'text':_0x6eced6(0x33e)},{'id':0x4,'text':_0x6eced6(0x330)}],'correct_choice_id':0x4,'solution':_0x6eced6(0x1f5),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x453),'choices':[{'id':0x1,'text':_0x6eced6(0x1e7)},{'id':0x2,'text':_0x6eced6(0x16b)},{'id':0x3,'text':'No\x20need\x20to\x20stop'},{'id':0x4,'text':_0x6eced6(0x18c)}],'correct_choice_id':0x2,'solution':'<p>In\x20a\x20post-mastectomy\x20patient\x20undergoing\x20therapy\x20with\x20<strong>tamoxifen</strong>,\x20it\x20should\x20be\x20<strong>stopped</strong>\x20<strong>for</strong>\x20<strong>3\x20months</strong>\x20before\x20she\x20can\x20<strong>conceive</strong>.</p>\x0a<p><strong>Tamoxifen</strong>&nbsp;is\x20a\x20selective\x20estrogen\x20receptor\x20modulator&nbsp;<strong>(SERM)</strong>&nbsp;and\x20is\x20used\x20as\x20a\x20chemotherapeutic\x20agent\x20in&nbsp;<strong>receptor\x20positive\x20breast\x20cancer&nbsp;</strong>patients\x20to\x20prevent\x20recurrence\x20after\x20surgery.\x20It\x20is\x20the\x20drug\x20of\x20choice\x20in&nbsp;<strong>pre-menopausal\x20women.</strong>&nbsp;It\x20has\x20an\x20agonistic\x20action\x20on\x20the\x20endometrium,\x20leading\x20to\x20an&nbsp;<strong>increased\x20risk</strong>&nbsp;of&nbsp;<strong>endometrial\x20cancers</strong>\x20(2\x20fold\x20risk)<strong>.</strong>&nbsp;Hence,\x20it\x20is\x20not\x20used\x20in\x20post-menopausal\x20women.</p>\x0a<p>It\x20is\x20<strong>contraindicated</strong>\x20in\x20<strong>pregnancy</strong>\x20due\x20to\x20teratogenic\x20effects\x20such\x20as\x20<strong>craniofacial\x20abnormalities&nbsp;</strong>and\x20reproductive\x20tract\x20abnormalities.\x20For\x20the\x20same\x20reason,\x20it\x20has\x20to\x20be\x20stopped\x20for\x20<strong>3\x20months</strong>\x20(due\x20to\x20long\x20half-life)\x20prior\x20to\x20<strong>conceiving</strong>.&nbsp;It\x20is\x20also\x20stopped\x20during\x20lactation\x20as\x20it\x20is\x20secreted\x20in\x20breast\x20milk.\x20Other\x20complications\x20of\x20tamoxifen\x20include\x20deep\x20vein\x20thrombosis,\x20pulmonary\x20embolism,\x20and\x20hot\x20flashes.</p>\x0a<p><strong>Other\x20breast\x20cancer\x20risk\x20reduction\x20techniques:</strong></p>\x0a<ol>\x0a<li\x20aria-level=\x221\x22><strong>Lifestyle\x20modification:</strong>&nbsp;Low-calorie\x20diet,\x20daily\x20exercise,\x20no\x20smoking,\x20no\x20drinking,\x20etc.</li>\x0a<li\x20aria-level=\x221\x22>More&nbsp;<strong>frequent\x20screening</strong>&nbsp;with\x20mammogram\x20+/-\x20MRI</li>\x0a<li\x20aria-level=\x221\x22>Chemoprevention<strong>:</strong>&nbsp;Preferred\x20in\x20women\x20&gt;35\x20years\x20of\x20age\x20in\x20patients\x20who\x20are\x20ER/PR\x20positive.\x20Given\x20for\x205-10\x20years.</li>\x0a<ul>\x0a<li\x20aria-level=\x222\x22><strong>SERMS</strong>&nbsp;(selective\x20estrogen\x20receptor\x20modulators)\x20-\x20Tamoxifen\x20and\x20raloxifene.\x20These\x20have\x20adverse\x20effects.&nbsp;</li>\x0a<li\x20aria-level=\x222\x22><strong>Aromatase\x20Inhibitors</strong>&nbsp;(AIs):\x20They\x20are\x20used\x20only\x20in\x20<strong>post-menopausal\x20women.</strong></li>\x0a</ul>\x0a<li\x20aria-level=\x221\x22><strong>Risk-reduction\x20surgeries:</strong>&nbsp;preferred\x20in\x20patients\x20with&nbsp;<strong>BRCA1/2</strong>&nbsp;mutations&nbsp;or\x20patients\x20with\x20first-degree\x20relatives\x20with\x20breast\x20cancers.\x20Provides\x20&gt;90%\x20risk-reduction.\x20preferred\x20in\x20patients\x20who\x20have\x20completed\x20their\x20family.</li>\x0a<ul>\x0a<li\x20aria-level=\x222\x22><strong>Bilateral\x20mastectomy</strong></li>\x0a<li\x20aria-level=\x222\x22><strong>Salpingo-oophorectomy:</strong>&nbsp;Best\x20results\x20when\x20done\x20&lt;\x2040\x20years\x20of\x20age.</li>\x0a</ul>\x0a</ol>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20young\x20boy\x20with\x20a\x20history\x20of\x20multiple\x20blood\x20transfusions\x20presents\x20with\x20bone\x20pain\x20for\x20the\x20past\x206\x20months.\x20\x20A\x20peripheral\x20smear\x20showed\x20sickle-shaped\x20RBCs.\x20Which\x20of\x20the\x20following\x20drugs\x20are\x20not\x20used\x20in\x20the\x20treatment\x20of\x20his\x20condition?','choices':[{'id':0x1,'text':_0x6eced6(0x18d)},{'id':0x2,'text':'Voxelotor'},{'id':0x3,'text':'Hydroxyurea'},{'id':0x4,'text':_0x6eced6(0x1e8)}],'correct_choice_id':0x1,'solution':'<p><strong>Bebtelovimab</strong>\x20is\x20not\x20used\x20in\x20the\x20treatment\x20of\x20<strong>sickle\x20cell\x20disease</strong>.\x20The\x20clinical\x20features\x20of\x20<strong>multiple\x20blood\x20transfusions</strong>,\x20<strong>bone\x20pain,</strong>\x20and\x20<strong>sickle\x20cells</strong>\x20on\x20peripheral\x20smear\x20are\x20suggestive\x20of\x20<strong>sickle\x20cell\x20disease</strong>.</p>\x0a<p>Bebtelovimab\x20is\x20the\x20new\x20monoclonal\x20antibody\x20used\x20for\x20the\x20treatment\x20of\x20COVID-19.\x20It&nbsp;works\x20by\x20binding\x20to\x20the\x20<strong>spike\x20protein</strong>\x20of\x20the\x20COVID-19\x20virus.\x20It\x20has\x20been\x20found\x20useful\x20in\x20reducing\x20the\x20risk\x20of\x20hospitalization\x20or\x20death.&nbsp;Bebtelovimab\x20retains\x20the\x20activity\x20against\x20the\x20<strong>omicron</strong>\x20variant.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20<strong>Voxelotor</strong>\x20is\x20an\x20inhibitor\x20of&nbsp;<strong>hemoglobin\x20S</strong>\x20<strong>polymerase\x20</strong>and<strong>&nbsp;stabilizer\x20</strong>of\x20sickle\x20cell\x20hemoglobin<strong>\x20(HbS)</strong>\x20that\x20is\x20used\x20in\x20the\x20therapy\x20of\x20sickle\x20cell\x20disease.</p>\x0a<p>Option\x20C:&nbsp;<strong>Hydroxyurea</strong>\x20improves\x20fetal\x20haemoglobin\x20<strong>(HbF)</strong>\x20and\x20is\x20the\x20primary\x20drug\x20for\x20<strong>controlling\x20HbS</strong>\x20in\x20sickle\x20cell\x20disease.\x20Thus\x20improving\x20the\x20oxygen-carrying\x20capacity\x20of\x20the\x20blood.&nbsp;Hydroxyurea\x20also\x20inhibits\x20the\x20enzyme\x20<strong>ribonucleotide\x20reductase\x20(RNR)</strong>,\x20which\x20is\x20a\x20rate-limiting\x20step\x20in\x20the\x20biosynthesis\x20of\x20DNA.\x20This\x20property\x20of\x20hydroxyurea\x20is\x20used\x20in\x20the\x20treatment\x20of\x20various\x20cancers,\x20and\x20myeloproliferative\x20disorders\x20like\x20chronic\x20myelogenous\x20leukemia,\x20and\x20polycythemia.</p>\x0a<p>Option\x20D:\x20<strong>L-glutamine</strong>&nbsp;is\x20a\x20naturally\x20occurring\x20amino\x20acid\x20with\x20<strong>antioxidant\x20properties</strong>.\x20It&nbsp;increases\x20the\x20availability\x20of\x20reduced\x20glutathione\x20which\x20may\x20lessen\x20oxidative\x20damage\x20in\x20sickle\x20red\x20blood\x20cells.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x13d),'choices':[{'id':0x1,'text':_0x6eced6(0x321)},{'id':0x2,'text':_0x6eced6(0x3a5)},{'id':0x3,'text':_0x6eced6(0x2e4)},{'id':0x4,'text':_0x6eced6(0x3bb)}],'correct_choice_id':0x1,'solution':'<p>The\x20half-life\x20of\x20<strong>letrozole</strong>\x20is\x20<strong>45\x20hours</strong>.</p>\x0a<p>Letrozole\x20is\x20a\x20<strong>reversible\x20aromatase\x20inhibitor</strong>.\x20It\x20is\x20a\x20non-steroidal\x20compound\x20that\x20inhibits\x20the\x20aromatization\x20of\x20estrogen\x20thereby\x20causing\x20<strong>estrogen\x20depletion</strong>.\x20Letrozole\x20is\x20rapidly\x20absorbed\x20with\x2099.9%\x20oral\x20bioavailability\x20and\x20has\x20a&nbsp;<strong>t&frac12;</strong>\x20of\x20around\x20<strong>41\x20hours</strong>.</p>\x0a<p>Letrozole\x20is\x20used\x20as\x20the\x20first-line\x20drug\x20for\x20<strong>estrogen-positive</strong>\x20breast\x20cancer\x20following\x20mastectomy\x20in\x20post-menopausal\x20women.</p>\x0a<p>Adverse\x20effects\x20of\x20letrozole\x20are\x20due\x20to\x20the\x20depletion\x20of\x20estrogen.\x20The\x20commonly\x20seen\x20adverse\x20effects\x20are\x20<strong>hot\x20flashes</strong>,\x20<strong>vaginal\x20dryness</strong>,\x20nausea,\x20diarrhea,\x20dyspepsia,\x20accelerated\x20bone\x20loss,\x20and\x20thinning\x20of\x20hair.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Identify\x20the\x20false\x20statement\x20about\x20eicosanoids.','choices':[{'id':0x1,'text':_0x6eced6(0x130)},{'id':0x2,'text':_0x6eced6(0x335)},{'id':0x3,'text':_0x6eced6(0x17e)},{'id':0x4,'text':'Synthesized\x20in\x20platelets'}],'correct_choice_id':0x1,'solution':_0x6eced6(0x44f),'explanation_video':'','question_images':[],'explanation_images':[_0x6eced6(0x3c9)]},{'text':_0x6eced6(0x3ca),'choices':[{'id':0x1,'text':'1'},{'id':0x2,'text':'2'},{'id':0x3,'text':'3'},{'id':0x4,'text':'4'}],'correct_choice_id':0x4,'solution':_0x6eced6(0x2a9),'explanation_video':'','question_images':[_0x6eced6(0x158)],'explanation_images':[]},{'text':_0x6eced6(0x2fa),'choices':[{'id':0x1,'text':'Gs'},{'id':0x2,'text':'Gi'},{'id':0x3,'text':'Gq'},{'id':0x4,'text':'Go'}],'correct_choice_id':0x3,'solution':_0x6eced6(0x391),'explanation_video':'','question_images':[],'explanation_images':[_0x6eced6(0x410)]},{'text':'A\x20patient\x20was\x20diagnosed\x20with\x20pulmonary\x20tuberculosis\x20and\x20was\x20started\x20on\x20first-line\x20antitubercular\x20drugs.\x20Which\x20of\x20the\x20following\x20drug\x20acts\x20by\x20inhibiting\x20the\x20synthesis\x20of\x20the\x20marked\x20layer\x20shown\x20in\x20the\x20image?','choices':[{'id':0x1,'text':_0x6eced6(0x38a)},{'id':0x2,'text':_0x6eced6(0x431)},{'id':0x3,'text':_0x6eced6(0x25c)},{'id':0x4,'text':_0x6eced6(0x19d)}],'correct_choice_id':0x1,'solution':'<p><strong>Isoniazid</strong>\x20is\x20the\x20first-line\x20antitubercular\x20drug\x20that\x20acts\x20by\x20inhibiting\x20the\x20synthesis\x20of&nbsp;<strong>mycolic\x20acid</strong>.</p>\x0a<p><strong>Isoniazid</strong>\x20is\x20a\x20first-line\x20bactericidal\x20drug\x20that\x20is\x20used\x20for\x20the\x20treatment\x20of\x20tuberculosis.\x20This\x20drug\x20enters\x20bacilli\x20by\x20<strong>passive\x20diffusion</strong>.\x20It\x20then\x20gets\x20activated\x20to\x20its\x20toxic\x20form\x20by\x20the\x20enzyme\x20<strong>catalase-peroxidase</strong>(the\x20enzyme\x20encoded\x20by\x20the\x20<strong>Kat\x20gene</strong>).</p>\x0a<p>Normally,\x20InhA\x20and\x20KasA\x20are\x20involved\x20in\x20the\x20synthesis\x20of\x20mycolic\x20acid.\x20Upon\x20activation,\x20the\x20reactive\x20metabolite\x20of\x20isoniazid\x20forms\x20complexes\x20with\x20<strong>NAD</strong>\x20that\x20inhibit\x20<strong>InhA</strong>\x20and\x20<strong>KasA</strong>.\x20Hence,\x20isoniazid\x20inhibits\x20the\x20production\x20of\x20<strong>mycolic\x20acid</strong>.</p>\x0a<p>The\x20reactive\x20isoniazid\x20metabolite\x20also\x20forms\x20complexes\x20with\x20<strong>NADP</strong>.\x20This\x20complex\x20inhibits\x20mycobacterial\x20dihydrofolate\x20reductase\x20which\x20results\x20in\x20the\x20interruption\x20of\x20<strong>DNA\x20synthesis</strong>.</p>\x0a<p>Side\x20effects\x20of\x20isoniazid\x20include:</p>\x0a<ul>\x0a<li><strong>Peripheral\x20neuritis</strong>\x20due\x20to\x20interference\x20with\x20the\x20production\x20of\x20active\x20coenzyme\x20pyridoxal\x20phosphate\x20from\x20pyridoxine.\x20Therefore,\x20<strong>pyridoxine\x2010mg/day\x20(vitamin\x20B6)</strong>\x20is\x20given\x20prophylactically\x20along\x20with\x20isoniazid\x20to\x20prevent\x20neurotoxicity.</li>\x0a<li><strong>Hepatitis</strong>\x20-\x20isoniazid\x20must\x20be\x20stopped\x20at\x20the\x20first\x20sign\x20of\x20hepatotoxicity.</li>\x0a<li>Rashes</li>\x0a<li>Anaemia</li>\x0a<li>Arthralgia</li>\x0a</ul>\x0a<p>Toxicity\x20of\x20isoniazid\x20results\x20in\x20<strong>metabolic\x20acidosis</strong>,&nbsp;<strong>seizures,\x20and\x20coma.</strong></p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:&nbsp;Rifampin\x20acts\x20by\x20binding\x20to\x20<strong>DNA-dependent\x20RNA\x20polymerase</strong>\x20to\x20form\x20a\x20stable\x20drug-enzyme\x20complex.\x20This\x20complex\x20suppresses\x20RNA\x20synthesis.\x20Side\x20effects\x20of\x20rifampin\x20are\x20hepatitis,<strong>&nbsp;flu-like\x20illness,\x20orange-red\x20colored\x20urine</strong>,\x20and\x20body\x20secretions.</p>\x0a<p>&nbsp;Option\x20C:\x20Pyrazinamide\x20is\x20a\x20prodrug,\x20it\x20is\x20converted\x20into\x20an\x20active\x20metabolite<strong>\x20pyrazinoic\x20acid\x20</strong>which\x20makes\x20the\x20intracellular\x20environment\x20<strong>acidic</strong>\x20and\x20collapses\x20the\x20transmembrane\x20proton\x20motive\x20force,\x20thereby\x20killing\x20the\x20bacteria.\x20Side\x20effects\x20include&nbsp;<strong>hyperuricemia</strong>\x20and\x20hepatotoxicity.&nbsp;</p>\x0a<p>Option\x20D:\x20Ethambutol<strong>\x20inhibits\x20arabinose\x20transferase\x20III,\x20</strong>thereby\x20decreasing\x20arabinogalactan\x20biosynthesis<strong>.\x20</strong>This\x20results\x20in&nbsp;disruption\x20in&nbsp;mycobacterial\x20cell\x20wall\x20synthesis.&nbsp;<strong>Optic\x20neuritis</strong>\x20is\x20an\x20important\x20side\x20effect\x20of<strong>\x20ethambutol</strong>.\x20It\x20results\x20in\x20decreased\x20visual\x20acuity\x20and&nbsp;<strong>loss\x20of\x20red-green\x20discrimination.</strong></p>','explanation_video':'','question_images':['https://cdn1.dailyrounds.org/uploads/ebe55c0cc99a42b383d1f16c8023a2ff.JPEG'],'explanation_images':[]},{'text':_0x6eced6(0x27b),'choices':[{'id':0x1,'text':_0x6eced6(0x1c6)},{'id':0x2,'text':_0x6eced6(0x425)},{'id':0x3,'text':_0x6eced6(0x3e2)},{'id':0x4,'text':_0x6eced6(0x439)}],'correct_choice_id':0x4,'solution':'<p><strong>Bradycardia</strong>\x20is\x20the\x20possible\x20presenting\x20feature\x20which\x20led\x20to\x20the\x20diagnosis\x20of\x20<strong>muscarinic</strong>\x20<strong>poisoning</strong>.</p>\x0a<p>Muscarinic\x20poisoning\x20occurs\x20due\x20to\x20the\x20consumption\x20of\x20<strong>poisonous\x20mushroom</strong>-like\x20<em>Inocybe</em>.\x20<strong>Muscarinic\x20symptoms</strong>\x20appear\x20within\x20an\x20hour\x20of\x20eating\x20the\x20mushroom.\x20These\x20symptoms\x20(along\x20with\x20nicotinic\x20symptoms)\x20can\x20also\x20be\x20seen\x20in\u00a0<strong>organophosphate\x20poisoning</strong>.</p>\x0a<p>There\x20are\x20<strong>5\u00a0subtypes</strong>\x20of\x20muscarinic\x20receptors\x20they\x20are\x20M<sub>1</sub>,\x20M<sub>2</sub>,\x20M<sub>3</sub>,\x20M<sub>4</sub>,\x20and\x20M<sub>5</sub>.\x20The\x20effects\x20exerted\x20by\x20the\x20<strong>M\x20receptors</strong>\x20are\x20given\x20below:</p>\x0a<ul>\x0a<li>M<sub>1</sub>:\x20Increased\x20seizure\x20activity.</li>\x0a<li>M<sub>2</sub>:\x20<strong>Tremors</strong>,\x20<span\x20class=\x22ILfuVd\x22\x20lang=\x22en\x22><span\x20class=\x22hgKElc\x22>bronchoconstriction,<strong>\x20bradycardia</strong>,\x20abdominal\x20cramping</span></span><sub><br\x20/></sub></li>\x0a<li>M<sub>3</sub>:\x20Increased\x20bladder\x20contraction,\x20<strong>miosis</strong>,\x20increased\x20salivary\x20secretion</li>\x0a<li>M<sub>4</sub>:\x20Cataplexy(sudden\x20muscle\x20weakness)</li>\x0a</ul>\x0a<p><strong>Atropine\u00a0</strong>is\x20used\x20for\x20the\x20management\x20of\x20muscarinic\x20poisoning.\x20It\x20<strong>competitively\x20</strong>blocks\x20the\x20acetylcholine\x20at\x20the\x20muscarinic\x20receptors.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x2029-year-old\x20lady\x20came\x20to\x20psychiatry\x20OPD\x20with\x20symptoms\x20of\x20hypomania.\x20There\x20is\x20a\x20past\x20history\x20of\x20maniac\x20episode.\x20Now,\x20she\x20is\x20planning\x20to\x20conceive.\x20\x20Which\x20drug\x20should\x20be\x20avoided\x20for\x20being\x20highly\x20teratogenic\x20to\x20the\x20fetus?','choices':[{'id':0x1,'text':_0x6eced6(0x437)},{'id':0x2,'text':_0x6eced6(0x380)},{'id':0x3,'text':_0x6eced6(0x409)},{'id':0x4,'text':'Olanzapine'}],'correct_choice_id':0x1,'solution':_0x6eced6(0x2d9),'explanation_video':'','question_images':[],'explanation_images':[_0x6eced6(0x37b),_0x6eced6(0x455)]},{'text':'True\x20statement\x20regarding\x20the\x20administration\x20of\x205\x20alpha-reductase\x20inhibitors\x20is/are:','choices':[{'id':0x1,'text':_0x6eced6(0x244)},{'id':0x2,'text':'1,\x203,\x204'},{'id':0x3,'text':_0x6eced6(0x1b6)},{'id':0x4,'text':_0x6eced6(0x45b)}],'correct_choice_id':0x3,'solution':'<p>True\x20statements\x20regarding\x20the\x20administration\x20of\x20<strong>5\x20alpha-reductase\x20inhibitors</strong>\x20are\x20<strong>1,4</strong>.\x20They\x20reduce\x20dihydrotestosterone\x20levels\x20and\x20decrease\x20prostate-specific\x20antigen\x20(PSA)\x20levels.</p>\x0a<p>5\x20alpha-reductase\x20inhibitors\x20are\x20the\x20<strong>competitive</strong>\x20inhibitors\x20of\x20the\x20enzyme\x205\x20α-reductase\x20which\x20converts\x20testosterone\x20into\x20the\x20more\x20active\x20dihydroxy\x20testosterone\x20(<strong>DHT</strong>).\x20This\x20enzyme\x20inhibition\x20results\x20in:</p>\x0a<ul>\x0a<li><strong>Decreased\x20DHT\x20</strong>levels</li>\x0a<li><strong>Decreased\x20PSA\x20</strong>levels</li>\x0a<li>Reduces\x20prostate\x20volume</li>\x0a</ul>\x0a<p>However,\x20plasma\x20<strong>testosterone</strong>\x20levels\x20and\u00a0<strong>LH</strong>\x20(luteinizing\x20hormone)\x20levels\x20remain\x20<strong>unchanged\u00a0</strong></p>\x0a<p><strong>Finasteride</strong>\x20and\x20<strong>dutasteride</strong>\x20are\x20the\x205\x20α-reductase\x20drugs\x20currently\x20in\x20use.\x20They\x20are\x20used\x20in\x20benign\x20prostatic\x20hyperplasia\x20(<strong>BPH</strong>)\x20along\x20with\x20surgery\x20and\x20adrenergic\x20α1\x20blockers\x20for\x20symptomatic\x20relief.\x20They\x20can\x20also\x20be\x20used\x20in\x20<strong>male\x20pattern\x20of\x20baldness</strong>\x20and\x20hirsutism.</p>\x0a<p>Side\x20effects\x20of\x205\x20α-reductase\x20drugs\x20are:</p>\x0a<ul>\x0a<li><strong>Impotence</strong></li>\x0a<li>Decreased\x20libido</li>\x0a<li>Gynecomastia</li>\x0a<li>Skin\x20rashes</li>\x0a</ul>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x324),'choices':[{'id':0x1,'text':'Spurious\x20drug'},{'id':0x2,'text':'Adulterated\x20drug'},{'id':0x3,'text':_0x6eced6(0x3c0)},{'id':0x4,'text':_0x6eced6(0x34f)}],'correct_choice_id':0x4,'solution':_0x6eced6(0x1a5),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20anti-diabetic\x20drugs\x20is\x20associated\x20with\x20the\x20increased\x20risk\x20of\x20fractures?','choices':[{'id':0x1,'text':'Rosiglitazone'},{'id':0x2,'text':_0x6eced6(0x3b9)},{'id':0x3,'text':_0x6eced6(0x275)},{'id':0x4,'text':_0x6eced6(0x3ee)}],'correct_choice_id':0x4,'solution':_0x6eced6(0x38f),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'The\x20active\x20metabolite\x20of\x20cyclophosphamide\x20is:','choices':[{'id':0x1,'text':_0x6eced6(0x1f1)},{'id':0x2,'text':_0x6eced6(0x45f)},{'id':0x3,'text':_0x6eced6(0x1eb)},{'id':0x4,'text':_0x6eced6(0x174)}],'correct_choice_id':0x2,'solution':_0x6eced6(0x46b),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Urinary\x20alkalinization\x20will\x20be\x20most\x20useful\x20in\x20toxicity\x20of\x20which\x20of\x20the\x20following\x20drugs?','choices':[{'id':0x1,'text':_0x6eced6(0x198)},{'id':0x2,'text':_0x6eced6(0x2f7)},{'id':0x3,'text':_0x6eced6(0x17d)},{'id':0x4,'text':_0x6eced6(0x165)}],'correct_choice_id':0x4,'solution':_0x6eced6(0x1cf),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x3cc),'choices':[{'id':0x1,'text':_0x6eced6(0x443)},{'id':0x2,'text':_0x6eced6(0x349)},{'id':0x3,'text':_0x6eced6(0x2f4)},{'id':0x4,'text':_0x6eced6(0x428)}],'correct_choice_id':0x2,'solution':_0x6eced6(0x281),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x2c4),'choices':[{'id':0x1,'text':_0x6eced6(0x30f)},{'id':0x2,'text':'It\x20cannot\x20be\x20reversed\x20by\x20levallorphan.'},{'id':0x3,'text':'It\x20is\x20caused\x20by\x20activation\x20of\x20the\x20Edinger-Westphal\x20nucleus.'},{'id':0x4,'text':_0x6eced6(0x218)}],'correct_choice_id':0x3,'solution':_0x6eced6(0x1d8),'explanation_video':'','question_images':[_0x6eced6(0x212)],'explanation_images':[]},{'text':_0x6eced6(0x224),'choices':[{'id':0x1,'text':_0x6eced6(0x3d3)},{'id':0x2,'text':_0x6eced6(0x1d9)},{'id':0x3,'text':_0x6eced6(0x164)},{'id':0x4,'text':_0x6eced6(0x371)}],'correct_choice_id':0x2,'solution':_0x6eced6(0x231),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x1c4),'choices':[{'id':0x1,'text':_0x6eced6(0x435)},{'id':0x2,'text':'1,\x202'},{'id':0x3,'text':_0x6eced6(0x172)},{'id':0x4,'text':_0x6eced6(0x244)}],'correct_choice_id':0x2,'solution':'<p><strong>1\x20and\x202</strong>\x20are\x20true\x20statements\x20regarding\x20memantine.</p>\x0a<p>Memantine\x20is\x20a\x20non-competitive&nbsp;<strong>NMDA\x20receptor\x20antagonist</strong>.\x20It\x20inhibits\x20glutamate\x20excitotoxicity.\x20It\x20delays\x20the\x20progression\x20of\x20dementia\x20in<strong>\x20Alzheimer\x27s\x20disease</strong>.\x20Commonly,\x20it\x20is\x20started\x20in\x20patients\x20with\x20<strong>moderate-to-severe</strong>\x20disease.</p>\x0a<p>It\x20can\x20be\x20given\x20both\x20as\x20<strong>monotherapy</strong>\x20or\x20can\x20be\x20given\x20<strong>along</strong>\x20with\x20<strong>cholinesterase\x20inhibitors</strong>.\x20It\x20can\x20be\x20started\x20at\x20a\x20dose\x20of\x20<strong>5\x20mg\x20once\x20daily</strong>\x20and\x20then\x20progressively\x20increased\x20<strong>up\x20to\x2010\x20mg\x20twice\x20daily</strong>\x20for\x20a\x20minimum\x20of\x206\x20months.&nbsp;</p>\x0a<p>It\x20can\x20cause\x20dizziness\x20and\x20headache.\x20Since\x20it\x20is\x20excreted\x20in\x20the\x20kidney,\x20careful\x20dose\x20adjustments\x20should\x20be\x20made\x20in\x20patients\x20with\x20renal\x20failure.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x41e),'choices':[{'id':0x1,'text':_0x6eced6(0x254)},{'id':0x2,'text':_0x6eced6(0x2fb)},{'id':0x3,'text':_0x6eced6(0x34b)},{'id':0x4,'text':_0x6eced6(0x2b0)}],'correct_choice_id':0x1,'solution':_0x6eced6(0x234),'explanation_video':'','question_images':[_0x6eced6(0x1b2)],'explanation_images':[_0x6eced6(0x449)]},{'text':'Which\x20of\x20the\x20following\x20statements\x20is\x20correct\x20regarding\x20clinical\x20trials?','choices':[{'id':0x1,'text':_0x6eced6(0x3f0)},{'id':0x2,'text':'Phase\x204\x20is\x20also\x20called\x20post-marketing\x20surveillance'},{'id':0x3,'text':_0x6eced6(0x308)},{'id':0x4,'text':_0x6eced6(0x290)}],'correct_choice_id':0x2,'solution':_0x6eced6(0x265),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x1b8),'choices':[{'id':0x1,'text':_0x6eced6(0x42a)},{'id':0x2,'text':_0x6eced6(0x2ae)},{'id':0x3,'text':'1-d,\x202-a,\x203-d,\x204-c'},{'id':0x4,'text':'1-d,\x202-c,\x203-b,\x204-a'}],'correct_choice_id':0x4,'solution':_0x6eced6(0x2ac),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x3b0),'choices':[{'id':0x1,'text':_0x6eced6(0x434)},{'id':0x2,'text':_0x6eced6(0x23e)},{'id':0x3,'text':'Prazosin'},{'id':0x4,'text':'Frusemide'}],'correct_choice_id':0x3,'solution':_0x6eced6(0x40f),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'An\x20experiment\x20is\x20being\x20conducted\x20on\x20a\x20cat\x20spine\x20to\x20study\x20the\x20effect\x20of\x20acetylcholine.\x20The\x20blood\x20pressure\x20is\x20recorded\x20at\x20each\x20intervention\x20and\x20is\x20shown\x20below.\x20What\x20does\x20phase\x204\x20in\x20the\x20graph\x20indicate?','choices':[{'id':0x1,'text':'Muscarinic\x20action\x20of\x20acetylcholine'},{'id':0x2,'text':_0x6eced6(0x185)},{'id':0x3,'text':'Antagonism\x20of\x20acetylcholine'},{'id':0x4,'text':_0x6eced6(0x3d6)}],'correct_choice_id':0x4,'solution':'<p>Phase\x204\x20in\x20the\x20graph\x20indicates\x20the\x20<strong>nicotinic\x20action</strong>&nbsp;of\x20acetylcholine\x20at<strong>\x20higher\x20doses</strong>.</p>\x0a<p>In\x20phases\x201\x20and\x202,\x20acetylcholine\x20(Ach)\x20acts\x20on\x20muscarinic\x20receptors\x20(at\x202\x20micrograms\x20and\x2050\x20micrograms)\x20bringing\x20down\x20blood\x20pressure.\x20<strong>Atropine</strong>\x20<strong>blocks</strong>\x20the\x20<strong>muscarinic\x20receptor</strong>,\x20so\x20this\x20action\x20of\x20acetylcholine\x20is\x20not\x20seen\x20in\x20phase\x203.\x20However,\x20in\x20phase\x204,\x20<strong>higher\x20doses</strong>\x20of\x20Ach\x20(like\x205\x20mg)\x20act\x20via\x20the\x20<strong>nicotinic\x20receptor</strong>,\x20shooting\x20up\x20the\x20blood\x20pressure.\x20This\x20phenomenon\x20is\x20called\x20the\x20reversal\x20of\x20Ach\x20in\x20blood\x20pressure\x20and\x20was\x20studied\x20by\x20Dale.&nbsp;</p>\x0a<p><strong>Nicotinic\x20receptors</strong>\x20are\x20<strong>ligand-gated</strong>\x20ion\x20channels.\x20It\x20can\x20be\x20divided\x20into\x20two\x20groups:\x20muscle\x20receptors\x20(N<sub>M</sub>),\x20which\x20are\x20found\x20at\x20the\x20skeletal\x20neuromuscular\x20junction,\x20and\x20<strong>neuronal\x20receptors</strong>\x20(N<sub>N</sub>),\x20which\x20are\x20found\x20in\x20the\x20ganglia\x20and\x20CNS.\x20When\x20stimulated\x20at\x20higher\x20doses,\x20Ach\x20acts\x20on\x20N<sub>N</sub>&nbsp;receptors,\x20leading\x20to\x20the\x20stimulation\x20of\x20<strong>sympathetic\x20ganglia</strong>\x20and\x20<strong>adrenal\x20medulla</strong>.\x20This&nbsp;<strong>increases</strong>\x20the\x20heart\x20rate,\x20<strong>blood\x20pressure</strong>,\x20and\x20myocardial\x20contractility.</p>\x0a<p><strong>Muscarinic</strong>\x20receptors\x20are\x20<strong>G-coupled\x20protein</strong>\x20receptors\x20involved\x20in\x20the\x20parasympathetic\x20nervous\x20system.&nbsp;M1,\x20M2,\x20M3,\x20M4,\x20and\x20M5\x20are\x20the\x20receptor\x20subtypes.\x20They\x20act\x20via\x20Gi\x20or\x20Gq\x20subunits.\x20When\x20<strong>Ach</strong>\x20is\x20administered,\x20it\x20acts\x20on&nbsp;muscarinic\x20receptors,\x20primarily\x20the<strong>\x20M3\x20receptors</strong>,\x20which\x20are\x20located\x20on\x20<strong>vascular\x20endothelial\x20cells</strong>.\x20It\x20stimulates\x20<strong>guanylyl\x20cyclase</strong>\x20and\x20promotes\x20relaxation\x20via\x20a\x20cyclic\x20GMP&ndash;dependent\x20mechanism.\x20At\x20higher\x20doses,\x20it\x20acts\x20on&nbsp;<strong>M2\x20receptors,</strong>\x20which\x20have\x20direct\x20effects\x20on\x20the\x20<strong>heart</strong>.\x20It\x20also\x20inhibits\x20the\x20release\x20of\x20norepinephrine\x20from\x20sympathetic\x20nerve\x20terminals\x20and\x20decreases\x20cyclic\x20AMP\x20levels.</p>','explanation_video':'','question_images':[_0x6eced6(0x23b)],'explanation_images':[]},{'text':_0x6eced6(0x42d),'choices':[{'id':0x1,'text':_0x6eced6(0x1d2)},{'id':0x2,'text':_0x6eced6(0x363)},{'id':0x3,'text':_0x6eced6(0x3a9)},{'id':0x4,'text':'Zidovudine'}],'correct_choice_id':0x2,'solution':_0x6eced6(0x34a),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x221),'choices':[{'id':0x1,'text':_0x6eced6(0x309)},{'id':0x2,'text':'Topical\x20ocular\x20carbonic\x20anhydrase\x20inhibitor'},{'id':0x3,'text':'Second-generation\x20sulfonylurea'},{'id':0x4,'text':_0x6eced6(0x33f)}],'correct_choice_id':0x2,'solution':'<p><strong>Dorzolamide</strong>\x20is\x20a\x20<strong>topical\x20ocular\x20carbonic\x20anhydrase\x20inhibitor</strong>.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20462\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>It\x20acts\x20on\x20carbonic\x20anhydrase\x20in\x20the\x20ciliary\x20processes\x20of\x20the\x20eye\x20and\x20mediates\x20the\x20formation\x20of\x20HCO<sub>3</sub><sup>-</sup><sub>&nbsp;</sub>in\x20aqueous\x20humor.\x20Inhibition\x20of\x20carbonic\x20anhydrase\x20decreases\x20the\x20rate\x20of\x20formation\x20of\x20aqueous\x20humor\x20and\x20consequently\x20reduces\x20intraocular\x20pressure.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20462\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>The\x20major\x20indication\x20for\x20carbonic\x20anhydrase\x20inhibitors\x20is\x20<strong>open-angle\x20glaucoma</strong>.\x20Dorzolamide\x20and\x20<strong>brinzolamide</strong>,\x20which\x20are\x20available\x20only\x20as\x20ophthalmic\x20<strong>drops</strong>,\x20are\x20used\x20for\x20this\x20purpose.</p>\x0a<p>Dorzolamide\x20may\x20be\x20used\x20for\x20secondary\x20glaucoma\x20and\x20in\x20acute\x20angle-closure\x20glaucoma\x20to\x20lower\x20intraocular\x20pressure\x20before\x20surgery.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x2bc),'choices':[{'id':0x1,'text':_0x6eced6(0x28d)},{'id':0x2,'text':_0x6eced6(0x2d4)},{'id':0x3,'text':_0x6eced6(0x3d1)},{'id':0x4,'text':_0x6eced6(0x3fc)}],'correct_choice_id':0x2,'solution':_0x6eced6(0x3ba),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x31d),'choices':[{'id':0x1,'text':_0x6eced6(0x2f6)},{'id':0x2,'text':'A-3,\x20B-4,\x20C-2,\x20D-1'},{'id':0x3,'text':_0x6eced6(0x2c9)},{'id':0x4,'text':_0x6eced6(0x1d9)}],'correct_choice_id':0x4,'solution':_0x6eced6(0x404),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Alkalinization\x20of\x20urine\x20will\x20be\x20helpful\x20in\x20the\x20removal\x20of\x20_____.','choices':[{'id':0x1,'text':'Weakly\x20basic\x20drugs'},{'id':0x2,'text':_0x6eced6(0x30c)},{'id':0x3,'text':_0x6eced6(0x3f1)},{'id':0x4,'text':_0x6eced6(0x13e)}],'correct_choice_id':0x4,'solution':'<p>Alkalinization\x20of\x20urine\x20will\x20be\x20helpful\x20in\x20the\x20removal\x20of\x20<strong>weakly\x20acidic\x20drugs</strong>\x20as\x20they\x20are\x20susceptible\x20to<strong>&nbsp;ion\x20trapping</strong>\x20in\x20the&nbsp;urine.</p>\x0a<p>Drugs\x20that\x20are\x20subjected\x20to\x20renal\x20clearance\x20are\x20excreted\x20into\x20the\x20urine\x20by\x20glomerular\x20filtration\x20and\x20active\x20tubular\x20secretion.\x20Nonionized\x20compounds\x20are\x20reabsorbed\x20more\x20rapidly\x20than\x20ionized\x20polar\x20molecules.\x20When\x20the\x20<strong>pH</strong>\x20of\x20the\x20<strong>urine&nbsp;increases</strong>,\x20more\x20salicylate\x20is\x20in\x20its\x20ionized\x20form\x20at\x20equilibrium.\x20Hence,\x20salicylic\x20acid\x20<strong>diffuses</strong>\x20into\x20the\x20<strong>tubular\x20lumen</strong>\x20of\x20the\x20kidney.\x20Urine\x20alkalinization\x20is\x20recommended\x20as\x20a\x20first-line\x20treatment\x20only\x20for\x20moderately\x20severe\x20salicylate\x20poisoning\x20that&nbsp;does\x20not\x20meet\x20the\x20criteria\x20for\x20hemodialysis.</p>\x0a<p>Alkalinization\x20of\x20the\x20urine\x20is\x20achieved\x20by\x20administration\x20of\x20<strong>100&ndash;150\x20mEq</strong>\x20of\x20<strong>sodium\x20bicarbonate</strong>\x20in\x201\x20L\x20of\x205%\x20dextrose\x20in\x20water\x20(D5W).\x20It\x20is\x20infused\x20intravenously&nbsp;at\x20twice\x20the\x20maintenance\x20fluid\x20requirements.</p>\x0a<p>Alkalinization\x20of\x20urine\x20is\x20<strong>contraindicated</strong>\x20in\x20<strong>renal\x20failure</strong>\x20or\x20if\x20fluid\x20administration\x20may\x20worsen&nbsp;<strong>pulmonary\x20edema</strong>\x20or\x20congestive\x20heart\x20failure.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'All\x20of\x20the\x20following\x20side\x20effects\x20are\x20more\x20commonly\x20seen\x20with\x20carbamazepine\x20than\x20oxcarbazepine,\x20except_____.','choices':[{'id':0x1,'text':'Hypotension'},{'id':0x2,'text':_0x6eced6(0x303)},{'id':0x3,'text':'Rash'},{'id':0x4,'text':_0x6eced6(0x206)}],'correct_choice_id':0x2,'solution':_0x6eced6(0x441),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Match\x20the\x20following\x20drugs\x20with\x20the\x20targets\x20of\x20their\x20actions.','choices':[{'id':0x1,'text':_0x6eced6(0x297)},{'id':0x2,'text':_0x6eced6(0x20b)},{'id':0x3,'text':_0x6eced6(0x2c8)},{'id':0x4,'text':_0x6eced6(0x1a2)}],'correct_choice_id':0x4,'solution':_0x6eced6(0x2a5),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x277),'choices':[{'id':0x1,'text':_0x6eced6(0x467)},{'id':0x2,'text':_0x6eced6(0x394)},{'id':0x3,'text':_0x6eced6(0x2d6)},{'id':0x4,'text':_0x6eced6(0x24d)}],'correct_choice_id':0x4,'solution':_0x6eced6(0x13f),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x423),'choices':[{'id':0x1,'text':'Fenofibrate\x20160\x20mg'},{'id':0x2,'text':_0x6eced6(0x320)},{'id':0x3,'text':_0x6eced6(0x2f9)},{'id':0x4,'text':_0x6eced6(0x162)}],'correct_choice_id':0x4,'solution':'<p><strong>Atorvastatin\x2080\x20mg</strong>\x20can\x20be\x20used\x20to\x20treat\x20this\x20condition.&nbsp;The\x20first\x20line\x20of\x20therapy\x20in\x20controlling\x20cholesterol\x20in\x20patients\x20with\x20atherosclerotic\x20cardiovascular\x20disease\x20(ASCVD)\x20is\x20starting\x20a\x20high-intensity\x20statin.\x20<strong>High-intensity\x20statins</strong>\x20include\x20<strong>atorvastatin</strong>\x20(40-80\x20mg)\x20and\x20<strong>rosuvastatin\x20</strong>(20-40\x20mg)<strong>.</strong></p>\x0a<p>Statins\x20are\x20<strong>competitive\x20inhibitors</strong>\x20of\x20<strong>HMG-CoA\x20reductase</strong>.\x20This\x20leads\x20to\x20a\x20decrease\x20in\x20cholesterol\x20biosynthesis.\x20Statins\x20are\x20also\x20effective\x20in\x20reducing\x20LDL\x20and\x20triglyceride\x20levels.&nbsp;</p>\x0a<p>Other\x20options:&nbsp;</p>\x0a<p>Option\x20A.\x20<strong>Fenofibrate</strong>\x20reduces\x20lipoprotein\x20levels\x20by\x20interacting\x20with\x20Peroxisome\x20proliferator-activated\x20receptor\x20(PPAR-&alpha;)\x20and\x20stimulating\x20<strong>lipoprotein\x20lipase</strong>.\x20They\x20are\x20used\x20as\x20drugs\x20of\x20choice\x20for\x20treating\x20hyperlipoproteinemia\x20and\x20severe\x20hypertriglyceridemia\x20(&gt;1000\x20mg/dL).</p>\x0a<p>Option\x20B.\x20<strong>Rosuvastatin\x20and\x20fenofibrate</strong>\x20combination\x20was\x20previously\x20used\x20to\x20reduce\x20atherosclerotic\x20cardiovascular\x20disease\x20risk.\x20But\x20recent\x20studies\x20have\x20indicated\x20no\x20change\x20in\x20reduction\x20and\x20hence\x20is\x20<strong>not\x20recommended\x20anymore</strong>.&nbsp;</p>\x0a<p>Option\x20C:\x20<strong>Rosuvastatin\x2010\x20mg</strong>\x20is\x20a<strong>\x20low-intensity\x20statin</strong>\x20and\x20is\x20mainly\x20used\x20for\x20<strong>primary\x20prevention</strong>\x20against\x20atherosclerotic\x20cardiovascular\x20disease.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x230),'choices':[{'id':0x1,'text':'Tocainide'},{'id':0x2,'text':_0x6eced6(0x15c)},{'id':0x3,'text':_0x6eced6(0x3ea)},{'id':0x4,'text':'Lignocaine'}],'correct_choice_id':0x3,'solution':_0x6eced6(0x459),'explanation_video':'','question_images':['https://cdn1.dailyrounds.org/uploads/9a743f063aa049a4abcbf92fcafe7d5e.PNG'],'explanation_images':['https://dhmbxeygs57ff.cloudfront.net/uploads/290d9cdbaa444b8590f4728bb58ece8fx1280x647.PNG','https://dhmbxeygs57ff.cloudfront.net/uploads/e807614673e74d1abc58bf1072520068x1280x719.PNG',_0x6eced6(0x3f4)]},{'text':_0x6eced6(0x388),'choices':[{'id':0x1,'text':_0x6eced6(0x20c)},{'id':0x2,'text':_0x6eced6(0x352)},{'id':0x3,'text':_0x6eced6(0x2f5)},{'id':0x4,'text':'With\x20the\x20long\x20term\x20use,\x20there\x20is\x20slight\x20increase\x20in\x20the\x20incidence\x20of\x20type\x202\x20diabetes\x20mellitus.'}],'correct_choice_id':0x3,'solution':_0x6eced6(0x40c),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x1a6),'choices':[{'id':0x1,'text':_0x6eced6(0x336)},{'id':0x2,'text':_0x6eced6(0x3a1)},{'id':0x3,'text':_0x6eced6(0x2fd)},{'id':0x4,'text':_0x6eced6(0x2bf)}],'correct_choice_id':0x2,'solution':_0x6eced6(0x457),'explanation_video':'','question_images':[_0x6eced6(0x383)],'explanation_images':[_0x6eced6(0x319)]},{'text':_0x6eced6(0x133),'choices':[{'id':0x1,'text':_0x6eced6(0x30b)},{'id':0x2,'text':_0x6eced6(0x44e)},{'id':0x3,'text':_0x6eced6(0x3f9)},{'id':0x4,'text':'2,\x203,\x20and\x204'}],'correct_choice_id':0x1,'solution':'<p>The\x20wrong\x20statement/s\x20regarding\x20disulfiram\x20is\x20only\x203.</p>\x0a<p>Disulfiram\x20is\x20an\x20<strong>irreversible\x20inhibitor</strong>\x20of\x20both\x20cytosolic\x20and\x20mitochondrial\x20forms\x20of\x20<strong>aldehyde\x20dehydrogenase.</strong>&nbsp;It\x20is\x20used\x20in\x20behavioral\x20modification\x20for\x20alcohol\x20de-addiction.&nbsp;The\x20principle\x20of\x20action\x20is\x20<strong>aversive\x20conditioning</strong>\x20(not\x20anti-craving).</p>\x0a<p>Disulfiram\x20can\x20be\x20given\x20only\x20to\x20<strong>highly\x20motivated</strong>\x20individuals.\x20It\x20should\x20not\x20be\x20administered\x20until\x20the\x20person\x20has\x20<strong>abstained</strong>\x20from\x20alcohol\x20for\x20<strong>at\x20least\x2012\x20hours</strong>.&nbsp;The\x20disulfiram-alcohol\x20reaction\x20may\x20persist\x20as\x20long\x20as\x2014\x20days\x20after\x20the\x20last\x20dose\x20of\x20disulfiram.</p>\x0a<p>Alcohol\x20consumption\x20during\x20disulfiram\x20therapy\x20can\x20lead\x20to\x20<strong>increased</strong>\x20concentrations\x20of\x20<strong>acetaldehyde</strong>.\x20This\x20can\x20cause\x20aversive\x20reactions,\x20resulting\x20in\x20flushing,\x20pulsating\x20headache,\x20throbbing\x20pain\x20in\x20the\x20head\x20and\x20neck,\x20nausea,\x20vomiting,\x20rashes,\x20<strong>respiratory\x20difficulties</strong>,\x20chest\x20pain,\x20and\x20autonomic\x20manifestations.</p>\x0a<p>Disulfiram\x20is\x20usually\x20given\x20in\x20the\x20dose\x20of\x20<strong>250\x20mg/day</strong>\x20(range\x20of\x20125&ndash;500\x20mg/day).</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'G6PD\x20can\x20manifest\x20with\x20which\x20of\x20the\x20following\x20drugs?','choices':[{'id':0x1,'text':_0x6eced6(0x138)},{'id':0x2,'text':_0x6eced6(0x151)},{'id':0x3,'text':'Penicillin'},{'id':0x4,'text':_0x6eced6(0x1da)}],'correct_choice_id':0x1,'solution':_0x6eced6(0x17a),'explanation_video':'','question_images':[],'explanation_images':['https://dhmbxeygs57ff.cloudfront.net/uploads/4dc646e0a7344b62b2f3ad958aed8038x1279x914.JPEG',_0x6eced6(0x3d8)]},{'text':_0x6eced6(0x1be),'choices':[{'id':0x1,'text':'1,3'},{'id':0x2,'text':_0x6eced6(0x257)},{'id':0x3,'text':_0x6eced6(0x12d)},{'id':0x4,'text':_0x6eced6(0x1c1)}],'correct_choice_id':0x3,'solution':_0x6eced6(0x202),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x1d3),'choices':[{'id':0x1,'text':_0x6eced6(0x33d)},{'id':0x2,'text':'Inj.\x20Amphotericin\x20\x20B\x208\x20weeks,\x20followed\x20by\x20oral\x20posaconazole'},{'id':0x3,'text':'Inj.\x20Fluconazole,\x20followed\x20by\x20oral\x20fluconazole'},{'id':0x4,'text':'Inj.\x20Amphotericin\x20\x20B,\x20followed\x20by\x20flucytosine'}],'correct_choice_id':0x2,'solution':_0x6eced6(0x350),'explanation_video':'','question_images':[_0x6eced6(0x2b6)],'explanation_images':[_0x6eced6(0x3fe)]},{'text':_0x6eced6(0x193),'choices':[{'id':0x1,'text':'Inhibits\x20HMG\x20CoA\x20reductase'},{'id':0x2,'text':'Activates\x20PPAR\x20alpha'},{'id':0x3,'text':_0x6eced6(0x141)},{'id':0x4,'text':_0x6eced6(0x1d0)}],'correct_choice_id':0x2,'solution':_0x6eced6(0x131),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'The\x20dose-response\x20curve\x20for\x20three\x20drugs\x20in\x20the\x20same\x20tissue\x20is\x20shown\x20in\x20the\x20image\x20below.\x20Which\x20of\x20the\x20following\x20statements\x20is\x20true?','choices':[{'id':0x1,'text':_0x6eced6(0x187)},{'id':0x2,'text':_0x6eced6(0x2e5)},{'id':0x3,'text':_0x6eced6(0x15f)},{'id':0x4,'text':_0x6eced6(0x15a)}],'correct_choice_id':0x3,'solution':_0x6eced6(0x29c),'explanation_video':'','question_images':[_0x6eced6(0x448)],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20drugs\x20is\x20a\x20β2\x20agonist?','choices':[{'id':0x1,'text':'1,\x202,\x203'},{'id':0x2,'text':'4,\x203,\x202,\x201'},{'id':0x3,'text':_0x6eced6(0x1cb)},{'id':0x4,'text':_0x6eced6(0x172)}],'correct_choice_id':0x3,'solution':_0x6eced6(0x34d),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x382),'choices':[{'id':0x1,'text':_0x6eced6(0x46a)},{'id':0x2,'text':_0x6eced6(0x3e3)},{'id':0x3,'text':_0x6eced6(0x192)},{'id':0x4,'text':_0x6eced6(0x2b2)}],'correct_choice_id':0x2,'solution':_0x6eced6(0x178),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x433),'choices':[{'id':0x1,'text':_0x6eced6(0x2bb)},{'id':0x2,'text':_0x6eced6(0x32f)},{'id':0x3,'text':_0x6eced6(0x156)},{'id':0x4,'text':'A\x20and\x20D'}],'correct_choice_id':0x2,'solution':_0x6eced6(0x3ac),'explanation_video':'','question_images':[],'explanation_images':[_0x6eced6(0x24a)]},{'text':_0x6eced6(0x161),'choices':[{'id':0x1,'text':_0x6eced6(0x3a0)},{'id':0x2,'text':_0x6eced6(0x434)},{'id':0x3,'text':_0x6eced6(0x3e7)},{'id':0x4,'text':_0x6eced6(0x2ea)}],'correct_choice_id':0x3,'solution':_0x6eced6(0x219),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x3be),'choices':[{'id':0x1,'text':'Varenicline'},{'id':0x2,'text':_0x6eced6(0x184)},{'id':0x3,'text':_0x6eced6(0x440)},{'id':0x4,'text':_0x6eced6(0x16e)}],'correct_choice_id':0x1,'solution':'<p><strong>Varenicline</strong>\x20is\x20the\x20most\x20effective\x20oral\x20drug\x20for\x20smoking\x20cessation.</p>\x0a<p><strong>Nicotine</strong>\x20is\x20the\x20principal\x20constituent\x20of\x20tobacco\x20responsible\x20for\x20its\x20addictive\x20behaviour.&nbsp;Varenicline\x20works\x20by\x20blocking\x20the\x20effects\x20of\x20nicotine\x20on\x20the\x20brain.\x20It\x20<strong>blocks</strong>\x20<strong>&alpha;4</strong>,\x20and<strong>\x20&beta;2\x20nicotinic\x20acetylcholine\x20receptor</strong>\x20subtypes\x20and&nbsp;<strong>inhibits\x20dopaminergic\x20activation</strong>\x20produced\x20by\x20smoking\x20through\x20their\x20<strong>partial\x20agonism.\x20</strong>It&nbsp;decreases\x20the\x20craving\x20and\x20withdrawal\x20syndrome\x20that\x20occurs\x20with\x20cessation\x20attempts.\x20It\x20prevents\x20nicotine\x20stimulation\x20of\x20the\x20mesolimbic\x20dopamine\x20system\x20associated\x20with\x20nicotine\x20addiction,\x20thus\x20helping\x20to\x20occlude\x20the\x20rewarding\x20effect\x20of\x20smoking.</p>\x0a<p>Varenicline\x20is\x20prescribed\x20only\x20to\x20patients\x20<strong>18\x20years</strong>\x20or\x20older.\x20It\x20is\x20taken\x20<strong>orally</strong>\x20and\x20the\x20dose\x20taken\x20is\x200.5\x20mg\x20once\x20daily\x20on\x20days\x201\x20to\x203,\x20increased\x20to\x200.5\x20mg\x20twice\x20daily\x20on\x20days\x204\x20through\x207,\x20and\x201\x20mg\x20twice\x20daily\x20after\x20day\x208\x20for\x2011\x20weeks.\x20Therapy\x20should\x20start\x20one\x20week\x20before\x20the\x20target\x20quit\x20date.\x20It\x20can\x20be\x20continued\x20for\x20another\x2012\x20weeks\x20(1\x20mg\x20BD)\x20to\x20maintain\x20abstinence.</p>\x0a<p>The\x20adverse\x20effects\x20include\x20nausea,\x20disturbed\x20sleep,\x20sleepwalking,\x20agitation,\x20drowsiness,\x20and\x20constipation,\x20and&nbsp;may\x20also\x20increase\x20the\x20risk\x20of\x20pancreatitis.\x20Varenicline\x20has\x20also\x20been\x20implicated\x20in\x20specific\x20skin\x20syndromes\x20such\x20as\x20<strong>Stevens-Johnson&nbsp;syndrome</strong>,\x20erythema\x20multiforme,\x20and\x20photosensitivity.\x20Varenicline\x20can\x20cause\x20renal\x20failure\x20and\x20kidney\x20stones,\x20thus\x20renal\x20function\x20must\x20be\x20monitored.</p>\x0a<p>The\x20FDA\x20has\x20issued\x20a\x20warning\x20about\x20<strong>mood</strong>\x20and\x20<strong>behavioural\x20changes</strong>\x20associated\x20with\x20its\x20use,\x20and\x20there\x20is\x20some\x20evidence\x20of\x20<strong>increased\x20cardiovascular\x20risk.</strong></p>\x0a<p><strong>Cevimeline</strong><span\x20data-preserver-spaces=\x22true\x22>&nbsp;is\x20a&nbsp;</span><strong><span\x20data-preserver-spaces=\x22true\x22>muscarinic\x20agonist</span></strong><span\x20data-preserver-spaces=\x22true\x22>&nbsp;with\x20an\x20affinity\x20for\x20both&nbsp;</span><strong><span\x20data-preserver-spaces=\x22true\x22>M1</span></strong><span\x20data-preserver-spaces=\x22true\x22>&nbsp;and</span><strong><span\x20data-preserver-spaces=\x22true\x22>&nbsp;M3&nbsp;</span></strong><span\x20data-preserver-spaces=\x22true\x22>receptors\x20on\x20the\x20lacrimal\x20and\x20salivary\x20glands.&nbsp;</span><span\x20data-preserver-spaces=\x22true\x22>While&nbsp;</span><strong><span\x20data-preserver-spaces=\x22true\x22>M1\x20activation&nbsp;</span></strong>results\x20in&nbsp;<strong><span\x20data-preserver-spaces=\x22true\x22>increased\x20secretion</span></strong><span\x20data-preserver-spaces=\x22true\x22>,&nbsp;</span><strong><span\x20data-preserver-spaces=\x22true\x22>M3\x20activation&nbsp;</span></strong>results\x20in<strong><span\x20data-preserver-spaces=\x22true\x22>&nbsp;smooth\x20muscle\x20contraction</span></strong><span\x20data-preserver-spaces=\x22true\x22>,\x20and\x20expulsion\x20of\x20the\x20secretions.&nbsp;</span><span\x20data-preserver-spaces=\x22true\x22>Cevimeline\x20enhances\x20lacrimal\x20secretions\x20in&nbsp;</span><strong><span\x20data-preserver-spaces=\x22true\x22>Sjogren&rsquo;s\x20syndrome.</span></strong></p>\x0a<p>&nbsp;</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Match\x20the\x20following\x20antiarrhythmic\x20drugs\x20with\x20their\x20mechanism\x20of\x20action:','choices':[{'id':0x1,'text':'1-d,\x202-b,\x203-a,\x204-c'},{'id':0x2,'text':_0x6eced6(0x252)},{'id':0x3,'text':'1-a,\x202-d,\x203-b,\x204-c'},{'id':0x4,'text':_0x6eced6(0x2f3)}],'correct_choice_id':0x3,'solution':_0x6eced6(0x3ed),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x348),'choices':[{'id':0x1,'text':_0x6eced6(0x302)},{'id':0x2,'text':'Netarsudil'},{'id':0x3,'text':_0x6eced6(0x1f2)},{'id':0x4,'text':_0x6eced6(0x3a2)}],'correct_choice_id':0x2,'solution':_0x6eced6(0x2af),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Finasteride\x20is\x20used\x20to\x20treat\x20male-pattern\x20baldness\x20acts\x20by\x20inhibiting\x20which\x20of\x20the\x20following\x20enzymes?','choices':[{'id':0x1,'text':_0x6eced6(0x436)},{'id':0x2,'text':_0x6eced6(0x1ba)},{'id':0x3,'text':_0x6eced6(0x3fa)},{'id':0x4,'text':_0x6eced6(0x1ad)}],'correct_choice_id':0x3,'solution':_0x6eced6(0x39a),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x6eced6(0x267),'choices':[{'id':0x1,'text':'Polyclonal\x20antibody\x20which\x20acts\x20against\x20CD20'},{'id':0x2,'text':_0x6eced6(0x256)},{'id':0x3,'text':'Monoclonal\x20antibody\x20which\x20acts\x20against\x20CD20'},{'id':0x4,'text':'Monoclonal\x20antibody\x20which\x20acts\x20against\x20CD50'}],'correct_choice_id':0x3,'solution':_0x6eced6(0x469),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20new\x20drug\x20application\x20is\x20filed\x20after\x20which\x20phase\x20of\x20clinical\x20trials?','choices':[{'id':0x1,'text':'4'},{'id':0x2,'text':'3'},{'id':0x3,'text':'2'},{'id':0x4,'text':'1'}],'correct_choice_id':0x2,'solution':_0x6eced6(0x29a),'explanation_video':'','question_images':[],'explanation_images':[]}],quizName=_0x6eced6(0x1e2);const quizFilename=_0x6eced6(0x203);let hierarchy=[_0x6eced6(0x3ab),_0x6eced6(0x2ba),_0x6eced6(0x1ee)];if(window['location']['pathname'][_0x6eced6(0x325)](_0x6eced6(0x2ca))){const customData=JSON[_0x6eced6(0x3c3)](localStorage[_0x6eced6(0x2c5)](_0x6eced6(0x283)));if(customData){const HcxHrN=_0x6eced6(0x23f)['split']('|');let TCHubQ=0x0;while(!![]){switch(HcxHrN[TCHubQ++]){case'0':document[_0x6eced6(0x33a)](_0x6eced6(0x1f9))['textContent']=questionsData[_0x6eced6(0x207)];continue;case'1':quizName=customData[_0x6eced6(0x35f)];continue;case'2':document['title']=quizName+_0x6eced6(0x1aa);continue;case'3':questionsData=customData[_0x6eced6(0x227)];continue;case'4':hierarchy=customData[_0x6eced6(0x420)];continue;case'5':document[_0x6eced6(0x33a)]('quizHierarchy')[_0x6eced6(0x147)]=hierarchy[_0x6eced6(0x3bf)]('\x20>\x20');continue;}break;}}}let currentQuestionIndex=0x0,selectedOption=null,currentMode=_0x6eced6(0x2e1),timer=null,timeRemaining=0x0,questionStartTime=Date[_0x6eced6(0x2e0)](),quizStartTime=Date['now'](),isQuizCompleted=![],questionStates=new Array(questionsData[_0x6eced6(0x207)])[_0x6eced6(0x311)](null)['map'](()=>({'status':_0x6eced6(0x344),'bookmarked':![],'markedForReview':![],'selectedAnswer':null,'timeSpent':0x0})),stats={'correctAnswers':0x0,'incorrectAnswers':0x0,'totalAttempted':0x0,'totalTime':0x0,'notAttempted':questionsData['length']};function saveProgress(){const _0x3141ad=_0x6eced6,_0x2ca320={'jvnzU':'incomplete','VNosc':_0x3141ad(0x462)};if(isQuizCompleted)return;const _0x256c42=JSON['parse'](localStorage[_0x3141ad(0x2c5)](_0x3141ad(0x462)))||{};_0x256c42[quizFilename]={'questionStates':questionStates,'stats':stats,'currentQuestionIndex':currentQuestionIndex,'currentMode':currentMode,'status':_0x2ca320['jvnzU'],'lastSeen':new Date()[_0x3141ad(0x282)]()},localStorage[_0x3141ad(0x269)](_0x2ca320[_0x3141ad(0x3dc)],JSON['stringify'](_0x256c42));}function _0x3e0e(_0x51784e,_0xff7993){const _0x30c2e0=_0x33d7();return _0x3e0e=function(_0x429c96,_0x466fe8){_0x429c96=_0x429c96-0x12b;let _0x389470=_0x30c2e0[_0x429c96];return _0x389470;},_0x3e0e(_0x51784e,_0xff7993);}function loadProgress(){const _0x2e9e6a=_0x6eced6,_0x54ba6f={'vtTXI':_0x2e9e6a(0x462),'lXUFk':'0|5|4|3|1|2'},_0x11f7fe=JSON[_0x2e9e6a(0x3c3)](localStorage['getItem'](_0x54ba6f['vtTXI']))||{},_0x3d40e4=_0x11f7fe[quizFilename];if(_0x3d40e4){const _0x3899b4=_0x54ba6f[_0x2e9e6a(0x1bc)][_0x2e9e6a(0x3d0)]('|');let _0x56ae74=0x0;while(!![]){switch(_0x3899b4[_0x56ae74++]){case'0':questionStates=_0x3d40e4[_0x2e9e6a(0x384)];continue;case'1':console[_0x2e9e6a(0x1b5)](_0x2e9e6a(0x323));continue;case'2':return!![];case'3':currentMode=_0x3d40e4[_0x2e9e6a(0x240)];continue;case'4':currentQuestionIndex=_0x3d40e4['currentQuestionIndex'];continue;case'5':stats=_0x3d40e4['stats'];continue;}break;}}return![];}function clearProgress(){const _0x49a6ea=_0x6eced6,_0x26dd51={'tOdzw':_0x49a6ea(0x462)},_0x90a39b=JSON[_0x49a6ea(0x3c3)](localStorage[_0x49a6ea(0x2c5)]('userHistory'))||{};_0x90a39b[quizFilename]&&(delete _0x90a39b[quizFilename],localStorage[_0x49a6ea(0x269)](_0x26dd51[_0x49a6ea(0x466)],JSON[_0x49a6ea(0x29d)](_0x90a39b)),console['log'](_0x49a6ea(0x21f)));}function markQuizAsCompleted(){const _0xe6f4b5=_0x6eced6,_0x115089={'TpGNn':'userHistory','XCerU':'completed'},_0x219880=JSON[_0xe6f4b5(0x3c3)](localStorage[_0xe6f4b5(0x2c5)](_0x115089[_0xe6f4b5(0x458)]))||{},_0x1ff894=questionsData[_0xe6f4b5(0x207)],_0x5e409d=stats[_0xe6f4b5(0x3ec)]||0x0;_0x219880[quizFilename]={'score':_0x5e409d,'total':_0x1ff894,'status':_0x115089[_0xe6f4b5(0x181)],'completedOn':new Date()[_0xe6f4b5(0x282)]()},localStorage[_0xe6f4b5(0x269)](_0x115089['TpGNn'],JSON[_0xe6f4b5(0x29d)](_0x219880));}const urlParams=new URLSearchParams(window[_0x6eced6(0x3e8)]['search']),startAt=parseInt(urlParams[_0x6eced6(0x3e9)]('startAt')),resume=urlParams[_0x6eced6(0x3e9)]('resume')===_0x6eced6(0x1b0);function goBack(){const _0x1d8ee6=_0x6eced6,_0x286f97={'dJHXh':function(_0x189996){return _0x189996();},'pJGzp':_0x1d8ee6(0x419)};if(!isQuizCompleted)_0x286f97[_0x1d8ee6(0x2d3)](saveProgress);window[_0x1d8ee6(0x3e8)][_0x1d8ee6(0x317)]=document[_0x1d8ee6(0x3c8)]||_0x286f97['pJGzp'];}function selectMode(_0x2394e6){const _0x4dfe12=_0x6eced6,_0x8d6c2c={'laucg':_0x4dfe12(0x1e1),'NgtJa':_0x4dfe12(0x35e)};currentMode=_0x2394e6,document['getElementById'](_0x8d6c2c[_0x4dfe12(0x132)])[_0x4dfe12(0x40d)]['display']=_0x8d6c2c['NgtJa'],initializeQuiz();}function initializeQuiz(){const _0x5517bd=_0x6eced6,_0x4d3b4c={'SRMnB':_0x5517bd(0x42e),'byrFy':_0x5517bd(0x15d),'CxNoq':function(_0x5936ad,_0x55b99b){return _0x5936ad===_0x55b99b;},'FyaQH':'test','cxlBg':function(_0x460b28,_0x5a4646){return _0x460b28===_0x5a4646;},'EMzGc':_0x5517bd(0x247),'ivLzp':_0x5517bd(0x14c),'fCojv':'studyModeLegend','FfCBc':_0x5517bd(0x35e),'mFtFH':_0x5517bd(0x3db),'cdroj':_0x5517bd(0x3d2),'DjPEL':'flex','JsYSs':function(_0x14969c,_0x5ef97b){return _0x14969c===_0x5ef97b;},'HaYND':_0x5517bd(0x1c9),'NKwyM':_0x5517bd(0x12c),'VZdRv':function(_0x2c15c7,_0x6f0a7a){return _0x2c15c7(_0x6f0a7a);},'dZFQC':function(_0x3a5da2,_0xd91ecc){return _0x3a5da2<_0xd91ecc;},'svwof':function(_0x407164){return _0x407164();},'ugALS':function(_0x4bb7a4){return _0x4bb7a4();}};quizStartTime=Date[_0x5517bd(0x2e0)]();const _0x4de7e2=document['getElementById'](_0x5517bd(0x416)),_0xfb9f78=document[_0x5517bd(0x33a)](_0x4d3b4c[_0x5517bd(0x3b6)]),_0x27fa99=document[_0x5517bd(0x33a)](_0x4d3b4c[_0x5517bd(0x179)]),_0x38e1c8=_0x4d3b4c[_0x5517bd(0x35c)](currentMode,_0x4d3b4c[_0x5517bd(0x216)])||_0x4d3b4c['cxlBg'](currentMode,_0x4d3b4c[_0x5517bd(0x2dc)]);document[_0x5517bd(0x33a)](_0x4d3b4c['ivLzp'])['style'][_0x5517bd(0x24e)]=_0x38e1c8?_0x5517bd(0x35e):_0x5517bd(0x3d2),document[_0x5517bd(0x33a)](_0x4d3b4c[_0x5517bd(0x389)])[_0x5517bd(0x40d)][_0x5517bd(0x24e)]=_0x38e1c8?_0x4d3b4c[_0x5517bd(0x43d)]:_0x5517bd(0x3d2),document[_0x5517bd(0x33a)](_0x4d3b4c['mFtFH'])['style']['display']=_0x38e1c8?_0x4d3b4c[_0x5517bd(0x233)]:_0x4d3b4c['FfCBc'],document[_0x5517bd(0x33a)](_0x5517bd(0x2fe))['style']['display']=_0x38e1c8?_0x4d3b4c['cdroj']:_0x4d3b4c[_0x5517bd(0x43d)],_0x4de7e2[_0x5517bd(0x40d)][_0x5517bd(0x24e)]=_0x38e1c8?'none':_0x4d3b4c[_0x5517bd(0x313)],_0xfb9f78[_0x5517bd(0x40d)][_0x5517bd(0x24e)]=_0x38e1c8?'flex':_0x4d3b4c[_0x5517bd(0x43d)],_0x27fa99[_0x5517bd(0x40d)]['display']=_0x38e1c8?_0x4d3b4c[_0x5517bd(0x313)]:_0x4d3b4c[_0x5517bd(0x43d)],(_0x4d3b4c[_0x5517bd(0x44b)](currentMode,'timed_study')||currentMode===_0x4d3b4c['EMzGc'])&&document[_0x5517bd(0x33a)](_0x4d3b4c[_0x5517bd(0x15b)])[_0x5517bd(0x209)][_0x5517bd(0x3fd)](_0x4d3b4c[_0x5517bd(0x326)]),!_0x4d3b4c[_0x5517bd(0x134)](isNaN,startAt)&&startAt>=0x0&&_0x4d3b4c['dZFQC'](startAt,questionsData['length'])&&(currentQuestionIndex=startAt),_0x4d3b4c[_0x5517bd(0x452)](loadBookmarkedQuestions),generateQuestionNav(),_0x4d3b4c['ugALS'](updateStats),_0x4d3b4c[_0x5517bd(0x22c)](displayQuestion);}function generateQuestionNav(){const _0x3df574=_0x6eced6,_0x58ac34={'jkOqq':_0x3df574(0x1ca),'xfKgx':function(_0x9cc140,_0x2974f1){return _0x9cc140<_0x2974f1;},'CrmpE':_0x3df574(0x3aa),'TYpWO':function(_0x540b64,_0x21f6e8){return _0x540b64+_0x21f6e8;},'fUWzq':_0x3df574(0x447)},_0x2b4b0d=document[_0x3df574(0x33a)](_0x58ac34[_0x3df574(0x1ac)]);_0x2b4b0d[_0x3df574(0x3a7)]='';for(let _0x6b408b=0x0;_0x58ac34[_0x3df574(0x1dc)](_0x6b408b,questionsData[_0x3df574(0x207)]);_0x6b408b++){const _0x23f0fb=document[_0x3df574(0x3b7)](_0x58ac34[_0x3df574(0x41c)]);_0x23f0fb['textContent']=_0x58ac34['TYpWO'](_0x6b408b,0x1),_0x23f0fb[_0x3df574(0x3ad)]=_0x58ac34['fUWzq'],_0x23f0fb['onclick']=()=>jumpToQuestion(_0x6b408b),_0x23f0fb['id']='navBtn_'+_0x6b408b,_0x2b4b0d[_0x3df574(0x1ff)](_0x23f0fb);}updateQuestionNav();}function updateQuestionNav(){const _0x42687a=_0x6eced6,_0x1eb4de={'NYaKH':_0x42687a(0x2b9),'wrpLc':_0x42687a(0x354),'hZiEj':function(_0x42a1d7,_0x20dde9){return _0x42a1d7<_0x20dde9;},'BMAms':function(_0x2c1fff,_0x9ddb12){return _0x2c1fff===_0x9ddb12;},'qcVuU':function(_0x371685,_0x49fde3){return _0x371685===_0x49fde3;},'ivZDk':'hzHQW','oHDRS':_0x42687a(0x1d4),'nIctD':_0x42687a(0x1f0),'oKeuP':_0x42687a(0x3c2),'kMdVk':function(_0x56d6b9,_0x6cdb64){return _0x56d6b9===_0x6cdb64;},'tCubr':_0x42687a(0x2e1),'yPzdq':'timed_study','iNwUs':function(_0x219ab2,_0x3b5728){return _0x219ab2===_0x3b5728;},'TsMTi':_0x42687a(0x17c),'NqgIA':_0x42687a(0x28f),'jyQUW':'incorrect','rxFpw':'nav-btn-incorrect','suBnf':_0x42687a(0x167),'cLzzJ':function(_0x5a25bf,_0x2b0875){return _0x5a25bf!==_0x2b0875;},'qovCm':_0x42687a(0x36b),'ZCchI':function(_0x568ed2,_0x3939c6){return _0x568ed2!==_0x3939c6;}};for(let _0x552d1c=0x0;_0x1eb4de[_0x42687a(0x361)](_0x552d1c,questionsData['length']);_0x552d1c++){const _0x3a0e8a=document[_0x42687a(0x33a)](_0x42687a(0x32e)+_0x552d1c),_0x5f234d=questionStates[_0x552d1c];let _0x269861='';if(_0x1eb4de['BMAms'](_0x552d1c,currentQuestionIndex))_0x1eb4de['qcVuU'](_0x1eb4de['ivZDk'],'uIISQ')?_0x28ddf7():_0x269861=_0x1eb4de[_0x42687a(0x1c7)];else{if(_0x5f234d[_0x42687a(0x38c)])_0x269861=_0x1eb4de[_0x42687a(0x314)];else{if(_0x5f234d['markedForReview'])_0x269861=_0x1eb4de[_0x42687a(0x338)];else{if(_0x1eb4de['kMdVk'](currentMode,_0x1eb4de[_0x42687a(0x195)])||currentMode===_0x1eb4de[_0x42687a(0x280)]){if(_0x1eb4de['iNwUs'](_0x5f234d[_0x42687a(0x329)],_0x1eb4de[_0x42687a(0x13b)]))_0x269861=_0x1eb4de[_0x42687a(0x12f)];else{if(_0x5f234d['status']===_0x1eb4de['jyQUW'])_0x269861=_0x1eb4de[_0x42687a(0x220)];else _0x269861=_0x1eb4de[_0x42687a(0x170)];}}else{if(_0x1eb4de['cLzzJ'](_0x1eb4de[_0x42687a(0x1b1)],_0x1eb4de[_0x42687a(0x1b1)])){const _0x2b0f41=_0x5fafa6[_0x42687a(0x33a)](_0x42687a(0x42e)),_0x978680=_0x29d682[_0x42687a(0x33a)](_0x42687a(0x444)),_0x37cf18=_0x1a73c4[_0x3cf4ba]['markedForReview'];_0x2b0f41[_0x42687a(0x3ad)]=_0x37cf18?_0x42687a(0x296):_0x42687a(0x26c),_0x978680[_0x42687a(0x147)]=_0x37cf18?_0x1eb4de[_0x42687a(0x245)]:_0x1eb4de[_0x42687a(0x44a)];}else{if(_0x1eb4de[_0x42687a(0x157)](_0x5f234d[_0x42687a(0x291)],null))_0x269861=_0x42687a(0x2e2);else _0x269861=_0x42687a(0x167);}}}}}_0x3a0e8a[_0x42687a(0x3ad)]=_0x42687a(0x260)+_0x269861;}}function jumpToQuestion(_0x177e01){const _0x253a66=_0x6eced6,_0x2d2c35={'qnXOc':function(_0x4f83f6,_0x4a048d){return _0x4f83f6<_0x4a048d;},'Jzprt':function(_0x5ce582,_0x435fb3){return _0x5ce582-_0x435fb3;},'pCaKh':function(_0x5b584d){return _0x5b584d();}};_0x177e01>=0x0&&_0x2d2c35[_0x253a66(0x28c)](_0x177e01,questionsData[_0x253a66(0x207)])&&(questionStartTime&&(questionStates[currentQuestionIndex]['timeSpent']+=_0x2d2c35[_0x253a66(0x2ce)](Date[_0x253a66(0x2e0)](),questionStartTime)),currentQuestionIndex=_0x177e01,_0x2d2c35['pCaKh'](displayQuestion),_0x2d2c35[_0x253a66(0x2e6)](saveProgress));}function updateStats(){const _0x4847db=_0x6eced6,_0x44cc2a={'AUyLy':function(_0x544f63,_0x5050d3){return _0x544f63===_0x5050d3;},'byUNI':_0x4847db(0x2e1),'fnDoA':_0x4847db(0x41b),'HKdrC':function(_0x3d1d24,_0x69bce6){return _0x3d1d24===_0x69bce6;},'mtVTa':_0x4847db(0x2a1),'opdKC':_0x4847db(0x36d),'JNKtB':_0x4847db(0x31f),'IsPxw':_0x4847db(0x232),'XsbbB':_0x4847db(0x148),'ykLXg':function(_0x1a4d57,_0x5f3761){return _0x1a4d57+_0x5f3761;},'RCCBn':function(_0x154190,_0x26fc3c){return _0x154190/_0x26fc3c;},'cjCgb':function(_0x426ba0,_0x36e960){return _0x426ba0%_0x36e960;},'HAcCk':_0x4847db(0x24c),'HuAhA':function(_0x57f3a7,_0x3cb1ec){return _0x57f3a7+_0x3cb1ec;}};if(_0x44cc2a['AUyLy'](currentMode,_0x44cc2a[_0x4847db(0x200)])||currentMode===_0x44cc2a[_0x4847db(0x339)]){if(_0x44cc2a[_0x4847db(0x40a)](_0x44cc2a['mtVTa'],_0x44cc2a[_0x4847db(0x414)])){const _0x3a5ce0={'quizName':_0x1744ab,'quizFile':_0x23516c[_0x4847db(0x3e8)][_0x4847db(0x401)][_0x4847db(0x3d0)]('/')[_0x4847db(0x14e)](),'questionIndex':_0x316cf8,'question':_0x2213ea[_0x2847cb],'hierarchy':_0x2d7811,'timestamp':_0x40c1bb[_0x4847db(0x2e0)]()};_0x444bee[_0x4847db(0x378)](_0x3a5ce0);}else{document[_0x4847db(0x33a)](_0x44cc2a[_0x4847db(0x196)])['textContent']=stats[_0x4847db(0x3ec)],document[_0x4847db(0x33a)](_0x44cc2a[_0x4847db(0x446)])[_0x4847db(0x147)]=stats['incorrectAnswers'],document[_0x4847db(0x33a)](_0x44cc2a[_0x4847db(0x152)])[_0x4847db(0x147)]=stats[_0x4847db(0x148)];const _0x269195=stats['totalAttempted']>0x0?Math[_0x4847db(0x364)](stats['correctAnswers']/stats['totalAttempted']*0x64):0x0;document[_0x4847db(0x33a)](_0x4847db(0x159))[_0x4847db(0x147)]=_0x44cc2a[_0x4847db(0x2d7)](_0x269195,'%'),stats[_0x4847db(0x408)]=questionStates['reduce']((_0x1ff643,_0x4c2dd6)=>_0x1ff643+_0x4c2dd6[_0x4847db(0x24c)],0x0);const _0x4bda92=Math[_0x4847db(0x278)](_0x44cc2a[_0x4847db(0x3af)](stats[_0x4847db(0x408)],0x3e8)),_0x38e883=Math['floor'](_0x4bda92/0x3c),_0x4514c6=_0x44cc2a['cjCgb'](_0x4bda92,0x3c);document[_0x4847db(0x33a)](_0x44cc2a[_0x4847db(0x1de)])[_0x4847db(0x147)]=_0x44cc2a[_0x4847db(0x312)](_0x38e883,':')+_0x4514c6[_0x4847db(0x2e3)]()[_0x4847db(0x1fd)](0x2,'0');}}}function setupVideo(_0x5e43c9,_0x35b6a0){const _0x4cf398=_0x6eced6,_0x161012={'JPbrm':function(_0x2cd104,_0x1dcdbc){return _0x2cd104(_0x1dcdbc);},'sLQEu':_0x4cf398(0x25f),'GXzlA':function(_0x3cdbff){return _0x3cdbff();},'dPDIJ':_0x4cf398(0x154),'VaawO':function(_0x36054b,_0x403a4d){return _0x36054b!==_0x403a4d;},'wlDAq':_0x4cf398(0x372)};if(Hls[_0x4cf398(0x1a9)]()){const _0x509a84=new Hls();_0x509a84[_0x4cf398(0x292)](_0x35b6a0),_0x509a84[_0x4cf398(0x35a)](_0x5e43c9);}else _0x5e43c9[_0x4cf398(0x14f)](_0x161012[_0x4cf398(0x1c3)])&&(_0x161012[_0x4cf398(0x418)]('tRvCS',_0x161012['wlDAq'])?_0x5e43c9[_0x4cf398(0x19c)]=_0x35b6a0:_0x161012[_0x4cf398(0x264)](_0x5914a6,_0x161012[_0x4cf398(0x22e)])&&(_0x475b77=0x0,_0x161012[_0x4cf398(0x3c7)](_0xe95651),_0x161012[_0x4cf398(0x3c7)](_0x3074e6)));}function displayQuestion(){const _0x5a6fdc=_0x6eced6,_0x468ae0={'mEhwq':function(_0x56c5d4,_0x202625){return _0x56c5d4===_0x202625;},'kKwdM':_0x5a6fdc(0x17c),'ldlNJ':'incorrect','JWoKS':'div','HXgsN':_0x5a6fdc(0x29f),'CPLxV':function(_0x53b5f6,_0x575f91){return _0x53b5f6+_0x575f91;},'dkZIN':function(_0x4d63fb){return _0x4d63fb();},'Ilazp':_0x5a6fdc(0x22d),'uyJvg':'JyXeY','nHRel':function(_0x1b7c84,_0x3f2f47){return _0x1b7c84(_0x3f2f47);},'ilsLS':function(_0x388f96,_0x21fbf8){return _0x388f96(_0x21fbf8);},'EknXh':_0x5a6fdc(0x392),'WbSwo':_0x5a6fdc(0x3a6),'VdNMZ':function(_0x17bc4c,_0x337f39){return _0x17bc4c*_0x337f39;},'QWDCr':_0x5a6fdc(0x3a4),'xupes':_0x5a6fdc(0x1ea),'ayFMy':_0x5a6fdc(0x12c),'pbiID':_0x5a6fdc(0x3cf),'AOJhN':'No\x20question\x20text\x20available','NTpSw':function(_0xe7833e,_0x3685e6){return _0xe7833e===_0x3685e6;},'lNZxy':'zjDoB','mDPGc':_0x5a6fdc(0x1e9),'rmsxt':_0x5a6fdc(0x358),'cUdhn':_0x5a6fdc(0x155),'uKDSD':function(_0x4e891b){return _0x4e891b();},'CQEEl':_0x5a6fdc(0x247),'SBlhL':_0x5a6fdc(0x306)};if(!questionsData||_0x468ae0[_0x5a6fdc(0x13a)](questionsData[_0x5a6fdc(0x207)],0x0)){document[_0x5a6fdc(0x33a)](_0x5a6fdc(0x3cf))['innerHTML']=_0x5a6fdc(0x18f);return;};const _0x2f2b79=questionsData[currentQuestionIndex];questionStartTime=Date[_0x5a6fdc(0x2e0)](),selectedOption=questionStates[currentQuestionIndex][_0x5a6fdc(0x291)];const _0x1d4ff2=_0x468ae0['VdNMZ'](_0x468ae0[_0x5a6fdc(0x30a)](currentQuestionIndex,0x1)/questionsData[_0x5a6fdc(0x207)],0x64);document[_0x5a6fdc(0x33a)](_0x468ae0['QWDCr'])[_0x5a6fdc(0x40d)][_0x5a6fdc(0x1f3)]=_0x468ae0['CPLxV'](_0x1d4ff2,'%'),document['getElementById'](_0x468ae0[_0x5a6fdc(0x263)])['textContent']=currentQuestionIndex+0x1,_0x468ae0['dkZIN'](updateQuestionNav),document[_0x5a6fdc(0x33a)](_0x5a6fdc(0x1a4))['disabled']=currentQuestionIndex===0x0,document[_0x5a6fdc(0x33a)](_0x5a6fdc(0x235))['classList'][_0x5a6fdc(0x168)](_0x468ae0[_0x5a6fdc(0x250)]),document['getElementById'](_0x468ae0[_0x5a6fdc(0x1bb)])[_0x5a6fdc(0x3a7)]=_0x2f2b79[_0x5a6fdc(0x38b)]||_0x468ae0[_0x5a6fdc(0x369)];let _0x21c246='';if(_0x2f2b79['question_audio'])_0x21c246+=_0x5a6fdc(0x1e6)+_0x2f2b79['question_audio']+_0x5a6fdc(0x406);if(_0x2f2b79[_0x5a6fdc(0x39c)])_0x21c246+=_0x5a6fdc(0x1dd)+_0x2f2b79['question_video']+_0x5a6fdc(0x353);if(_0x2f2b79[_0x5a6fdc(0x316)]){if(_0x468ae0['NTpSw'](_0x5a6fdc(0x16f),_0x468ae0[_0x5a6fdc(0x346)]))_0x2f2b79['question_images'][_0x5a6fdc(0x1ab)](_0x47159c=>{const _0x34cdbe=_0x5a6fdc;if(_0x47159c)_0x21c246+='<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22'+_0x47159c+_0x34cdbe(0x3f3);});else{_0x25b301[_0x5a6fdc(0x209)]['remove'](_0x5a6fdc(0x32a));if(_0x468ae0['mEhwq'](_0x1595b9,_0x13673e))_0x9521ab[_0x5a6fdc(0x209)][_0x5a6fdc(0x168)](_0x468ae0[_0x5a6fdc(0x3c4)]);else{if(_0x468ae0[_0x5a6fdc(0x13a)](_0x2235ef,_0x13e2c7)&&!_0x48079a)_0x1f0b76[_0x5a6fdc(0x209)][_0x5a6fdc(0x168)](_0x468ae0[_0x5a6fdc(0x327)]);}}}document[_0x5a6fdc(0x33a)](_0x468ae0[_0x5a6fdc(0x20f)])[_0x5a6fdc(0x3a7)]=_0x21c246;const _0x3e7bca=document[_0x5a6fdc(0x33a)](_0x468ae0['rmsxt']);_0x3e7bca[_0x5a6fdc(0x3a7)]='',_0x3e7bca['classList'][_0x5a6fdc(0x3fd)](_0x468ae0[_0x5a6fdc(0x3ce)]);_0x2f2b79[_0x5a6fdc(0x18a)]&&Array['isArray'](_0x2f2b79[_0x5a6fdc(0x18a)])&&(_0x2f2b79[_0x5a6fdc(0x18a)][_0x5a6fdc(0x1ab)]((_0x459f73,_0x2a179f)=>{const _0x1e4c6b=_0x5a6fdc,_0x254672=String['fromCharCode'](0x41+_0x2a179f),_0x1e785d=_0x468ae0[_0x1e4c6b(0x13a)](selectedOption,_0x2a179f),_0x264337=document[_0x1e4c6b(0x3b7)](_0x468ae0[_0x1e4c6b(0x210)]);_0x264337[_0x1e4c6b(0x3a7)]=_0x1e4c6b(0x16a)+(_0x1e785d?_0x1e4c6b(0x32a):'')+'\x22\x20data-option-index=\x22'+_0x2a179f+'\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>'+_0x254672+_0x1e4c6b(0x21d)+(_0x459f73[_0x1e4c6b(0x38b)]||_0x468ae0[_0x1e4c6b(0x31a)]+_0x468ae0[_0x1e4c6b(0x30a)](_0x2a179f,0x1))+_0x1e4c6b(0x213),_0x3e7bca['appendChild'](_0x264337);}),_0x3e7bca[_0x5a6fdc(0x18b)](_0x5a6fdc(0x355),function(_0x7df033){const _0x1bd1c7=_0x5a6fdc,_0x49b49a={'ErCmd':function(_0x49b555){const _0x59aa84=_0x3e0e;return _0x468ae0[_0x59aa84(0x421)](_0x49b555);}},_0x407912=_0x7df033[_0x1bd1c7(0x3bc)][_0x1bd1c7(0x28e)](_0x468ae0[_0x1bd1c7(0x337)]);if(_0x407912){if(_0x468ae0[_0x1bd1c7(0x13a)](_0x468ae0[_0x1bd1c7(0x208)],_0x468ae0[_0x1bd1c7(0x208)])){const _0x2b0e96=_0x468ae0[_0x1bd1c7(0x214)](parseInt,_0x407912[_0x1bd1c7(0x373)](_0x1bd1c7(0x34c)));_0x468ae0[_0x1bd1c7(0x214)](selectOption,_0x2b0e96);}else _0x49b49a[_0x1bd1c7(0x456)](_0x363a93);}}));_0x468ae0['uKDSD'](updateBookmarkButton),_0x468ae0['dkZIN'](updateMarkReviewButton);if((currentMode===_0x5a6fdc(0x41b)||currentMode===_0x468ae0[_0x5a6fdc(0x1d1)])&&!isQuizCompleted){if(_0x468ae0['SBlhL']===_0x468ae0['SBlhL'])startTimer();else{let _0x8d680a;try{_0x8d680a=FZBbcj[_0x5a6fdc(0x3d5)](_0x1a3b8c,FZBbcj[_0x5a6fdc(0x30a)](FZBbcj['CPLxV'](FZBbcj['EknXh'],FZBbcj[_0x5a6fdc(0x21c)]),');'))();}catch(_0x4a3a6f){_0x8d680a=_0x2b0574;}return _0x8d680a;}}}function selectOption(_0x52c886){const _0x2cda48=_0x6eced6,_0x4e10f2={'ijZSl':_0x2cda48(0x22d),'vfFDX':function(_0x36e9fa,_0x4e18fb){return _0x36e9fa(_0x4e18fb);},'smwNr':_0x2cda48(0x34c),'RiLUJ':_0x2cda48(0x32a),'bJYfo':_0x2cda48(0x358),'wkaBl':_0x2cda48(0x155),'ONHKE':function(_0x366dec,_0x42bd22){return _0x366dec!==_0x42bd22;},'ywkCP':_0x2cda48(0x403),'jOklR':_0x2cda48(0x1fc),'yaOXt':function(_0x325770,_0x1cfd53){return _0x325770-_0x1cfd53;},'EJMgG':'study','hjNUX':function(_0x23aae7,_0x2af3ed){return _0x23aae7===_0x2af3ed;},'XwjBD':function(_0x20cb17,_0x1ae2ba){return _0x20cb17!==_0x1ae2ba;},'ADYLz':_0x2cda48(0x2a2),'uxSVJ':function(_0xe75a5f,_0x1d43f9){return _0xe75a5f===_0x1d43f9;},'jOSoq':_0x2cda48(0x344),'vGCMB':function(_0x2bb7d8){return _0x2bb7d8();}},_0x3b7ca0=document[_0x2cda48(0x33a)](_0x4e10f2[_0x2cda48(0x37c)]);if(_0x3b7ca0[_0x2cda48(0x209)][_0x2cda48(0x262)](_0x4e10f2[_0x2cda48(0x3f7)]))return;if(questionStartTime){if(_0x4e10f2[_0x2cda48(0x405)](_0x4e10f2['ywkCP'],_0x4e10f2[_0x2cda48(0x28b)]))questionStates[currentQuestionIndex][_0x2cda48(0x24c)]+=_0x4e10f2[_0x2cda48(0x29b)](Date['now'](),questionStartTime),questionStartTime=Date[_0x2cda48(0x2e0)]();else{const _0x5d0a3f=_0x4781ab['target'][_0x2cda48(0x28e)](_0x4e10f2[_0x2cda48(0x2df)]);if(_0x5d0a3f){const _0x5a334b=_0x4e10f2[_0x2cda48(0x137)](_0x1ac91f,_0x5d0a3f[_0x2cda48(0x373)](_0x4e10f2[_0x2cda48(0x399)]));_0x4e10f2['vfFDX'](_0x2bdc1a,_0x5a334b);}}}selectedOption=_0x52c886,questionStates[currentQuestionIndex][_0x2cda48(0x291)]=_0x52c886,document[_0x2cda48(0x25a)](_0x4e10f2[_0x2cda48(0x2df)])[_0x2cda48(0x1ab)]((_0x4ee900,_0xc9d17e)=>{const _0x4b7eb2=_0x2cda48;_0x4ee900[_0x4b7eb2(0x209)][_0x4b7eb2(0x238)](_0x4e10f2['RiLUJ'],_0xc9d17e===_0x52c886);});if(currentMode===_0x4e10f2[_0x2cda48(0x169)]||_0x4e10f2[_0x2cda48(0x1af)](currentMode,'timed_study')){if(_0x4e10f2['XwjBD'](_0x2cda48(0x2a2),_0x4e10f2[_0x2cda48(0x340)])){const _0x47aaba=_0x57aba0[_0x2cda48(0x25d)](_0x2c14f6,arguments);return _0x3615c6=null,_0x47aaba;}else processAnswer();}else _0x4e10f2['uxSVJ'](questionStates[currentQuestionIndex][_0x2cda48(0x329)],_0x4e10f2[_0x2cda48(0x385)])&&(questionStates[currentQuestionIndex]['status']=_0x4e10f2[_0x2cda48(0x3f7)],stats[_0x2cda48(0x148)]++,stats[_0x2cda48(0x2b7)]--),_0x4e10f2[_0x2cda48(0x376)](updateQuestionNav);_0x4e10f2[_0x2cda48(0x376)](saveProgress);}function processAnswer(){const _0x23d5e3=_0x6eced6,_0x58a4a8={'pmste':function(_0x16e702,_0x1da144){return _0x16e702===_0x1da144;},'IeVsn':_0x23d5e3(0x344),'hycXV':function(_0x48f74a,_0x2e57ae){return _0x48f74a!==_0x2e57ae;},'bipUa':'yLzmu','zxiHD':'NJsJE','CzJWF':_0x23d5e3(0x17c),'qmokG':_0x23d5e3(0x3b3),'NGmAK':function(_0x15e82c){return _0x15e82c();},'oQZXW':function(_0x3481e7){return _0x3481e7();}},_0x4c6383=questionsData[currentQuestionIndex],_0x239c42=_0x4c6383[_0x23d5e3(0x27e)];if(_0x58a4a8[_0x23d5e3(0x379)](selectedOption,null))return;const _0x384f07=_0x4c6383['choices'][selectedOption],_0x56239d=_0x384f07['id']===_0x239c42;if(_0x58a4a8[_0x23d5e3(0x379)](questionStates[currentQuestionIndex]['status'],_0x58a4a8['IeVsn'])){if(_0x58a4a8['hycXV'](_0x58a4a8[_0x23d5e3(0x2ad)],_0x58a4a8[_0x23d5e3(0x19e)])){stats[_0x23d5e3(0x148)]++,stats[_0x23d5e3(0x2b7)]--;if(_0x56239d)stats['correctAnswers']++;else stats[_0x23d5e3(0x22b)]++;}else _0x4e38bb();}questionStates[currentQuestionIndex][_0x23d5e3(0x329)]=_0x56239d?_0x58a4a8[_0x23d5e3(0x27d)]:_0x58a4a8['qmokG'],_0x58a4a8[_0x23d5e3(0x242)](updateStats),showInlineFeedback(_0x56239d),_0x58a4a8[_0x23d5e3(0x45c)](updateQuestionNav);}function showInlineFeedback(_0x55c745){const _0x111c8f=_0x6eced6,_0x26191d={'Nfhul':_0x111c8f(0x32a),'IIzNA':function(_0x5e5105,_0x4aa1f5){return _0x5e5105===_0x4aa1f5;},'RebNE':'correct','EYPgE':function(_0x5ac76b,_0x5a613d){return _0x5ac76b===_0x5a613d;},'MrLlU':'incorrect','xNNBV':function(_0x5638f7,_0x52360b){return _0x5638f7!==_0x52360b;},'bsgXA':_0x111c8f(0x2e1),'zQAaS':function(_0xa6215e,_0x180498){return _0xa6215e!==_0x180498;},'YIRTb':'timed_study','sYtkA':_0x111c8f(0x358),'LdGse':_0x111c8f(0x22d),'yFszI':_0x111c8f(0x155),'CViqQ':function(_0x392e2f){return _0x392e2f();}};if(_0x26191d['xNNBV'](currentMode,_0x26191d[_0x111c8f(0x1d5)])&&_0x26191d['zQAaS'](currentMode,_0x26191d[_0x111c8f(0x3f8)]))return;const _0x4db9d0=document[_0x111c8f(0x33a)](_0x26191d[_0x111c8f(0x15e)]),_0x457448=_0x4db9d0[_0x111c8f(0x25a)](_0x26191d[_0x111c8f(0x12b)]),_0x1e0942=questionsData[currentQuestionIndex],_0x93ba12=_0x1e0942[_0x111c8f(0x27e)];let _0x1c3cf3=_0x1e0942[_0x111c8f(0x18a)][_0x111c8f(0x41a)](_0x24f314=>_0x24f314['id']===_0x93ba12);_0x4db9d0[_0x111c8f(0x209)][_0x111c8f(0x168)](_0x26191d[_0x111c8f(0x239)]),_0x457448[_0x111c8f(0x1ab)]((_0x4bf6ce,_0x436234)=>{const _0x2dd72b=_0x111c8f;_0x4bf6ce['classList']['remove'](_0x26191d[_0x2dd72b(0x31e)]);if(_0x26191d[_0x2dd72b(0x2d0)](_0x436234,_0x1c3cf3))_0x4bf6ce[_0x2dd72b(0x209)][_0x2dd72b(0x168)](_0x26191d[_0x2dd72b(0x1e3)]);else{if(_0x26191d[_0x2dd72b(0x1a3)](_0x436234,selectedOption)&&!_0x55c745)_0x4bf6ce['classList'][_0x2dd72b(0x168)](_0x26191d[_0x2dd72b(0x304)]);}}),_0x26191d[_0x111c8f(0x3cd)](showSolution);}function showSolution(){const _0x6e252f=_0x6eced6,_0x1f663d={'mRRZi':function(_0x46dd15,_0x112cd9){return _0x46dd15===_0x112cd9;},'wzoAK':_0x6e252f(0x17c),'lalJV':_0x6e252f(0x1cc),'BqYSH':function(_0x3d8aeb,_0x19a5c9){return _0x3d8aeb!==_0x19a5c9;},'CoXNN':_0x6e252f(0x35b),'ouEmB':function(_0x5be194,_0x36f1b){return _0x5be194!==_0x36f1b;},'ZsyZP':_0x6e252f(0x41b),'GIPBR':_0x6e252f(0x3f6),'EGgyG':'No\x20solution\x20provided','XvKOh':_0x6e252f(0x2ab),'oWMst':_0x6e252f(0x40b),'oWlPD':_0x6e252f(0x12c),'TwLxp':_0x6e252f(0x2f0),'CAAQi':'solutionContainer'};if(_0x1f663d[_0x6e252f(0x3cb)](currentMode,'study')&&_0x1f663d[_0x6e252f(0x3cb)](currentMode,_0x1f663d[_0x6e252f(0x40e)]))return;const _0x55445f=questionsData[currentQuestionIndex];document[_0x6e252f(0x33a)](_0x1f663d['GIPBR'])[_0x6e252f(0x3a7)]=_0x55445f[_0x6e252f(0x2f1)]||_0x1f663d['EGgyG'];const _0x284ec3=document['getElementById'](_0x1f663d['XvKOh']),_0x555def=document['getElementById'](_0x1f663d['oWMst']),_0x3ddb84=_0x55445f['explanation_video'];if(_0x3ddb84){_0x284ec3[_0x6e252f(0x209)]['remove'](_0x1f663d[_0x6e252f(0x374)]);if(_0x3ddb84[_0x6e252f(0x43c)](_0x1f663d['TwLxp']))setupVideo(_0x555def,_0x3ddb84);else _0x555def[_0x6e252f(0x19c)]=_0x3ddb84;}else _0x284ec3['classList'][_0x6e252f(0x168)](_0x1f663d[_0x6e252f(0x374)]);const _0x268f33=document[_0x6e252f(0x33a)](_0x6e252f(0x430));_0x268f33[_0x6e252f(0x3a7)]='';_0x55445f[_0x6e252f(0x43e)]&&(_0x268f33[_0x6e252f(0x3a7)]+=_0x6e252f(0x37e)+_0x55445f[_0x6e252f(0x43e)]+_0x6e252f(0x406));_0x55445f[_0x6e252f(0x1c2)]&&(_0x268f33[_0x6e252f(0x3a7)]+=_0x6e252f(0x21a)+_0x55445f[_0x6e252f(0x1c2)]+_0x6e252f(0x406));const _0x3a51ec=document[_0x6e252f(0x33a)](_0x6e252f(0x223));_0x3a51ec[_0x6e252f(0x3a7)]='',_0x55445f[_0x6e252f(0x415)]&&_0x55445f['explanation_images'][_0x6e252f(0x1ab)](_0x589702=>{const _0x5bb229=_0x6e252f;if(_0x1f663d[_0x5bb229(0x45d)](_0x1f663d[_0x5bb229(0x251)],_0x5bb229(0x35b))){const _0x3402dd=_0x27ba76[_0x5bb229(0x18a)][_0x2cb77e[_0x5bb229(0x291)]];_0x1f663d['mRRZi'](_0x3402dd['id'],_0x6b84d8)?(_0x1f45e3=_0x1f663d[_0x5bb229(0x136)],_0x5d5c7c=_0x1f663d[_0x5bb229(0x272)]):(_0xa23bec=_0x5bb229(0x3b3),_0x335b0c=_0x5bb229(0x299));}else{if(_0x589702)_0x3a51ec[_0x5bb229(0x3a7)]+='<div\x20class=\x22mt-4\x22><img\x20src=\x22'+_0x589702+'\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>';}}),document[_0x6e252f(0x33a)](_0x1f663d[_0x6e252f(0x3b1)])['classList'][_0x6e252f(0x3fd)](_0x6e252f(0x12c));}function submitQuiz(){const _0x1c6571=_0x6eced6,_0x35a9ac={'jPrLf':_0x1c6571(0x416),'DslDU':'Bookmark','akeZA':'AWmxd','CeBCO':function(_0x24bdf2,_0x483558){return _0x24bdf2!==_0x483558;},'bXcsa':_0x1c6571(0x2ec),'UJDjd':_0x1c6571(0x3b3),'TGToS':function(_0x529611,_0x1e3ad5){return _0x529611(_0x1e3ad5);},'gzbbg':function(_0x38cbcb,_0x37f616){return _0x38cbcb(_0x37f616);},'Xoayp':function(_0x27b559,_0x236435){return _0x27b559-_0x236435;},'qIAnz':function(_0xe5d9c7,_0x2ae974){return _0xe5d9c7+_0x2ae974;},'WDVwJ':_0x1c6571(0x310),'EFhnR':function(_0x39470a){return _0x39470a();},'EVGFF':function(_0x49deba,_0x24933d){return _0x49deba-_0x24933d;}};if(timer)_0x35a9ac['TGToS'](clearInterval,timer);if(!_0x35a9ac['gzbbg'](confirm,_0x1c6571(0x2b5)))return;isQuizCompleted=!![];let _0x28fa7d=0x0,_0xb18311=0x0;const _0x1b421b=_0x35a9ac[_0x1c6571(0x3c6)](Date['now'](),quizStartTime);questionsData[_0x1c6571(0x1ab)]((_0x4b6369,_0x3ff5cb)=>{const _0x3cf535=_0x1c6571,_0x299d1b={'okzNs':_0x35a9ac[_0x3cf535(0x268)],'hajmn':'bookmarkText','pXosA':'gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','qYzPd':_0x3cf535(0x12e),'esJfq':_0x35a9ac[_0x3cf535(0x3fb)]};if(_0x3cf535(0x3d7)===_0x35a9ac[_0x3cf535(0x2be)]){const _0xa8d627=_0x29e876?function(){if(_0x3112ae){const _0x174e5a=_0x3a21b5['apply'](_0x443214,arguments);return _0x506fa2=null,_0x174e5a;}}:function(){};return _0x32fd74=![],_0xa8d627;}else{const _0x3ffd27=questionStates[_0x3ff5cb];if(_0x35a9ac[_0x3cf535(0x41d)](_0x3ffd27['selectedAnswer'],null)){if(_0x35a9ac[_0x3cf535(0x41d)](_0x35a9ac[_0x3cf535(0x33c)],_0x35a9ac['bXcsa'])){const _0x57ea4b=_0x2b38f7['getElementById'](_0x299d1b[_0x3cf535(0x27c)]),_0x4d1ec6=_0x20f4ea[_0x3cf535(0x33a)](_0x299d1b[_0x3cf535(0x2d5)]),_0x319dad=_0x292062[_0x5d4ec2][_0x3cf535(0x38c)];_0x57ea4b[_0x3cf535(0x3ad)]=_0x319dad?_0x299d1b[_0x3cf535(0x31c)]:_0x299d1b[_0x3cf535(0x3f2)],_0x4d1ec6[_0x3cf535(0x147)]=_0x319dad?_0x3cf535(0x34e):_0x299d1b[_0x3cf535(0x412)];}else _0x4b6369['choices'][_0x3ffd27[_0x3cf535(0x291)]]['id']===_0x4b6369['correct_choice_id']?(_0x28fa7d++,_0x3ffd27['status']=_0x3cf535(0x17c)):(_0xb18311++,_0x3ffd27['status']=_0x35a9ac['UJDjd']);}}});const _0x4fa3e5=JSON[_0x1c6571(0x3c3)](localStorage[_0x1c6571(0x2c5)](_0x1c6571(0x310)))||[];_0x4fa3e5['push']({'quizName':quizName,'hierarchy':hierarchy,'timestamp':Date[_0x1c6571(0x2e0)](),'totalTime':_0x1b421b,'stats':{'correct':_0x28fa7d,'incorrect':_0xb18311,'notAttempted':_0x35a9ac[_0x1c6571(0x3c6)](questionsData[_0x1c6571(0x207)],_0x35a9ac[_0x1c6571(0x36e)](_0x28fa7d,_0xb18311))}}),localStorage[_0x1c6571(0x269)](_0x35a9ac[_0x1c6571(0x153)],JSON['stringify'](_0x4fa3e5)),stats['correctAnswers']=_0x28fa7d,stats[_0x1c6571(0x22b)]=_0xb18311,_0x35a9ac['EFhnR'](markQuizAsCompleted),showPerformanceAnalysis(_0x28fa7d,_0xb18311,_0x35a9ac[_0x1c6571(0x2ed)](questionsData[_0x1c6571(0x207)],_0x28fa7d+_0xb18311),_0x1b421b);}function showPerformanceAnalysis(_0x148e62,_0x3940f8,_0x17c997,_0x38a0f3){const _0x133fb3=_0x6eced6,_0xd2c3e8={'OoBYb':_0x133fb3(0x3da),'Hxwaz':function(_0x3541ed,_0xaa8445){return _0x3541ed>_0xaa8445;},'KthjY':function(_0x715f47,_0x1c2e43){return _0x715f47+_0x1c2e43;},'STqfS':function(_0x17e9ec,_0x469b09){return _0x17e9ec*_0x469b09;},'UoxXp':function(_0x5ebb0a,_0x148b11){return _0x5ebb0a/_0x148b11;},'dTAFD':function(_0x2c0cfd,_0x238e4f){return _0x2c0cfd*_0x238e4f;},'wkDDk':function(_0x316f04,_0x19af47){return _0x316f04*_0x19af47;},'HMVul':_0x133fb3(0x1f4),'OCEYu':function(_0x458e00,_0x49999b){return _0x458e00-_0x49999b;},'ZBRLt':function(_0x498653,_0x29713e){return _0x498653/_0x29713e;},'MMNnV':_0x133fb3(0x25e),'CyQwm':_0x133fb3(0x194),'MZmqU':'incorrectResult','TnrQO':_0x133fb3(0x279),'vXKLO':function(_0x324f7c,_0x5c8a61){return _0x324f7c/_0x5c8a61;},'gVkTL':function(_0x2d0c6d,_0x1f2d5f){return _0x2d0c6d%_0x1f2d5f;},'ZhTjm':_0x133fb3(0x3d4),'sAbUe':function(_0x25bcd4,_0x48fb84){return _0x25bcd4/_0x48fb84;},'tsFSA':_0x133fb3(0x2a7)},_0x3e9394=document['getElementById'](_0xd2c3e8[_0x133fb3(0x177)]),_0x2b8de1=_0xd2c3e8[_0x133fb3(0x438)](_0xd2c3e8['KthjY'](_0x148e62,_0x3940f8),0x0)?Math[_0x133fb3(0x364)](_0xd2c3e8[_0x133fb3(0x2cb)](_0xd2c3e8['UoxXp'](_0x148e62,_0x148e62+_0x3940f8),0x64)):0x0,_0x5583e7=_0xd2c3e8[_0x133fb3(0x24f)](_0xd2c3e8[_0x133fb3(0x1f8)](0x2,Math['PI']),0x41),_0x2689dc=document['getElementById'](_0xd2c3e8['HMVul']);_0x2689dc[_0x133fb3(0x40d)][_0x133fb3(0x2ff)]=_0x5583e7+'\x20'+_0x5583e7,_0x2689dc['style']['strokeDashoffset']=_0xd2c3e8['OCEYu'](_0x5583e7,_0xd2c3e8['dTAFD'](_0xd2c3e8[_0x133fb3(0x3b5)](_0x2b8de1,0x64),_0x5583e7)),document['getElementById'](_0x133fb3(0x2c2))[_0x133fb3(0x147)]=_0x2b8de1+'%',document[_0x133fb3(0x33a)](_0xd2c3e8['MMNnV'])[_0x133fb3(0x147)]=questionsData[_0x133fb3(0x207)],document['getElementById'](_0xd2c3e8[_0x133fb3(0x211)])[_0x133fb3(0x147)]=_0x148e62,document['getElementById'](_0xd2c3e8['MZmqU'])['textContent']=_0x3940f8,document[_0x133fb3(0x33a)](_0xd2c3e8[_0x133fb3(0x1a1)])['textContent']=_0x17c997;const _0x15cad3=Math['floor'](_0xd2c3e8[_0x133fb3(0x2d1)](_0x38a0f3,0xea60)),_0x12a54e=Math[_0x133fb3(0x278)](_0xd2c3e8[_0x133fb3(0x345)](_0x38a0f3,0xea60)/0x3e8);document[_0x133fb3(0x33a)](_0xd2c3e8[_0x133fb3(0x143)])['textContent']=_0x15cad3+':'+_0x12a54e[_0x133fb3(0x2e3)]()['padStart'](0x2,'0');const _0x53d812=_0xd2c3e8['sAbUe'](_0x38a0f3,questionsData[_0x133fb3(0x207)]),_0xb4e3ed=Math[_0x133fb3(0x278)](_0x53d812/0xea60),_0x3a5015=Math[_0x133fb3(0x278)](_0xd2c3e8[_0x133fb3(0x3b5)](_0xd2c3e8['gVkTL'](_0x53d812,0xea60),0x3e8));document['getElementById'](_0xd2c3e8[_0x133fb3(0x145)])[_0x133fb3(0x147)]=_0xb4e3ed+':'+_0x3a5015[_0x133fb3(0x2e3)]()[_0x133fb3(0x1fd)](0x2,'0'),_0x3e9394['classList'][_0x133fb3(0x3fd)](_0x133fb3(0x12c));}function closePerformanceModal(){const _0x2e4c86=_0x6eced6,_0x20aaa7={'mQeOm':_0x2e4c86(0x3da)};document[_0x2e4c86(0x33a)](_0x20aaa7[_0x2e4c86(0x307)])[_0x2e4c86(0x209)][_0x2e4c86(0x168)](_0x2e4c86(0x12c));}function reviewQuestions(){const _0x10eb31=_0x6eced6,_0x48e1c9={'TNZlq':'correct','ukLmm':function(_0x2ffe4d,_0x2cf81f){return _0x2ffe4d===_0x2cf81f;},'UOZfc':_0x10eb31(0x1b4),'ypjgx':'border-red-500','tTrHx':function(_0x61ddf6,_0x4eee70){return _0x61ddf6+_0x4eee70;},'HJewH':function(_0xedd966,_0xa75294){return _0xedd966===_0xa75294;},'EJDXD':'incorrect','kYCvQ':_0x10eb31(0x2a4),'iDPUi':function(_0x619501,_0x111fc5){return _0x619501!==_0x111fc5;},'gEmVH':_0x10eb31(0x135),'WJKwn':_0x10eb31(0x35d),'hFHCT':_0x10eb31(0x14a),'StHUw':function(_0x394bf1,_0x4e11d7){return _0x394bf1===_0x4e11d7;},'UqqXs':function(_0x4f27a9,_0x86729d){return _0x4f27a9===_0x86729d;},'EKDLe':_0x10eb31(0x370),'TjDOI':_0x10eb31(0x417),'omcWi':_0x10eb31(0x1cc),'ysSZC':_0x10eb31(0x299),'TZaCx':_0x10eb31(0x1d7),'yoJFg':_0x10eb31(0x259),'KOJuW':_0x10eb31(0x2c3),'YQcNb':'gray','vKtXz':_0x10eb31(0x293),'CnKax':_0x10eb31(0x273),'VscvI':'hidden','AYmBb':function(_0x44f085){return _0x44f085();}};document[_0x10eb31(0x33a)](_0x48e1c9['CnKax'])[_0x10eb31(0x209)][_0x10eb31(0x3fd)](_0x48e1c9[_0x10eb31(0x28a)]);const _0x35283d=document[_0x10eb31(0x33a)](_0x10eb31(0x2e9));_0x35283d['innerHTML']='',questionsData[_0x10eb31(0x1ab)]((_0x419dde,_0x4bfa5a)=>{const _0x413010=_0x10eb31,_0x257cb6={'ERlvb':function(_0x2c1ae9,_0x1a35c3){const _0x1a26bc=_0x3e0e;return _0x48e1c9[_0x1a26bc(0x1a0)](_0x2c1ae9,_0x1a35c3);},'VPcJM':'nav-btn-correct','UlfYG':_0x48e1c9[_0x413010(0x1bf)],'tBgIU':_0x48e1c9['kYCvQ'],'OlFId':_0x413010(0x167)};if(_0x48e1c9[_0x413010(0x3b2)](_0x48e1c9[_0x413010(0x1c8)],_0x48e1c9[_0x413010(0x1c8)]))_0xcab8e0++,_0x47dfa0[_0x413010(0x329)]=_0x48e1c9['TNZlq'];else{const _0x4d100b=questionStates[_0x4bfa5a],_0x22c433=_0x419dde['correct_choice_id'];let _0x634557=_0x48e1c9[_0x413010(0x204)],_0x24901b=_0x48e1c9[_0x413010(0x44d)];if(_0x48e1c9[_0x413010(0x3b2)](_0x4d100b[_0x413010(0x291)],null)){const _0x4deee3=_0x419dde[_0x413010(0x18a)][_0x4d100b[_0x413010(0x291)]];if(_0x48e1c9[_0x413010(0x228)](_0x4deee3['id'],_0x22c433)){if(_0x48e1c9[_0x413010(0x3dd)](_0x48e1c9['EKDLe'],_0x48e1c9[_0x413010(0x450)])){if(_0x257cb6[_0x413010(0x3ff)](_0x436fbf[_0x413010(0x329)],'correct'))_0x3ae936=_0x257cb6['VPcJM'];else{if(_0x257cb6[_0x413010(0x3ff)](_0xbd94b8['status'],_0x257cb6[_0x413010(0x3de)]))_0x10c1a5=_0x257cb6['tBgIU'];else _0x3a324d=_0x257cb6[_0x413010(0x407)];}}else _0x634557=_0x48e1c9[_0x413010(0x42c)],_0x24901b=_0x48e1c9[_0x413010(0x271)];}else _0x634557=_0x413010(0x3b3),_0x24901b=_0x48e1c9[_0x413010(0x305)];}const _0x46ef03=document[_0x413010(0x3b7)](_0x48e1c9['TZaCx']);_0x46ef03[_0x413010(0x3ad)]=_0x413010(0x30e)+_0x634557;let _0x14d0ff=(_0x419dde['choices']||[])[_0x413010(0x390)]((_0x5b1590,_0x14e660)=>{const _0x187fe9=_0x413010,_0x5b183b=_0x48e1c9[_0x187fe9(0x465)](_0x4d100b['selectedAnswer'],_0x14e660),_0x502815=_0x48e1c9[_0x187fe9(0x465)](_0x5b1590['id'],_0x22c433);let _0x4a2c3a='border-gray-600';if(_0x502815)_0x4a2c3a=_0x48e1c9[_0x187fe9(0x343)];else{if(_0x5b183b)_0x4a2c3a=_0x48e1c9[_0x187fe9(0x237)];}return _0x187fe9(0x2b8)+_0x4a2c3a+_0x187fe9(0x334)+String[_0x187fe9(0x248)](_0x48e1c9['tTrHx'](0x41,_0x14e660))+'</span><span>'+_0x5b1590[_0x187fe9(0x38b)]+'</span></div>';})[_0x413010(0x3bf)]('');const _0x3891bf=_0x419dde[_0x413010(0x3c1)]?_0x413010(0x2d2)+_0x4bfa5a+_0x413010(0x3e4)+_0x419dde[_0x413010(0x3c1)]+'\x22\x20class=\x22w-full\x20rounded-lg\x22\x20controls></video></div>':'';let _0x1d0a4e='';if(_0x419dde[_0x413010(0x43e)])_0x1d0a4e+=_0x413010(0x36f)+_0x419dde[_0x413010(0x43e)]+_0x413010(0x406);if(_0x419dde[_0x413010(0x1c2)])_0x1d0a4e+=_0x413010(0x289)+_0x419dde[_0x413010(0x1c2)]+'\x22\x20controls\x20class=\x22w-full\x22></audio></div>';let _0x41631c=(_0x419dde[_0x413010(0x415)]||[])[_0x413010(0x390)](_0x206491=>_0x206491?_0x413010(0x2e7)+_0x206491+'\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>':'')[_0x413010(0x3bf)]('');_0x46ef03['innerHTML']=_0x413010(0x300)+(_0x4bfa5a+0x1)+'</h4>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<span\x20class=\x22text-sm\x20px-3\x20py-1\x20rounded-full\x20bg-'+(_0x634557===_0x48e1c9[_0x413010(0x42c)]?_0x48e1c9[_0x413010(0x1a8)]:_0x48e1c9['HJewH'](_0x634557,_0x48e1c9['EJDXD'])?_0x48e1c9[_0x413010(0x189)]:_0x48e1c9['YQcNb'])+'-600\x20text-white\x22>'+_0x24901b+'</span>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20mb-4\x22>'+_0x419dde[_0x413010(0x38b)]+_0x413010(0x17b)+_0x14d0ff+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22bg-green-900\x20bg-opacity-20\x20p-4\x20rounded-lg\x20border\x20border-green-700\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h5\x20class=\x22text-green-400\x20font-bold\x20mb-2\x22>Explanation:</h5>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20text-opacity-90\x22>'+(_0x419dde['solution']||_0x48e1c9[_0x413010(0x460)])+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20'+_0x3891bf+_0x413010(0x3df)+_0x1d0a4e+_0x413010(0x3df)+_0x41631c+'\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>',_0x35283d['appendChild'](_0x46ef03);}}),_0x48e1c9[_0x10eb31(0x2ef)](initializeReviewVideos);}function initializeReviewVideos(){const _0x36fdb7=_0x6eced6,_0xf1ffe8={'ZLDLN':function(_0x25fe63,_0x279a44){return _0x25fe63(_0x279a44);},'ejRXu':function(_0x9dcd7,_0x146e50){return _0x9dcd7===_0x146e50;},'FVExk':_0x36fdb7(0x247),'uPujY':_0x36fdb7(0x2f0),'rRuTY':function(_0x2df9e8,_0x34a0c0){return _0x2df9e8===_0x34a0c0;},'cNxNJ':'LUqPY','WaIuO':_0x36fdb7(0x26f)};document[_0x36fdb7(0x25a)](_0xf1ffe8[_0x36fdb7(0x3d9)])[_0x36fdb7(0x1ab)](_0x4c8c62=>{const _0x221a10=_0x36fdb7,_0x51b9a6={'GGyGh':function(_0x55eda5,_0x3d32cf){const _0xbbda4b=_0x3e0e;return _0xf1ffe8[_0xbbda4b(0x398)](_0x55eda5,_0x3d32cf);},'nYSkI':function(_0x5a55d3,_0x33ff9c){return _0xf1ffe8['ejRXu'](_0x5a55d3,_0x33ff9c);},'VclQZ':_0xf1ffe8[_0x221a10(0x274)],'zGaGM':function(_0x562055){return _0x562055();},'nVwhg':function(_0x48ccff){return _0x48ccff();}},_0x1db28b=_0x4c8c62[_0x221a10(0x1ae)][_0x221a10(0x19c)];if(_0x1db28b&&_0x1db28b['includes'](_0xf1ffe8[_0x221a10(0x2fc)]))setupVideo(_0x4c8c62,_0x1db28b);else _0x1db28b&&(_0xf1ffe8['rRuTY'](_0xf1ffe8[_0x221a10(0x176)],_0xf1ffe8[_0x221a10(0x176)])?_0x4c8c62[_0x221a10(0x19c)]=_0x1db28b:(_0x51b9a6[_0x221a10(0x1df)](_0x7da237,_0x5b8542),_0x51b9a6[_0x221a10(0x26a)](_0x25af8b,_0x51b9a6[_0x221a10(0x201)])?_0x51b9a6[_0x221a10(0x217)](_0x50ca67):_0x51b9a6['nVwhg'](_0x5ab0a2)));});}function retakeQuiz(){const _0x39edc8=_0x6eced6,_0x3e5053={'xPMTp':function(_0x539a14,_0x388826){return _0x539a14/_0x388826;},'jIUOK':function(_0x2c64de,_0x353dcb){return _0x2c64de+_0x353dcb;},'QtlTC':_0x39edc8(0x1b3),'GguGH':function(_0x4dd326,_0x2cbbe0){return _0x4dd326!==_0x2cbbe0;},'XcMkf':'ODTKm','atmej':_0x39edc8(0x283),'oZVxZ':function(_0x2d3316){return _0x2d3316();}};if(confirm(_0x3e5053['QtlTC'])){if(window[_0x39edc8(0x3e8)][_0x39edc8(0x401)]['endsWith']('custom_quiz.html')){if(_0x3e5053[_0x39edc8(0x454)](_0x3e5053[_0x39edc8(0x2ee)],_0x39edc8(0x301)))localStorage[_0x39edc8(0x24b)](_0x3e5053[_0x39edc8(0x39e)]);else{const _0x4f69e1=_0x5f40c0[_0x39edc8(0x278)](_0x3e5053['xPMTp'](_0x1f1abc,0x3c)),_0x2557e6=_0x5a64b8%0x3c;_0x3101dd[_0x39edc8(0x33a)](_0x39edc8(0x461))[_0x39edc8(0x147)]=_0x3e5053[_0x39edc8(0x284)](_0x4f69e1+':',_0x2557e6[_0x39edc8(0x2e3)]()[_0x39edc8(0x1fd)](0x2,'0'));}}_0x3e5053[_0x39edc8(0x1b9)](clearProgress),location[_0x39edc8(0x2b4)]();}}function loadBookmarkedQuestions(){const _0x9025e3=_0x6eced6,_0x4d9159={'GUkML':_0x9025e3(0x395),'JTDNO':function(_0x567f79,_0x3ac606){return _0x567f79+_0x3ac606;},'BXTvb':_0x9025e3(0x1f9),'FwZtN':_0x9025e3(0x295),'QZuwb':'\x20>\x20','dVgzf':function(_0x3b1041,_0x1cbaa3){return _0x3b1041!==_0x1cbaa3;},'FQZkc':_0x9025e3(0x1c5),'ttBeu':function(_0x53510c,_0x10c1da){return _0x53510c<_0x10c1da;},'aAQiO':_0x9025e3(0x1f6),'NpkkT':_0x9025e3(0x249)},_0xae8bd2=JSON[_0x9025e3(0x3c3)](localStorage[_0x9025e3(0x2c5)](_0x4d9159[_0x9025e3(0x276)]))||[];_0xae8bd2['forEach'](_0x27787e=>{const _0x3573f2=_0x9025e3,_0x5dd7a7={'JWTBe':function(_0x5541ac){return _0x5541ac();}};if(_0x27787e[_0x3573f2(0x1db)][_0x3573f2(0x43c)](quizName[_0x3573f2(0x2c7)]()[_0x3573f2(0x3a8)](/ /g,'-'))){if(_0x4d9159[_0x3573f2(0x43f)]('qLgST',_0x4d9159[_0x3573f2(0x23c)]))_0x38319d[_0x18291e]['markedForReview']=!_0x1b0bf1[_0x1651cb]['markedForReview'],_0x1e5d48(),_0x5dd7a7[_0x3573f2(0x163)](_0x18a2ce);else{if(_0x4d9159[_0x3573f2(0x341)](_0x27787e['questionIndex'],questionsData[_0x3573f2(0x207)])){if(_0x4d9159['dVgzf'](_0x4d9159[_0x3573f2(0x377)],_0x3573f2(0x451)))questionStates[_0x27787e[_0x3573f2(0x2dd)]][_0x3573f2(0x38c)]=!![];else{const _0xee96eb=_0x4d9159[_0x3573f2(0x20e)]['split']('|');let _0x4a871b=0x0;while(!![]){switch(_0xee96eb[_0x4a871b++]){case'0':_0x12948d=_0x16adc9[_0x3573f2(0x35f)];continue;case'1':_0x3c0774[_0x3573f2(0x367)]=_0x4d9159['JTDNO'](_0x5dce15,_0x3573f2(0x1aa));continue;case'2':_0x3bc6f7[_0x3573f2(0x33a)](_0x4d9159[_0x3573f2(0x43b)])[_0x3573f2(0x147)]=_0x4d7b6e[_0x3573f2(0x207)];continue;case'3':_0x4101e6=_0x1beb42['questions'];continue;case'4':_0x4c5112=_0x9dafc4[_0x3573f2(0x420)];continue;case'5':_0x5206a8[_0x3573f2(0x33a)](_0x4d9159['FwZtN'])['textContent']=_0x52a57c[_0x3573f2(0x3bf)](_0x4d9159[_0x3573f2(0x197)]);continue;}break;}}}}}});}function toggleBookmark(){const _0x5a4fd6=_0x6eced6,_0x3e1f9a={'IGuxr':_0x5a4fd6(0x249),'WtCTI':function(_0x2f9d63,_0x536b79){return _0x2f9d63!==_0x536b79;},'iHCts':_0x5a4fd6(0x2a8),'xOIWb':function(_0x19de98){return _0x19de98();}},_0x409094=!questionStates[currentQuestionIndex][_0x5a4fd6(0x38c)];questionStates[currentQuestionIndex]['bookmarked']=_0x409094;let _0x4cf6e4=JSON['parse'](localStorage[_0x5a4fd6(0x2c5)](_0x3e1f9a[_0x5a4fd6(0x45e)]))||[];if(_0x409094){const _0x2519b8={'quizName':quizName,'quizFile':window[_0x5a4fd6(0x3e8)][_0x5a4fd6(0x401)]['split']('/')['pop'](),'questionIndex':currentQuestionIndex,'question':questionsData[currentQuestionIndex],'hierarchy':hierarchy,'timestamp':Date[_0x5a4fd6(0x2e0)]()};_0x4cf6e4[_0x5a4fd6(0x378)](_0x2519b8);}else{if(_0x3e1f9a[_0x5a4fd6(0x2c0)](_0x3e1f9a[_0x5a4fd6(0x186)],_0x5a4fd6(0x2a8))){const _0xa2e3a6={'mPuyI':function(_0x31ad54,_0x4fed52){return _0x31ad54<_0x4fed52;}},_0x2957b5=_0x4b085e['parse'](_0x121e1b[_0x5a4fd6(0x2c5)]('bookmarkedQuestions'))||[];_0x2957b5['forEach'](_0x11a4a5=>{const _0x1cce20=_0x5a4fd6;_0x11a4a5['quizFile'][_0x1cce20(0x43c)](_0x426cf7['toLowerCase']()[_0x1cce20(0x3a8)](/ /g,'-'))&&(_0xa2e3a6[_0x1cce20(0x43a)](_0x11a4a5[_0x1cce20(0x2dd)],_0x270429[_0x1cce20(0x207)])&&(_0x3b4b7d[_0x11a4a5[_0x1cce20(0x2dd)]]['bookmarked']=!![]));});}else _0x4cf6e4=_0x4cf6e4[_0x5a4fd6(0x229)](_0x28a8ce=>!(_0x28a8ce[_0x5a4fd6(0x1db)][_0x5a4fd6(0x43c)](quizName[_0x5a4fd6(0x2c7)]()[_0x5a4fd6(0x3a8)](/ /g,'-'))&&_0x28a8ce['questionIndex']===currentQuestionIndex));}localStorage['setItem'](_0x3e1f9a['IGuxr'],JSON[_0x5a4fd6(0x29d)](_0x4cf6e4)),_0x3e1f9a[_0x5a4fd6(0x315)](updateBookmarkButton),_0x3e1f9a[_0x5a4fd6(0x315)](updateQuestionNav);}function updateBookmarkButton(){const _0x549a2f=_0x6eced6,_0x5533d7={'OXHjE':_0x549a2f(0x416),'YZKBM':_0x549a2f(0x12e),'PKPCx':_0x549a2f(0x34e),'YjXnY':_0x549a2f(0x146)},_0xbe2da8=document['getElementById'](_0x5533d7[_0x549a2f(0x26d)]),_0x179bd6=document[_0x549a2f(0x33a)](_0x549a2f(0x139)),_0x1e4e11=questionStates[currentQuestionIndex][_0x549a2f(0x38c)];_0xbe2da8[_0x549a2f(0x3ad)]=_0x1e4e11?'gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center':_0x5533d7['YZKBM'],_0x179bd6[_0x549a2f(0x147)]=_0x1e4e11?_0x5533d7['PKPCx']:_0x5533d7['YjXnY'];}function toggleMarkForReview(){const _0x273b7b=_0x6eced6,_0x25b4a0={'oWJhz':function(_0x2d7f8f){return _0x2d7f8f();},'THQEV':function(_0x26e728){return _0x26e728();}};questionStates[currentQuestionIndex][_0x273b7b(0x36a)]=!questionStates[currentQuestionIndex][_0x273b7b(0x36a)],_0x25b4a0['oWJhz'](updateMarkReviewButton),_0x25b4a0['THQEV'](updateQuestionNav);}function updateMarkReviewButton(){const _0x1d3518=_0x6eced6,_0x879e9c={'bMfXr':'markReviewBtn','bfqge':_0x1d3518(0x444),'TzZIm':_0x1d3518(0x296),'JLCMl':_0x1d3518(0x26c),'DsvoO':_0x1d3518(0x2b9),'mDAdI':'Mark\x20for\x20Review'},_0x1c36c5=document[_0x1d3518(0x33a)](_0x879e9c[_0x1d3518(0x266)]),_0x3e8a28=document[_0x1d3518(0x33a)](_0x879e9c[_0x1d3518(0x42f)]),_0x449eb0=questionStates[currentQuestionIndex][_0x1d3518(0x36a)];_0x1c36c5[_0x1d3518(0x3ad)]=_0x449eb0?_0x879e9c[_0x1d3518(0x2a6)]:_0x879e9c[_0x1d3518(0x205)],_0x3e8a28['textContent']=_0x449eb0?_0x879e9c[_0x1d3518(0x175)]:_0x879e9c['mDAdI'];}function previousQuestion(){const _0x1209fe=_0x6eced6,_0x4d8727={'afhLv':function(_0x551206,_0x8f0a6c){return _0x551206>_0x8f0a6c;},'COdbj':function(_0x5150e2,_0x3eab4c){return _0x5150e2!==_0x3eab4c;},'otnnh':_0x1209fe(0x270),'THtoD':function(_0x3c8578,_0x19d159){return _0x3c8578-_0x19d159;},'Mmdbr':function(_0x1d4d92){return _0x1d4d92();}};_0x4d8727[_0x1209fe(0x140)](currentQuestionIndex,0x0)&&(questionStartTime&&(_0x4d8727[_0x1209fe(0x357)](_0x1209fe(0x23a),_0x4d8727[_0x1209fe(0x21e)])?questionStates[currentQuestionIndex][_0x1209fe(0x24c)]+=_0x4d8727['THtoD'](Date['now'](),questionStartTime):_0x2a7ccf[_0x1209fe(0x19c)]=_0x5e33b6),currentQuestionIndex--,_0x4d8727[_0x1209fe(0x362)](displayQuestion),_0x4d8727[_0x1209fe(0x362)](saveProgress));}function nextQuestion(){const _0x1a9df2=_0x6eced6,_0x5087d0={'HiGoB':function(_0x36c8d6,_0x8636f0){return _0x36c8d6-_0x8636f0;},'HYmEb':function(_0x344ee7,_0x48afa7){return _0x344ee7===_0x48afa7;},'mlPch':_0x1a9df2(0x1f7),'ceNlS':'ayRDL','bKdWL':function(_0x5d070b){return _0x5d070b();},'IMNLd':'test','NvlfQ':function(_0x196b27,_0x198893){return _0x196b27!==_0x198893;},'JhQbX':function(_0x3cf337,_0x80891c){return _0x3cf337(_0x80891c);},'GVFRe':_0x1a9df2(0x360),'KjmSR':function(_0x2f7599,_0x48fb73){return _0x2f7599(_0x48fb73);},'lGhPN':_0x1a9df2(0x25f),'fIUbq':function(_0x54fad6){return _0x54fad6();}};questionStartTime&&(questionStates[currentQuestionIndex][_0x1a9df2(0x24c)]+=_0x5087d0[_0x1a9df2(0x422)](Date[_0x1a9df2(0x2e0)](),questionStartTime));if(currentQuestionIndex<_0x5087d0[_0x1a9df2(0x422)](questionsData[_0x1a9df2(0x207)],0x1)){if(_0x5087d0[_0x1a9df2(0x222)](_0x5087d0[_0x1a9df2(0x2bd)],_0x5087d0[_0x1a9df2(0x20a)])){const _0x34aed7=new _0x23cf5f();_0x34aed7[_0x1a9df2(0x292)](_0x3953fd),_0x34aed7['attachMedia'](_0x1e828a);}else currentQuestionIndex++,displayQuestion(),_0x5087d0['bKdWL'](saveProgress);}else{if(_0x5087d0[_0x1a9df2(0x222)](currentMode,_0x5087d0[_0x1a9df2(0x190)])||_0x5087d0[_0x1a9df2(0x222)](currentMode,'timed_exam')){if(_0x5087d0['NvlfQ'](_0x1a9df2(0x171),_0x1a9df2(0x171))){const _0x2913e5=_0x425120[_0x1a9df2(0x25d)](_0x25e758,arguments);return _0x5ced69=null,_0x2913e5;}else _0x5087d0[_0x1a9df2(0x464)](confirm,_0x5087d0[_0x1a9df2(0x365)])&&_0x5087d0[_0x1a9df2(0x45a)](submitQuiz);}else _0x5087d0['KjmSR'](confirm,_0x5087d0[_0x1a9df2(0x19b)])&&(currentQuestionIndex=0x0,_0x5087d0[_0x1a9df2(0x226)](displayQuestion),_0x5087d0[_0x1a9df2(0x45a)](saveProgress));}}function startTimer(){const _0x138883=_0x6eced6,_0x1caa76={'LqHih':function(_0x1e6508,_0x36f7cf){return _0x1e6508>_0x36f7cf;},'HdbgV':function(_0x5297c8,_0x3cf84f){return _0x5297c8+_0x3cf84f;},'tKUzR':function(_0x1e989c,_0x10dc88){return _0x1e989c/_0x10dc88;},'gsfZC':function(_0x175fb4,_0x11ecd8){return _0x175fb4*_0x11ecd8;},'tMeZj':'scoreCircle','GypBz':function(_0x1140bf,_0x1113d5){return _0x1140bf-_0x1113d5;},'GBIjg':function(_0xb4bd08,_0x2ed317){return _0xb4bd08*_0x2ed317;},'Hunbe':function(_0x1bc7a0,_0x49eeb6){return _0x1bc7a0/_0x49eeb6;},'BeJnH':'accuracyScore','lIlsg':_0x138883(0x194),'XFqbK':_0x138883(0x279),'fOiKV':function(_0x52c182,_0x48c273){return _0x52c182/_0x48c273;},'CBoTI':function(_0x2ccb8c,_0x3d5406){return _0x2ccb8c/_0x3d5406;},'sgMLc':function(_0x1d7ea5,_0x58f13e){return _0x1d7ea5%_0x58f13e;},'Tnxkk':function(_0x34be10,_0x1a27d){return _0x34be10/_0x1a27d;},'RXsUS':function(_0x5a9042,_0x1e38cd){return _0x5a9042/_0x1e38cd;},'dQOBA':function(_0x56393b,_0x3d5552){return _0x56393b/_0x3d5552;},'CTHnP':function(_0x34a8bb,_0x1e56bd){return _0x34a8bb%_0x1e56bd;},'IDVMA':_0x138883(0x2a7),'OkhOG':function(_0x5d461f){return _0x5d461f();},'ICgMg':function(_0x1c34ea,_0x20cebb){return _0x1c34ea<=_0x20cebb;},'Uqath':function(_0x4e54fe,_0xd7a845){return _0x4e54fe(_0xd7a845);},'gGSep':_0x138883(0x247),'Hktww':function(_0x2778b1){return _0x2778b1();},'aBpTf':function(_0xae09e4,_0x3cf5df){return _0xae09e4!==_0x3cf5df;},'ExYZA':_0x138883(0x2cd),'dsjkZ':function(_0x5b2bd0,_0x213ce4){return _0x5b2bd0(_0x213ce4);},'KKWMC':function(_0x509353,_0x4dea11,_0x124064){return _0x509353(_0x4dea11,_0x124064);}};if(timer)_0x1caa76[_0x138883(0x144)](clearInterval,timer);timeRemaining=0x78,_0x1caa76[_0x138883(0x42b)](updateTimerDisplay),timer=_0x1caa76[_0x138883(0x2db)](setInterval,()=>{const _0x1dc1cb=_0x138883;timeRemaining--,_0x1caa76['OkhOG'](updateTimerDisplay);if(_0x1caa76[_0x1dc1cb(0x150)](timeRemaining,0x0)){_0x1caa76[_0x1dc1cb(0x14d)](clearInterval,timer);if(currentMode===_0x1caa76[_0x1dc1cb(0x30d)])_0x1caa76[_0x1dc1cb(0x42b)](submitQuiz);else{if(_0x1caa76[_0x1dc1cb(0x285)](_0x1dc1cb(0x347),_0x1caa76[_0x1dc1cb(0x2d8)]))_0x1caa76['Hktww'](nextQuestion);else{const _0x40a741=_0x5386c9['getElementById'](_0x1dc1cb(0x3da)),_0x9de8b=_0x1caa76[_0x1dc1cb(0x21b)](_0x1caa76[_0x1dc1cb(0x199)](_0x19a446,_0xfd218),0x0)?_0xdecbfc[_0x1dc1cb(0x364)](_0x1caa76['tKUzR'](_0x46400e,_0x1caa76[_0x1dc1cb(0x199)](_0x49e5ea,_0x1f1ef0))*0x64):0x0,_0x29f2ba=_0x1caa76[_0x1dc1cb(0x17f)](_0x1caa76[_0x1dc1cb(0x17f)](0x2,_0x20c9e1['PI']),0x41),_0x3b4c03=_0x37320e['getElementById'](_0x1caa76[_0x1dc1cb(0x26e)]);_0x3b4c03[_0x1dc1cb(0x40d)][_0x1dc1cb(0x2ff)]=_0x29f2ba+'\x20'+_0x29f2ba,_0x3b4c03[_0x1dc1cb(0x40d)]['strokeDashoffset']=_0x1caa76[_0x1dc1cb(0x1ce)](_0x29f2ba,_0x1caa76['GBIjg'](_0x1caa76['Hunbe'](_0x9de8b,0x64),_0x29f2ba)),_0x15df90[_0x1dc1cb(0x33a)](_0x1caa76[_0x1dc1cb(0x375)])['textContent']=_0x9de8b+'%',_0x3d3292['getElementById']('totalQuestionsResult')['textContent']=_0x1be1e9[_0x1dc1cb(0x207)],_0x3182e9[_0x1dc1cb(0x33a)](_0x1caa76[_0x1dc1cb(0x3e5)])['textContent']=_0x2d67cf,_0x37fc5c[_0x1dc1cb(0x33a)](_0x1dc1cb(0x1fa))[_0x1dc1cb(0x147)]=_0x6dc85b,_0x5acd41[_0x1dc1cb(0x33a)](_0x1caa76[_0x1dc1cb(0x38e)])[_0x1dc1cb(0x147)]=_0x17bcfc;const _0x40975e=_0x198703[_0x1dc1cb(0x278)](_0x1caa76[_0x1dc1cb(0x188)](_0x3a4bbd,0xea60)),_0x3a42fb=_0x5b1873['floor'](_0x1caa76['CBoTI'](_0x1caa76[_0x1dc1cb(0x32b)](_0x321ca7,0xea60),0x3e8));_0x1e126b[_0x1dc1cb(0x33a)](_0x1dc1cb(0x3d4))[_0x1dc1cb(0x147)]=_0x40975e+':'+_0x3a42fb[_0x1dc1cb(0x2e3)]()[_0x1dc1cb(0x1fd)](0x2,'0');const _0xe42b78=_0x1caa76[_0x1dc1cb(0x182)](_0x12e665,_0x3490e5[_0x1dc1cb(0x207)]),_0x472ba7=_0x10e9a8[_0x1dc1cb(0x278)](_0x1caa76[_0x1dc1cb(0x402)](_0xe42b78,0xea60)),_0x49f51d=_0x3ea71e[_0x1dc1cb(0x278)](_0x1caa76[_0x1dc1cb(0x359)](_0x1caa76[_0x1dc1cb(0x322)](_0xe42b78,0xea60),0x3e8));_0x13800a[_0x1dc1cb(0x33a)](_0x1caa76[_0x1dc1cb(0x396)])[_0x1dc1cb(0x147)]=_0x472ba7+':'+_0x49f51d[_0x1dc1cb(0x2e3)]()[_0x1dc1cb(0x1fd)](0x2,'0'),_0x40a741['classList'][_0x1dc1cb(0x3fd)](_0x1dc1cb(0x12c));}}}},0x3e8);}function updateTimerDisplay(){const _0x544dfa=_0x6eced6,_0x18463c=Math[_0x544dfa(0x278)](timeRemaining/0x3c),_0x1c01a0=timeRemaining%0x3c;document[_0x544dfa(0x33a)](_0x544dfa(0x461))[_0x544dfa(0x147)]=_0x18463c+':'+_0x1c01a0[_0x544dfa(0x2e3)]()[_0x544dfa(0x1fd)](0x2,'0');}function toggleSidebar(){const _0xec5843=_0x6eced6,_0x4791d7={'WlGZU':_0xec5843(0x1c0),'scttb':'open'};document[_0xec5843(0x33a)](_0x4791d7['WlGZU'])[_0xec5843(0x209)][_0xec5843(0x238)](_0x4791d7[_0xec5843(0x2cc)]);}document[_0x6eced6(0x18b)](_0x6eced6(0x1fb),()=>{const _0x1881b7=_0x6eced6,_0x22148a={'NwFcD':'index.html','GUrqb':function(_0x60bcb6,_0x6d838e){return _0x60bcb6-_0x6d838e;},'NznxF':function(_0x148ade,_0x209e9d){return _0x148ade===_0x209e9d;},'PaPHJ':'YLHrG','jYBHz':_0x1881b7(0x429),'KMLCu':function(_0x5893c9){return _0x5893c9();},'VgHcY':_0x1881b7(0x1e1),'pZBMa':_0x1881b7(0x35e),'CFydJ':_0x1881b7(0x333),'OQgLN':function(_0xf49117){return _0xf49117();},'tpajZ':_0x1881b7(0x294),'VeHMW':function(_0xe7e4ac,_0x431b64){return _0xe7e4ac!==_0x431b64;},'BPMzZ':_0x1881b7(0x1d6),'WkOGE':_0x1881b7(0x258),'bVeYH':'KPkBi'};if(resume){if(_0x22148a[_0x1881b7(0x2de)](_0x22148a[_0x1881b7(0x31b)],_0x22148a[_0x1881b7(0x18e)])){if(!_0x4bb822)_0x268676();_0x794a[_0x1881b7(0x3e8)]['href']=_0x46f8f4[_0x1881b7(0x3c8)]||_0x22148a[_0x1881b7(0x16c)];}else _0x22148a['KMLCu'](loadProgress)?(document['getElementById'](_0x22148a[_0x1881b7(0x286)])[_0x1881b7(0x40d)][_0x1881b7(0x24e)]=_0x22148a[_0x1881b7(0x424)],_0x22148a[_0x1881b7(0x2a0)](initializeQuiz)):'gMcGl'===_0x22148a['CFydJ']?(_0x22148a['OQgLN'](clearProgress),document[_0x1881b7(0x33a)](_0x22148a[_0x1881b7(0x286)])['style'][_0x1881b7(0x24e)]=_0x22148a['tpajZ']):_0x23db5e['quizFile'][_0x1881b7(0x43c)](_0x368f2c[_0x1881b7(0x2c7)]()[_0x1881b7(0x3a8)](/ /g,'-'))&&(_0x32ce0e[_0x1881b7(0x2dd)]<_0x13b0fe[_0x1881b7(0x207)]&&(_0x5e7e67[_0x5546a1[_0x1881b7(0x2dd)]][_0x1881b7(0x38c)]=!![]));}else!window[_0x1881b7(0x3e8)][_0x1881b7(0x401)][_0x1881b7(0x325)]('custom_quiz.html')?_0x22148a[_0x1881b7(0x32c)](_0x22148a[_0x1881b7(0x2f2)],_0x22148a[_0x1881b7(0x243)])?(_0x22148a['OQgLN'](clearProgress),document['getElementById'](_0x1881b7(0x1e1))[_0x1881b7(0x40d)][_0x1881b7(0x24e)]=_0x1881b7(0x294)):(_0x529b5b[_0x215afe]['timeSpent']+=_0x22148a['GUrqb'](_0x3aa6d1[_0x1881b7(0x2e0)](),_0x267890),_0x139e85=_0x4a440f[_0x1881b7(0x2e0)]()):_0x22148a[_0x1881b7(0x32c)](_0x22148a[_0x1881b7(0x3e1)],_0x22148a[_0x1881b7(0x3e1)])?_0x49e8a2[_0x1881b7(0x3a7)]+='<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22'+_0x50772d[_0x1881b7(0x1c2)]+_0x1881b7(0x406):initializeQuiz();}),document[_0x6eced6(0x18b)](_0x6eced6(0x400),function(_0x3d3537){const _0x9db7c3=_0x6eced6,_0x132e06={'MUCTM':_0x9db7c3(0x1f0),'PRJEy':'(((.+)+)+)+$','NVCEw':function(_0x29b30b,_0x2d7093){return _0x29b30b-_0x2d7093;},'eovTs':function(_0x226619,_0x4267e3){return _0x226619!==_0x4267e3;},'oJSuY':_0x9db7c3(0x1e1),'fxzwq':_0x9db7c3(0x3da),'SMwNd':_0x9db7c3(0x12c),'YYyIP':function(_0x2e69b5,_0x421913){return _0x2e69b5>=_0x421913;},'GOJFj':function(_0x5e5353,_0x29ca20){return _0x5e5353<=_0x29ca20;},'hDfgG':'vGBhE','ZRomv':function(_0xe3ac5a,_0x53bb58){return _0xe3ac5a(_0x53bb58);},'JBbMS':_0x9db7c3(0x22d),'HMZIY':function(_0x247166,_0x81e32d){return _0x247166<_0x81e32d;},'KVOnd':function(_0x215edf,_0x323b8e){return _0x215edf(_0x323b8e);},'eMuAZ':_0x9db7c3(0x14b),'nsMxv':function(_0x115322){return _0x115322();},'bZtqz':_0x9db7c3(0x1bd),'qSSbL':function(_0x21d2ed,_0x2871f8){return _0x21d2ed===_0x2871f8;},'UGiRn':_0x9db7c3(0x411),'Ncnoj':_0x9db7c3(0x2cf),'dFimx':function(_0x3cf909,_0x57131a){return _0x3cf909===_0x57131a;},'zeEwW':'study','SqqJK':'timed_study','JYSVE':function(_0x1d355c,_0x239df3){return _0x1d355c===_0x239df3;},'NUkVG':function(_0x178c09,_0x18b861){return _0x178c09===_0x18b861;},'EfQzB':_0x9db7c3(0x2e8),'QtIfz':function(_0x3af489,_0x4b9476){return _0x3af489===_0x4b9476;},'DDddo':_0x9db7c3(0x247),'PfitN':_0x9db7c3(0x3bd)};if(_0x132e06[_0x9db7c3(0x44c)](document[_0x9db7c3(0x33a)](_0x132e06['oJSuY'])['style'][_0x9db7c3(0x24e)],_0x9db7c3(0x35e)))return;if(document['getElementById'](_0x132e06[_0x9db7c3(0x287)])['classList']['contains'](_0x132e06[_0x9db7c3(0x19a)])===![])return;if(_0x132e06[_0x9db7c3(0x160)](_0x3d3537[_0x9db7c3(0x1a7)],'1')&&_0x132e06[_0x9db7c3(0x1ef)](_0x3d3537['key'],'4')){if(_0x132e06['eovTs'](_0x132e06[_0x9db7c3(0x16d)],_0x9db7c3(0x2da))){const _0x30e704=_0x132e06[_0x9db7c3(0x1ec)](_0x132e06[_0x9db7c3(0x37f)](parseInt,_0x3d3537['key']),0x1),_0x49b409=document[_0x9db7c3(0x25a)](_0x132e06[_0x9db7c3(0x261)]);if(_0x132e06[_0x9db7c3(0x1ed)](_0x30e704,_0x49b409['length']))_0x132e06['KVOnd'](selectOption,_0x30e704);}else _0xdd594b=_0x132e06[_0x9db7c3(0x236)];}else{if(_0x3d3537[_0x9db7c3(0x1a7)]===_0x132e06[_0x9db7c3(0x298)])_0x132e06[_0x9db7c3(0x3e0)](previousQuestion);else{if(_0x3d3537[_0x9db7c3(0x1a7)]===_0x132e06['bZtqz']||_0x132e06[_0x9db7c3(0x386)](_0x3d3537[_0x9db7c3(0x1a7)],'\x20')){if(_0x132e06[_0x9db7c3(0x386)](_0x132e06[_0x9db7c3(0x3c5)],_0x132e06['Ncnoj']))return _0x370366[_0x9db7c3(0x2e3)]()[_0x9db7c3(0x342)](SrljSC['PRJEy'])['toString']()[_0x9db7c3(0x191)](_0x2f32e9)[_0x9db7c3(0x342)]('(((.+)+)+)+$');else _0x3d3537['preventDefault'](),nextQuestion();}else{if(_0x132e06[_0x9db7c3(0x386)](_0x3d3537[_0x9db7c3(0x1a7)][_0x9db7c3(0x2c7)](),'b')&&(_0x132e06[_0x9db7c3(0x3ef)](currentMode,_0x132e06[_0x9db7c3(0x468)])||_0x132e06[_0x9db7c3(0x3ef)](currentMode,_0x132e06['SqqJK'])))toggleBookmark();else{if(_0x132e06[_0x9db7c3(0x3f5)](_0x3d3537[_0x9db7c3(0x1a7)][_0x9db7c3(0x2c7)](),'m')&&(_0x132e06['NUkVG'](currentMode,_0x132e06[_0x9db7c3(0x387)])||_0x132e06[_0x9db7c3(0x215)](currentMode,_0x132e06[_0x9db7c3(0x2eb)])))toggleMarkForReview();else _0x3d3537[_0x9db7c3(0x1a7)]['toLowerCase']()==='s'&&(_0x132e06[_0x9db7c3(0x397)](currentMode,_0x132e06[_0x9db7c3(0x387)])||_0x132e06[_0x9db7c3(0x3f5)](currentMode,_0x9db7c3(0x247)))&&(_0x132e06[_0x9db7c3(0x44c)](_0x9db7c3(0x3bd),_0x132e06[_0x9db7c3(0x246)])?_0x452237[_0x7c23a5]['timeSpent']+=_0x132e06[_0x9db7c3(0x1ec)](_0x415455[_0x9db7c3(0x2e0)](),_0x2802ee):_0x132e06[_0x9db7c3(0x3e0)](submitQuiz));}}}}});</script>

</body></html>